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iRÉSUMÉ EN FRANÇAIS
Le glioblastome multiforme (GBM) représente la tumeur cérébrale primaire la
plus agressive et la plus vascularisée chez l’adulte. La survie médiane après le
diagnostic est de moins d’un an en l’absence de traitement. Malheureusement, 90%
des patients traités avec de la radiothérapie après la résection chirurgicale d’un GBM
développent une récidive tumorale. Récemment, le traitement des GBM avec
radiothérapie et témozolomide, un agent reconnu pour ses propriétés
antiangiogéniques, a permis de prolonger la survie médiane à 14,6 mois.  Des efforts
sont déployés pour identifier des substances naturelles capables d’inhiber, de retarder
ou de renverser le processus de carcinogenèse.  Epigallocatechin-3-gallate (EGCG),
un polyphénol retrouvé dans le thé vert, est reconnu pour ses propriétés
anticancéreuses et antiangiogéniques.  L’EGCG pourrait sensibiliser les cellules
tumorales cérébrales et les cellules endothéliales dérivées des tumeurs aux traitements
conventionnels.
Le chapitre II décrit la première partie de ce projet de doctorat.  Nous avons
tenté de déterminer si l’EGCG pourrait sensibiliser la réponse des GBM à l’irradiation
(IR) et si des marqueurs moléculaires spécifiques sont impliqués.  Nous avons
documenté que les cellules U-87 étaient relativement radiorésistantes et que Survivin,
une protéine inhibitrice de l’apoptose, pourrait être impliquée dans la radiorésistance
des GBM.  Aussi, nous avons démontré que le pré-traitement des cellules U-87 avec
de l’EGCG pourrait annuler l’effet cytoprotecteur d’une surexpression de Survivin et
potentialiser l’effet cytoréducteur de l’IR.
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Au chapitre III, nous avons caractérisé l’impact de l’IR sur la survie de cellules
endothéliales microvasculaires cérébrales humaines (HBMEC) et nous avons
déterminé si l’EGCG pouvait optimiser cet effet.  Bien que les traitements individuels
avec l’EGCG et l’IR diminuaient la survie des HBMEC, le traitement combiné
diminuait de façon synergique la survie cellulaire.  Nous avons documenté que le
traitement combiné augmentait la mort cellulaire, plus spécifiquement la nécrose.
Au chapitre IV, nous avons investigué l’impact de l’IR sur les fonctions
angiogéniques des HBMEC résistantes à l’IR, notamment la prolifération cellulaire, la
migration cellulaire en présence de facteurs de croissance dérivés des tumeurs
cérébrales, et la capacité de tubulogenèse.  La voie de signalisation des Rho a aussi été
étudiée en relation avec les propriétés angiogéniques des HBMEC radiorésistantes.
Nos données suggèrent que l’IR altère significativement les propriétés angiogéniques
des HBMEC.  La réponse aux facteurs importants pour la croissance tumorale et
l’angiogenèse ainsi que la tubulogenèse sont atténuées dans ces cellules.
En conclusion, ce projet de doctorat confirme les propriétés cytoréductrices de
l’IR sur les gliomes malins et propose un nouveau mécanisme pour expliquer la
radiorésistance des GBM.  Ce projet documente pour la première fois l’effet
cytotoxique de l’IR sur les HBMEC.  Aussi, ce projet reconnaît l’existence de
HBMEC radiorésistantes et caractérise leurs fonctions angiogéniques altérées.  La
combinaison de molécules naturelles anticancéreuses et antiangiogéniques telles que
l’EGCG avec de la radiothérapie pourrait améliorer l’effet de l’IR sur les cellules
tumorales et sur les cellules endothéliales associées, possiblement en augmentant la
mort cellulaire.  Cette thèse supporte l’intégration de nutriments avec propriétés
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anticancéreuses et antiangiogéniques dans le traitement des gliomes malins pour
sensibiliser les cellules tumorales et endothéliales aux traitements conventionnels.
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vSUMMARY
Glioblastoma multiform (GBM) represents the most aggressive and
vascularised primary cerebral neoplasm in adults. Median length of survival without
further therapy is usually less than one year from the time of diagnosis. Unfortunately,
90% of patients receiving radiotherapy following GBM resection develop a tumor
recurrence. More recently, treatment of GBM with combined radiotherapy and
temozolomide, an agent recognized for its antiangiogenic activity, increased the
median survival to 14,6 months.  Efforts have been oriented towards identifying
naturally occurring substances capable of inhibiting, delaying or reversing the multi-
stage carcinogenesis process.  Epigallocatechin-3-gallate (EGCG), a green tea
polyphenol, has been recognized for its anticancerous and antiangiogenic property.
EGCG may represent a potential agent capable of sensitizing brain tumor cells and
their derived endothelial cells (ECs) to conventional treatments.
In chapter II, the first part of this doctorate project aimed at determining if
EGCG, in synergy with radiotherapy, can sensitize GBM’s response to radiation and
whether specific molecular markers are involved.  We documented that U-87 cells
were relatively radioresistant and that Survivin, an inhibitor of apoptosis protein, may
be involved in GBM’s radioresistance.  We also found that pre-treatment of U-87 cells
with EGCG could overcome the cytoprotective effect of Survivin overexpression and
potentiate the cytoreductive effect of irradiation (IR).
In chapter III, we characterized the impact of IR on human brain microvascular
endothelial cell (HBMEC) survival and determined whether EGCG, could optimize
this effect.  We found that although EGCG treatment and IR individually decreased
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HBMEC survival, the combined treatment synergistically reduced survival.  We
documented that the combined treatment increased cell death, more specifically
necrosis.
In chapter IV, we investigated the impact of IR exposure on the angiogenic
functions i.e. cell proliferation, cell migration in response to brain tumor-derived
growth factors, and capacity for tubulogenesis of surviving human brain tumor-
derived ECs.  The Rho signalling pathway was also investigated in relation to the
functional properties of radioresistant HBMEC.  Our data suggests that IR
significantly alters radioresistant HBMEC migration response to tumor-secreted
growth factors and tubulogenesis.  Response to growth factors important for tumor
expansion and angiogenesis is significantly attenuated in these cells.
In conclusion, this doctorate project confirmed IR’s cytoreductive properties
on malignant gliomas.  We proposed a novel mechanism to explain GBMs’
radioresistance.  This project documented for the first time IR’s cytotoxic effect in
HBMEC.  It also described the existence of radioresistant HBMEC and characterized
their altered angiogenic functions.  The combination of natural anticancerous and
antiangiogenic molecules such as EGCG with radiotherapy could improve IR’s effect
on human malignant glioma cells and microvascular ECs, especially through increased
necrosis of HBMEC.  The thesis supports integrating nutrients bearing anticancerous
and antiangiogenic properties, such as EGCG, in the management of gliomas to
sensitize tumor and tumor-associated ECs to conventional therapies.
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CHAPTER I INTRODUCTION
1.1 The brain
1.1.1 General anatomy
The human central nervous system (CNS) is divided in the spinal cord, the
cerebellum, and the brain.  The brain is further subdivided in two cerebral
hemispheres, a diencephalon, a brain stem, and a cerebellum (Figure 1).  Each specific
region has general and more specific functions, working in unison to realize the most
complex movements and translate perceptions, emotions, and thoughts.
Figure 1. The central nervous system. A) Location of the central nervous system in the body.
B) The major divisions of the central nervous system are: (1) cerebral hemispheres, (2)
diencephalon, the brain stem composed of the(3) midbrain, (4) pons, and (6) medulla, (5) the
cerebellum and (7) spinal cord [1].
21.1.2 Brain cellular components and their function
1.1.2.1 Nerve cells
Three types of cells compose the nervous tissue: nerve cells, glial cells, and
endothelial cells.  These cells interact together within the extracellular matrix.  The
nerve cell, or neuron, is the functional cellular unit of the nervous system.  There is a
great diversity of structural and functional characteristics possessed by the various
cells that are named neuron.  However, they have properties related to their function in
common.  Neurons are polarized cells derived from epithelial origins.  They are
composed of dendrites, cell body and axon terminals (Figure 2).  Dendrites and the
cell body receive information from other neurons at specialized contact sites called
synapses. The nucleus and cellular organelles reside in the cell body.  The axon
conducts electrical information encoded in action potentials to axon terminals.
Dendrites and neuronal cell bodies in the CNS are located in cortical areas and
in nuclei located beneath the cortical surface, giving the appearance of grey matter.
Regions rich in axons surrounded by cells rich in myelin form the white matter.
3Figure 2. Neurons, the functional cellular unit of the nervous system. A schematic nerve cell
is shown, illustrating the dendrites, cell body, and axon.  The presynaptic terminals of the
neuron are shown synapsing on the cell body of the postsynaptic neurons.  The inset showns
the spatial relation of three components of the synapse, the axon terminal, the synaptic cleft,
and the cell body of the postsynaptic neuron.  Adapted from [1]
41.1.2.2 Glial cells
Glial cells outnumber neurons in a 10:1 ratio.  They are divided in two major
classes: microglia and macroglia.  Most microglia originate from bone marrow-
derived monocytes which enter the brain during early development.  They function as
resident immune cells and phagocytes in the CNS, exerting a scavenger role in
response to nervous system infection, trauma, and inflammation.  Macroglia, including
oligodendrocytes, Schwann cells, ependymal cells, and astrocytes, subserve support
and nutritive functions. Oligodendrocytes form the myelin shealth around axons in the
CNS.  In addition to myelinization and axonal support in the peripheral nervous
system, Schwann cells can promote axonal regeneration.  Ependymal cells line the
ventricles and the central canal in the spinal cord.  Astrocytes are the most abundant
cell within the CNS.  Although there are many subtypes of astrocytes, the presence of
a unique population of intermediate filaments enriched in glial fibrillary acidic protein
is common to all astrocytes.  These cells are important for structural support,
homeostatic regulation of the CNS microenvironment and regulation of energy
metabolism.  Astrocytes processes surround many other CNS (Figure 3) such as blood
vessels, implicating them in the blood-brain barrier (BBB) [2].  In the presence of
CNS pathology, reactive astrocytes’ may secrete a variety of substances that can
inhibit or promote axonal regeneration, brain repair, and neuronal function [2].
5Figure 3. Relationships between astrocytes and other central nervous system cells.  Astrocyte
processes surround blood vessels (BV), synapses, nodes of Ranvier, neuronal cell bodies (N),
and groups of myelinated axons (A). Myelin (m)  Adapted from [2]
1.1.2.3 Endothelial cells
In the adult brain, the total surface area of microvasculature is 12m2.  A BBB is
present in more than 99% of the brain capillaries [2].  Brain capillary endothelial cells
(ECs) are surrounded by astrocytes, pericytes, neurons, microglia and extracellular
matrix.  In addition to composing the BBB, they have highly specialized properties
and functions.  Brain capillary ECs constitute a continuous lining given the lack of
fenestrations and the presence of tight junctions between each ECs [3], hindering the
passage of small and large molecules between blood and brain.  Also, brain capillary
ECs are characterized by low pinocytic activity.  Only highly lipophylic molecules can
6relatively easily pass the BBB, other molecules depend on selective specialized
transport mechanisms.
1.2 Primary brain tumors
1.2.1 Generalities
1.2.1.1 Epidemiology of primary brain tumors
Primary brain tumors arise from intrinsic cellular elements found in the CNS.
In contrast, secondary tumors originate outside the nervous system and reach neural
tissues either by contiguity or hematogenous spread.  In the most recent compilation of
primary brain and CNS tumors in the United States, the overall annual incidence rate
of primary brain and CNS tumors was 11.5/100 000 persons/year.  The calculated
annual incidence rates for benign tumors varied from 2.1-8.9/100 000 persons/year
throughout the various regions analyzed.  The calculated annual incidence rates for
malignant tumors varied from 5.9-7.8/100 000 persons/year [4].
Tumors most frequently occur within the brain parenchyma with 39% located
in the supratentorial region [4] (Figure 4).
7Figure 4. Distribution of all primary brain and central nervous system tumors by location,
CBTRUS 1990-1994. CBTRUS, Central Brain Tumor Registry of the United States; not
otherwise specified (NOS) [4].
The most frequently reported histopathologies are meningiomas (24.0%),
glioblastomas (22.6%), and astrocytomas (13,7%, including diffuse, anaplastic, not
otherwise specified) [4] (Table 1).  The highest mean age at diagnosis is found in
meningiomas (62 years) and glioblastomas (62 years).  The lowest mean age at
diagnosis is found in pilocytic astrocytomas (17 years) and medulloblastomas (14
years) [4].
8Table 1. Distribution and incidence rate of primary brain and central nervous
system tumors by histology
Adapted from [4]
91.2.1.2 Classification of primary brain tumors
Many classification systems have been proposed to organize tumors of the
CNS.  In the nineteenth century, Cohnheim proposed that neoplasms develop from
nests of embryonic cells [5].  The suffix –oma was added to the name of the cell from
which the tumor was believed to originate.  This cytogenetic concept was used in the
first tumor classification scheme written by Bailey and Cushing [5].  They attributed a
histopronostic value to each tumor depending on its cellular differentiation.
Later on, Kernohan proposed that tumor cells originate from differentiated
cells that undergo anaplasia.  He introduced in his classification grades of malignancy
depending on their differentiation and degree of anaplasia.
The most recent classification, the 2007 World Health Organization (WHO)
classification of tumours of the CNS, builds on the previous classification schemes
[6].  It is based on the consensus of an international working group of pathologists and
geneticists and represents the standard for the definition of brain tumors [6].  Two
basic concepts are used in the WHO system to classify tumors.  First, recognition of
the cellular component of the tumor either by histology or immunocytochemical
methods [7].  Primary CNS tumors may origin from neuroepithelial tissue, cranial and
paraspinal nerves, meninges, germ cells, lymphomas and haematopoetic neoplasm,
sellar region [7].
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Second, each tumor is graded according to a scheme that is a malignancy scale,
predicting the biological behavior of the neoplasm [5, 6].  Grade I is reserved for
lesions with low proliferative potential and the possibility of cure following surgery.
Grade II designates infiltrative lesions with low proliferative activity.  Grade III is
attributed to lesions with anaplastic characteristics including nuclear atypia and brisk
mitotic activity.  Grade IV is reserved for cytologically malignant lesions with high
mitotic activity, endothelial proliferation and necrosis [6].  Adequate sampling of the
tumor is important in order to determine its type and judge its malignant potential
1.2.2 Classification and grading of astrocytomas
Tumors that originate from glial cells are grouped together as gliomas.
Gliomas include tumors that originate from astrocytes (astrocytomas),
oligodendrocytes (oligodendrogliomas), ependymal cells (ependymomas) and
choroids plexus.  Furthermore, some tumors of glial origin contain more than one type
of neoplastic cells and are referred to as mixed tumors (oligoastrocytomas) [6].
Numerous grading systems have been systematically evaluated and
successfully applied to astrocytomas.  Currently, the two most commonly used
classifications are the St. Anne/Mayo, also named the Daumas-Duport system [8] and
the WHO [7] grading systems.  The St. Anne/Mayo classification system is restricted
to fibrillary, protoplasmic, gemistocytic, anaplastic astrocytomas and glioblastomas.  It
assesses the presence or absence of four morphologic criteria: nuclear atypia, mitoses,
endothelial proliferation, and necrosis.  The summary score is translated into a grade
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as follows: 0 criterion = grade 1, 1 criterion = grade 2, 2 criteria = grade 3, 3 or 4
criteria = grade 4 [8].  Grade I is attributed to diffuse astrocytoma without atypia.
The WHO classification includes in grade I pilocytic astrocytoma and
subependymal giant cell astrocytoma.  The diffusely infiltrative astrocytic tumors are
graded II through IV.  Grade II astrocytic tumors (diffuse astrocytoma) present little
cellularity and minimal pleomorphic changes.  Grade III (anaplastic astrocytoma) is
reserved for tumors showing moderate cellularity and pleomorphism but no necrosis.
Grade IV (glioblastoma) is attributed to highly cellular tumors with nuclear and
cellular pleomorphism, numerous mitotic figures, endothelial proliferation or
glomeruloid microvascular proliferations and necrosis [6, 9].  Tumor grade has an
important prognostic significance, influencing the choice of adjuvant therapies such as
radiation and chemotherapy (Table 2) [10].
Table 2. Classification of malignant gliomas and prognostic significance
Adapted from [10]
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1.2.3. Cellular origins of gliomas
Although the WHO classification scheme implies a cell of origin for most
brain tumors, that cell of origin has not been unequivocally identified for any of them.
As such, astrocytomas and oligodengrogliomas are believed to arise from astrocytic or
oligodendroglial precursors.  Stem cells, progenitor cells and differentiated cells may
acquire genetic alterations leading to the development of neoplastic cells.
Analysis of the genetic profile of both cellular components of mixed tumors
oligoastrocytomas has revealed that both cell types present loss of heterozygosity of
1p and 19q, suggesting that oligodendroglial and astrocytic cells derived from a single
precursor cell [11].  Similarly, genetic analysis of the glial and sarcomatous elements
revealed that both components carried identical p53 mutations, suggesting a common
origin of the two cellular components from a multipotent neural stem cell or an early
glial progenitor cell [12].
Neural stem cells have been identified in the adult CNS within its specialized
microenvironment named the niche which can regulate stem cell quiescence,
asymmetrical self-renewal, and differentiation into mature astrocytes and neurons
(Figure 5) [13].
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Figure 5. Current concept of the stem cell niche.  The multipotent stem-cell like astrocytes are
closely opposed to the ventricular lining and basal lamina associated with the pial
microvasculature. Asymmetric division gives rise to self-renewal (green arrow) and a transient
amplifying population (blue arrow).  These cells can migrate out of the germinal niche and
differentiate into neurons and glia (brown arrow) [13].
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The occurrence of a genetic mutation in neural stem cells (NSC) or early glial
progenitors could lead the cells to become independent of growth signals or to resist
antigrowth signal.  These cells could undergo uncontrolled proliferation and possible
tumorigenesis (Figure 6) [14].
Figure 6. Comparison of the niches under normal and cancerous conditions.  The stem cell
niche under normal physiological conditions provides an environment that predominantly
inhibits proliferation and differentiation.  A transient signal is required to support ongoing
tissue regeneration.  In cancer, internal mutations or change in the niche’s signals results in
abnormal cell proliferation and growth [14].
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Brain tumor stem cells (BTSC) have been identified in human brain tumors of
different phenotypes from both children and adults [15].  Studies have shown that
BTSC isolated from astrocytomas, when explanted into naive mouse brains, result in
the development of tumors identical to the parent tumor [16].  Isolated tumor stem
cells form neurospheres, possess the capacity for self-renewal, express genes
associated with NSC such as the neural precursor cell surface marker CD133, generate
daughter cells of different phenotypes from one mother cell, and differentiate into the
phenotypically diverse populations of cells similar to those present in the initial GBM
[16].  Also it has been found that CD133(+) and CD133(-) primary glioblastoma-
derived cancer stem cells show molecular differences and different biological growth
pattern in vitro an in vivo [17].  This might suggest that CD133(+) and CD133(-)
cancer stem cell lines might reflect two biologically different glioblastoma subtypes in
primary glioblastomas [17].
Another possible source of transformed glial cell with properties resembling
those of stem cells is the mature astrocyte or oligodendrocyte that may be brought to
dedifferentiate in response to extrinsic signals or genetic mutations [18].  Recent
studies have shown that explanted mature astrocytes isolated from embryonic cortical
tissue are able to dedifferentiate in the recipient brain into an earlier glia-like
phenotype and acquire proliferative and migratory capabilities that these progenitor
cells possess early in CNS development [18].
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1.3 Glioblastoma multiforme
1.3.1 Epidemiology of glioblastoma
Every year, approximately 18,000 patients are diagnosed with malignant
primary brain tumors in the United States [19].  More than half of these patients have
glioblastoma multiforme (GBM), making this the most common malignant brain
tumor in adults [4, 19].  The incidence of GBM is highest in elderly patients, peaking
at age 65 to 74 years (Figure 7) [20].  GBM seem to occur more frequently in men and
Caucasians [4, 20].
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Figure 7. Incidence rates of primary brain tumors by major neuroepithelial tissue and
meningeal histologic types and age group.  CBTRUS, 1992-1997.  The astrocytoma category
includes diffuse astrocytomas, anaplastic astrocytomas, unique astrocytomas and astrocytomas
not otherwise specified.  Adapted from [20].
1.3.2 Risk factors
1.3.2.1 Hereditary syndromes and familial aggregation
In most cases, malignant gliomas occur sporadically.  However, the inheritance
of certain genes may influence the risk of developing primary brain tumors. Patients
with some hereditary syndromes – such as tuberous sclerosis, neurofibromatosis type
1 and 2, nevoid basal cell carcinoma syndrome, Li-Fraumeni syndrome, and
syndromes involving adenomatous polyps – seem to be predisposed to malignant
gliomas [20] (Table 3).  Interestingly, primary brain tumors can also occur in families
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without a known predisposing hereditary disease [21].  Environmental exposures may
be important in the etiology of this familial aggregation [21].
Table 3. Principal tumor suppressor genes altered in brain tumors and involved
in hereditary tumoral syndromes.
Adapted from [22]
1.3.2.2 Polymorphisms in genes relevant to cancer causation or prevention
It has been proposed that polymorphisms in genes might influence the
susceptibility to brain tumors in concert with other external factors [20].  Alteration in
genes involved in oxidative metabolism, detoxification of carcinogens, DNA stability
and repair might confer genetic susceptibility to brain tumors [20].
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1.3.2.3 Ionizing radiation
Therapeutic ionizing radiation (IR) has been recognized as a risk factor for
brain tumors [20, 23, 24].  Authors observed a high prevalence (17%) of previous
radiation therapy with an average dose of 48.5 Gray (Gy) and an average latency
period of 15 years between initial therapy and GBM diagnosis [23].  Studies have
found that radiation-induced gliomas are nearly all astrocytic in their differentiation,
present as high grade lesions, and occur in a younger patient population than would be
expected [24, 25].  Unfortunately, little is known regarding the susceptibility of
individuals within the general population to radiation-induced tumorigenesis [26]
Diagnostic radiation techniques have not been associated with an increased risk of
glioma [27].
1.3.3 Clinical presentation of glioblastomas
Glioblastomas become clinically eloquent due to infiltration, compression and
destruction of normal brain structures by tumor, edema, and sometimes hemorrhage.
Cerebral spinal fluid flow may be compromised by the tumor, leading to further
increased intracranial pressure.  Most often, symptoms install progressively, over
weeks to months.  However, acute apoplectic clinical presentations do occur, for
example following intratumoral hemorrhage or de novo seizures due to cortical
stimulation.  The signs and symptoms depend on the tumor’s mass effect and its
location.  General manifestations may occur such as mental changes, headaches,
nausea, vomiting and generalized seizures.  Focal manifestations include focal
seizures, weakness, sensory abnormalities, speech disturbances, and visual deficits [2].
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The clinical features at presentation may be used as a measure of the outcome
of treatment.  The karnofsky performance scale (KPS) is a standardized tool
describing the patient’s capabilities (Table 4) [2].  Although a KPS of 70 or more at
diagnosis has favourable impact on survival, clinical parameters do not fully account
for the variation of survival rates [28].
Table 4.  Karnofsky performance scale for brain tumor patients
Adapted from [2]
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1.3.4 Radiological characteristics
Magnetic resonance imaging (MRI) is more sensitive and accurate than
computed tomography (CT) in studying gliomas [29, 30].  Glioblastomas typically
present as irregular supratentorial white matter masses with infiltrated margins, poor
demarcation and extensive edema.  Necrosis, cysts and thick irregular margin are
common findings [31].  Spontaneous hemorrhage can be seen and is believed to
correlate with histologic grade [32].  Following contrast injection, a thick ring of
enhancement surrounding central necrosis is commonly found, although a solid,
nodular or patchy appearance may be visualized.  The enhancement seen on MRI and
CT following contrast injection correlates with the area of greatest vascularity [2, 31]
(Figure 8).  The aggressiveness of GBM may be suggested by its infiltration through
the adjacent brain parenchyma, best approximated by the hyperintensity on T2-
weighted images [33] (Figure 8).  However, tumor cells are found infiltrating the brain
beyond the hyperintensity signal changes in T2-weighted images when results of
stereotactic biopsies are compared with MRI [33, 34].  Newer techniques are being
developed to improve diagnosis accuracy, to determine the most appropriate biopsy
site, and to evaluate tumor recurrence [31] such as MRI perfusion, magnetic resonance
spectroscopy, positron emission tomography, diffusion tensor imaging.
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Figure 8. Characteristic radiological features of glioblastoma.
A) Axial contrast enhanced CT shows strong, heterogeneous, irregular rim enhancement
surrounding a hypodense necrotic core.  B) Axial T2 weighted image MR shows a
heterogeneous mass with surrounding hyperintense signal compatible with tumor infiltration
and vasogenic edema.  C) Axial T1 weighted image MR with gadolineum demonstrating a
hazy, heterogeneous peripheral enhancement.
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The most common differential diagnosis include brain metastasis, enhancing
anaplastic astrocytoma, primary CNS lymphoma, and non-neoplastic disorders such as
an abscess, multiple sclerosis, cerebral infarction, vascular malformation [31].  The
final diagnosis can be confirmed only by histopathological examination.
1.3.5 Histological characteristics
Intraneoplasm and interneoplasm heterogeneity is characteristic of GBM.
Although some areas have the characteristics of a low grade astrocytoma or anaplastic
astrocytoma, the significant amount of microvascular proliferation and the presence of
necrosis are key features distinguishing GBM from grade 2 and 3 astrocytomas [9].
The cellular morphology of GBM is highly variable.  A spectrum ranging from
small tightly packed, round or elongated cells to giant elements with significant
nuclear atypia can be encountered within the same tumor.  GBM are highly cellular
tumors with cellular pleomorphism and numerous mitotic figures with corresponding
elevated proliferation marker indexes.  Endothelial proliferation or glomeruloid
microvascular proliferations are highly suggestive of GBM.  Necrosis on the other
hand is characteristic of grade IV astrocytomas as it results of a pathological tumor
microvasculature [9] (Figure 9).
GBM cells tend to infiltrate adjacent brain by spreading along white matter
tracts, through the adjacent extracellular matrix or along the basement membranes [2].
Therefore islets of GBM cells can be found at distance from the primary tumor site.
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Figure 9. Characteristic histopathological features of glioblastomas.
A) Cellular pleomorphism seen as variable nuclear:cytoplasmic ratio. B)
Neovascularisation seen as buds of capillary endothelial proliferation among neoplastic
cells. C) Pseudopalisading of cells around necrotic areas. Adapted from [9].
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1.3.6 Primary and secondary glioblastomas
GBM seem to develop from one of two ways.  The majority of cases (>90%)
are primary glioblastomas that develop rapidly de novo from glial cells without
clinical or histological evidence of a less malignant precursor lesion.  Typically, they
become clinically manifest within less than 6 months of diagnosis.  Approximately
50% of patients with primary GBM have a clinical history of less than 3 months [35].
Primary GBM is most common in older patients [36].  Secondary GBM develops over
months to years from pre-existing low-grade astrocytomas [37].  Neuroimaging or
histologic evidence of evolution from a less malignant precursor lesion is mandatory
to diagnose secondary GBM.  This subtype of GBM predominantly affects younger
patients, average age at diagnosis is 39 years [36].
Primary and secondary GBM represent distinct entities that arise through
different genetic pathways.  The development of primary GBM is associated with
over-expression or amplification of the epidermal growth factor (EGF) gene.
Additional genetic alterations leading to this subtype of GBM include amplification or
over-expression of murine double minute 2 (MDM2), loss of heterozygosity (LOH)
10q, deletion or mutation of the phosphatase and tensin homolog deleted from
chromosome 10 (PTEN), p16(INK4a) deletion [37].  In the pathway to secondary
glioblastoma, p53 mutations are the most frequent and earliest detectable genetic
alteration, already present more than 60% of precursor low-grade astrocytomas.  It is
also associated with overexpression of platelet-derived growth factor (PDGF) ligands
and receptors and LOH 10q [35, 37, 38] (Figure 10).  Although histological
characteristics of  primary and secondary glioblastomas are reported identical [39],
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differences in their pattern of promoter methylation and in expression profiles at RNA
and protein levels seem to have implications for therapeutic options [37].
 
Figure 10. Formation of primary and secondary glioblastoma multiform (GBM).  Multiple
genetic changes are involved in the development of primary and secondary
glioblastomas.Abbreviation: DCC, deleted in colorectal cancer; EGFR, epidermal growth
factor receptor; LOH, loss of heterozygosity; MDM2, murine double minute 2; PDGF,
platelet-derived growth factor; PTEN, phosphate and tensin homolog deleted on chromosome
10; RB1, retinoblastoma 1 gene; WHO, World Health Organization.  Adapted from [38]
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1.3.7 Overview of altered molecular pathways in glioblastoma
1.3.7.1 Signal transduction
Altered signal transduction may contribute to gliomatogenesis.  Critical signals
are initiated in GBM by members of the tyrosine kinase receptor family involving, for
instance, EGF receptor (EGFR), PDGF receptor (PDGFR), basic fibroblast growth
factor receptor (bFGFR).  Increased production of the growth factor or increased
production or activity of the growth factor receptor may occur through various
mutations.  As a result, downstream pathways exhibit increased activity such as
increased PI3K, Akt, or Ras which may contribute to tumor formation and tumor
progression [40].  Also, mutations of tumor suppressor genes may result in an
oncogenic signal.  For example loss of PTEN function in glioma cells may participate
in astrocytic tumor pathogenesis and progression through activation of the prosurvival
PI3K/Akt pathway [39, 40].
1.3.7.2 Cell cycle
In glioblastoma, regulatory controls of the cell cycle are often disrupted,
leading to uncontrolled proliferation of transformed cells.  The Rb and p53 pathways
normally maintain cells in G1 arrest.  Other cell cycle regulators such as
p21/WAF1/Cip1 and p27/Kip1 also regulate the progression from the G1 to the S
phase.  Loss of function of such regulators promotes accelerated growth and malignant
transformation in astrocytes [2, 41].
28
1.3.7.3 Programmed cell death
Apoptosis, a specialized mechanism of cell death, is an important mechanism
for maintaining genetic stability. If damage is beyond repair, p53 activates a series of
pro-apoptotic members.  In glioblastoma cells, altered signal transduction pathways
modify the balance between pro-apoptotic and anti-apoptotic activities.  An example
of such a protein is Survivin, an inhibitor of apoptosis protein (IAP), that has been
reported to increase survival in GBM by suppressing caspase-mediated apoptosis [42-
44].  Survivin can bind specifically to the terminal effector cell death proteases,
caspase-3 and caspase-7 [45].  Studies with a transgenic mouse model of transgenic
expression of Survivin in the skin have shown that this IAP can also be antiapoptotic
by inhibiting the intrinsic caspase-9-dependent pathway [46]. Recently Survivin has
been recognized to also inhibit cell death in various cell lines through a caspase-
independent pathway although the mechanisms have not yet been elucidated [47, 48].
In addition to being involved in the modulation of apoptosis[42-44, 49].  Survivin is
implicated in the regulation of cell growth [42], in the regulation of mitotic events
such as chromosomal segregation and cytokinesis [50, 51], and in the process of
angiogenesis [52, 53].
Other types of cell death less well studied in glioblastoma possibly contribute
to the survival versus death balance such as autophagy, necrosis, and mitotic
catastrophe [54].  In the context of cancer therapy, senescence consisting in permanent
growth arrest, is also considered a type of cell death.  The biological and
morphological characteristics of each cell death pathway are presented in table 5.
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Table 5. Cell death pathway characteristics
Adapted from [54]. Abbreviations: ER, endoplasmic reticulum; HDGF, hepatoma-derived
growth factor; HMGB1, high-mobility group box 1 protein; LC3, microtubule-associated
protein 1, light chain 3.
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1.4 Angiogenesis
In addition to their agressive character, malignant gliomas are also recognized
as the most intensively vascularized solid tumors [2]. The process of angiogenesis is
essential for tumor progression.  Indeed, malignant gliomas become more angiogenic
with increasing tumor grade, suggesting that the vascular component plays an
important role in their malignant progression [55].
1.4.1 Distinction between vasculogenesis and angiogenesis
New vessel formation occurs via two distinct processes: vasculogenesis and
angiogenesis [56].  Vasculogenesis is defined as the formation of blood vessels from
endothelial-cell precursors, the angioblasts.  During embryologic and fetal
development, angioblasts arise in the mesoderm and differentiate into endothelial cells
that proliferate to form a primitive vascular network in an avascular tissue [56, 57].  In
the postnatal period, circulating bone marrow-derived endothelial progenitor cells
(EPCs) may home to sites of physiological and pathological neovascularisation [58,
59].  Postnatal vasculogenesis is subject to regulation by many factors, including
cytokines such as vascular endothelial growth factor (VEGF) and growth factors such
as PDGF [59].
The primitive vascular network is modified by the process of angiogenesis
leading to the formation of new vascular segments.  Normal angiogenesis occurs in
physiological conditions such as wound healing and female reproduction system [56].
Aberrant angiogenesis is present in pathological non-malignant conditions such as
ischemia and inflammatory reactions as well as in malignancies [56].
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1.4.2 Steps in angiogenesis and implicated molecular players
1.4.2.1 The angiogenic switch
Initially, it was proposed that tumors exist in two phases: avascular and
vascular.  In the avascular phase, solid tumors of 2-3 mm3 or less obtain the necessary
oxygen and nutrient supplies required for growth and survival and eliminate metabolic
waste products by simple passive diffusion.  However, tumors larger than 2mm3
require blood supply for further growth.  This concept has been challenged by the
discovery of a subset of tumors that initiate growth by co-opting existing host vessels.
Co-opted vessels overexpress angiopoietin-2 (Ang-2) which leads to vessel regression
[60].  Vessel collapse and increased tumor growth occurs when anaplastic
astrocytomas progress to glioblastoma.  Hypoxic conditions induce the activation of  a
hypoxia-inducible factor (HIF-1).  This transcription factor binds to hypoxia-
responsive elements and induces the transcription of many angiogenic factors such as
VEGF, PDGF, Angiopoietin (Ang)-1 and -2 [61], stem cell factor (SCF) [62].  In
addition, hypoxia increases VEGF messenger RNA (mRNA) stability through binding
of several RNA-binding proteins [56].  Hypoxia and subsequent necrosis is
pathognomonic of glioblastoma and is the principal stimulus for new vessels
formation.  Interestingly, high SCF expression has been documented in glioma cells
but also in normal host neurons, possibly in response to the glioma-induced damage in
normal brain parenchyma [62].  The areas of neuronal and glioma SCF overexpression
correspond to areas of sprouting angiogenesis.  Therefore, normal brain cells may also
participate to induce pathological angiogenesis and support tumor growth and
infiltration [62].  Activation of SCF/c-Kit signalling pathway in ECs has been found to
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enhance ECs’ proliferation, survival and migration, even in the absence of growth
factors believed to be obligate such as VEGF [62].  Most probably, various pro-
angiogenic factors have complementary roles in tumors with significant angiogenesis
such as gliomas.
In all circumstances, tumor progression requires the induction of a tumor
vasculature, termed the angiogenic switch [63].  The angiogenic switch can occur at
different stages of the tumor-progression pathway, depending on the tumor type and
its environment [57].  Although angiogenesis is necessary, it is not in itself sufficient
for tumor growth [63].  Induction of the angiogenic switch depends on the balance
between angiogenic stimulators and inhibitors, termed the angiogenic balance (Figure
11) [63].
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Figure 11. The angiogenic balance. Angiogenesis is orchestrated by a variety of activators
and inhibitors – only a few of which are listed above.  Activators are mainly receptor
tyrosine kynase ligands such as vascular endothelial growth factor (VEGF), fibroblast
growth factors (FGFs), platelet-derived growth factor (PDGF) and epidermal growth factor
(EGF), but can also be of various origin such as lysophosphatic acid (LPA).  Inhibitors
include thrombospondin-1 and the statins.  Adapted from [57].
Expression of such regulators may be in response to physiological stimuli, such as
hypoxia, resulting from increased tissue mass, and also to oncogene activation or
tumor suppressor mutation in tumor cells [57].  Tumor cells may upregulate
expression of angiogenic activators or downregulate expression of angiogenic
inhibitors, mobilize angiogenic proteins from the extracellular matter, recruit host cells
such as macrophages which produce their own angiogenic proteins [63].
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1.4.2.2  Mechanism of sprouting angiogenesis
Angiogenesis may occur via sprouting and non-sprouting mechanisms.
Sprouting angiogenesis is a multi-step process involving interplay between cells,
soluble factors, and extracellular matrix components.  Angiogenic activators such as
VEGF, placental growth factor and Ang-1 may initiate angiogenesis [57].
Angiogenesis begins with vasodilation and increased vascular permeability in
response to VEGF and loosening of pericytes covering host vessels.  The vascular
basement membrane and extracellular matrix are locally degraded by proteolytic
enzymes such as cathepsin B and matrix metalloproteinases (MMPs) [57].
Endothelial cells may migrate into the interstitial space towards chemotactic
angiogenic stimuli.  Endothelial cells proliferate at the migrating tip, forming a solid
vessel sprout. The sphingolipid sphingosine-1-phosphate (S1P) and S1P(3) receptors
enhance ECs proliferation and migration, playing a key role in angiogenesis [64].
Endothelial cells change shape and adhere to each other to form a lumen.  A new
basement membrane is produced around the newly formed blood vessel with
recruitment of pericytes.  Finally vascular sprouts fuse with other sprouts to form
loops and blood may flow in the newly vascularized area [57].
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1.4.3 Tumor vasculature
1.4.3.1 Types of tumor angiogenesis
Tumor vasculature is not necessarily derived from sprouting angiogenesis: it
can also occur through non-sprouting processes [65].  Cancer tissue can acquire its
vasculature by intussusceptive angiogenesis, recruitement of circulating endothelial
precursor cells, co-option of pre-existing vessels, mosaic vessel formation, and
vasculogenic mimicry [65] (Figure 12).
Figure 12.  Mechanisms of tumor angiogenesis.  The mechanisms of tumor angiogenesis are:
A) Sprouting; B) Intussuceptive angiogenesis; C) Recruitment of precursor cells; D) Vessel
co-option; E) Mosaic vessel formation; F) Vasculogenic mimicry. Adapted from [65].
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Intussusceptive angiogenesis refers to vessel network formation by insertion of
connective tissue columns, called tissue pillars into the vessel lumen and to subsequent
growth of these pillars, resulting in partitioning of the vessel lumen [66].  Vessel co-
option may occur as cancer cells proliferate along pre-existing microvessels, without a
tumor capsule, eliciting an invasive character [57, 60, 66].  Mosaic vessels refers to
the presence of tumor cells within the walls of tumor vasculature.  Vasculogenic
mimicry may contribute to tumor angiogenesis in various malignancies such as
melanomas, breast, prostate and lung cancers.  These cancers have the ability to
express an endothelial cell phenotype and to form three dimentional vessel-like
networks, mimicking the pattern of embryonic vascular networks [67, 68].
Astrocytomas also feature another mechanism of tumor angiogenesis named
glomeruloid angiogenesis.  In fact, glomeruloid bodies are best known in high grade
astrocytomas where they are one of the diagnostic histopathological features of GBM
[69].  These bodies are tufted collections of newly formed microvessels surrounded by
variably thickened basement membrane with an incomplete layer of pericytes [66, 69].
It has been proposed that hypoxic astrocytoma cells in areas surrounding central
necrosis up-regulate the expression and secretion of VEGF, which induces vascular
hyperplasia of nearby vessels that develops in glomeruloid bodies (Figure 13) [70].
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Figure 13. Glomeruloid vascular proliferation in glioblastoma multiform.  Hypoxic
astrocytoma cells in zones surrounding central necrosis up-regulate the expression and
secretion of VEGF, which acts on nearby vessels to cause vascular hyperplasia, inducing
glomeruloid vascular proliferation.  Adapted from [70].
1.4.3.2 Macroscopic and microscopic characteristics of tumor blood vessels
The appropriate balance between activators and inhibitors is lost in tumor
angiogenesis, resulting in extensive blood vessel growth and failure to mature.
Histological examination of glioblastoma tissue reveals an architecturally specific
vasculature, different from normal brain counterparts.  Macroscopically, two main
types of vascular patterns have been described in glioblastoma [71, 72].  The
glomeruloid/garland like type, which refers to glomeruloid angiogenesis, is
characterized by unevenly distributed vascular formations.  The ‘classic’ capillary like
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vascular pattern shows irregularly shaped, dilated and tortuous vessels, with
occasional dead ends [57].  Tumor blood vessels share characteristics of venules,
arterioles and capillaries. Blood flow is irregular in tumor vessels, moving slowly,
sometimes oscillating and even flowing in reverse sense [73].  The vascular network is
often leaky and hemorrhagic [74].  The perivascular cells that are usually in contact
with endothelial cells are more loosely apposed and less abundant than in normal
vasculature [57].  Endothelial cells derived from GBM have a flat appearance, with
large nuclei, abundant cytoplasm and multiple nucleoli [75].  Normal brain endothelial
cells are smaller, with limited cytoplasm [76].
It has been proposed that vascular patterns influence clinical outcome of
patients with astroglial brain tumors [77].  However, other authors observed that poor
observer agreement on vascular patterns in patients with glioblastoma limits the
clinical utility of these factors [78].  Improved methodologies for morphologic
assessment of glioblastoma vascularization need to be identified.  In addition, regional
tumor heterogeneity may limit the clinical relevance of these histopathological
assessments [79].
1.4.3.3 Cellular characteristics of brain tumor endothelial cells
GBM-associated ECs express typical endothelial markers such as vWF,
CD105, CD31, similarly to normal ECs.  For some markers, the level of expression
and the distribution of expression varies between studies given the heterogeneity of
ECs sampled [75].  For instance, the expression of CD34, a marker for EPCs, has been
reported elevated, similar, or decreased in comparison to control ECs [75].  Expression
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of CD144 (VE-cadherin), a tight junction protein, is reduced in GBM-associated ECs
[76].  This may contribute to the leakiness of GBM’s vessels [80].  The reduced
expression of other tight junction proteins in tumor microvessels such as claudin-1,
claudin-5, and occludin may also contribute to the tumor’s leakiness [81].
Interestingly, 50% of GBM-associated ECs express α-SMA, a cytosqueletal protein
implicated in initiation of cell contraction that is mostly expressed by mural cells and
absent from control ECs [75].  Its expression may be related to tumor-associated ECs’
enhanced migratory potential.
Although some authors have found that GBM endothelial cells proliferate
faster than normal ECs [80], others have documented a slower rate of replication [75,
76].  This discrepancy might be explained by tumor vasculature heterogeneity:
endothelial cells isolated from the periphery of a tumor may proliferate more than
those obtained close to hypoxic or necrotic regions [75].  Furthermore, glioblastoma-
derived ECs were found to migrate more than those in normal brain, based on results
of modified Boyden chamber migration assays.  [76].  Glioblastoma-derived ECs also
have enhanced survival properties.  Authors have documented that these cells undergo
less apoptosis after serum starvation [76].  Migration activity and proliferative and
apoptotic activities might be mutually exclusive behaviours in tumor ECs, as was
proposed for astrocytoma cells [82].
Tumor endothelial cells also produce angiogenic growth factors [83].  Studies
have documented an increased expression of VEGF, endothelin-1 (ET-1) and
interleukin-8 (IL-8) in comparison to normal counterparts [76, 83].  Also, the
expression of VEGF receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), as well
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as that of IL-8 receptors CXCR1 and CXCR2, was documented on GBM-derived
endothelial cells [83].  Endothelial cells derived from GBM maintain angiogenic
properties, they have the capacity to form tubules [84].
1.4.4 Angiogenesis as a therapeutic target
Given the requirement of angiogenesis for growth and progression of tumors,
the tumor vasculature is an attractive target for tumor therapy.  Therapeutic vascular
targeting is of two types: anti-antiangiogenic approaches which aims to prevent
neovascularization in tumors and vascular disrupting approaches which aims to disrupt
established tumor vasculature [85], both approaches culminate in tumor cell death.
Many targets have been explored and the VEGF/VEGFR-2 signalling has been
strongly suggested as the primary target [86].  However, studies have shown that
targeting only one signalling pathway may result in the activation of alternative pro-
angiogenic pathways [86].  Therefore, targeting multiple angiogenic signalling
pathways by polyvalent inhibitors or combinations of agents with distinct
antiangiogenic properties has been attempted to optimize antiangiogenic agents [86].
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1.5 Therapeutic management of glioblastomas
1.5.1 Surgery
Depending on the clinical state of the patient and the radiological
characteristics, surgical goals should be adjusted to each patient.  Surgery should
enable to obtain a tissue diagnosis.  Although the diagnosis of a malignant glioma is
highly suspected with the presence of contrast enhancement on CT and MRI, up to
approximately 40% of malignant gliomas do not enhance following contrast injection
[87].  Given that a radiological diagnosis is not reliable, a tissue sample is required in
essentially all cases [88].  For patients in whom resection is not possible because of
advanced age, multiple or severe comorbidities, tumor location and/or extent, a biopsy
should be performed to determine the histology of the tumor [88].  Biopsies may be
performed either openly, through a mini-craniotomy or through a burr hole with
stereotaxy or neuronavigation guidance.
When surgical resection is possible, total tumor resection should be the goal.
Decreasing local tumor mass can improve neurological function, reduce steroid
dependence, and prevent early death [2].  Decrease in tumor burden has been reported
to be a significant prognostic indicator for survival.  In deed, gross-total tumor
resection is associated with longer survival in patients with GBM.  Functional
mapping has been used to maximize the extent of tumor removal and avoid injury to
cortex essential for language, motor and sensory functions.  Intraoperative magnetic
resonance guidance, fluorescence-guided surgery, and neuronavigation systems have
been used to achieve a more complete removal of deep-seated tumor than with
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conventional techniques [89].  However, the benefit of such technologies have yet to
be clearly demonstrated.
The amount of tumor remaining after surgery has been shown to be a
significant prognostic indicator for survival [90].  In addition, the post-operative
residual tumor area is an important baseline variable that affects the efficacy of
adjuvant therapies [91].
1.5.2 Radiotherapy
1.5.2.1 Overview of radiobiology
1.5.2.1.1 Types of rays
Radiations used for radiotherapy are of two types either particulate or
electromagnetic.  Particulate radiation includes electrons but also neutrons, protons,
alpha particles, heavy ions, helium ions [92].  These charged particles do not penetrate
deeply the tissue as they interact with tissue cells within the first centimetres
penetrated [93].  Photon radiation such as x-rays and gamma rays have no electric
charge and are called electromagnetic radiation.  They are generated electrically by
machines such as the linear accelerator, or produced through spontaneous
desintegration of natural or artificial radioactive material such as cobalt 60, iodine 125
[93, 94].  The unit of dose delivery in radiation therapy is the Gray (Gy), which is
defined by the amount of energy delivered to a mass of tissue.
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1.5.2.1.2 Effects of radiation: physical, cellular, tissular
Immediately after exposure, particular and electromagnetic radiations exert
their effect at the physical and cellular level.  The physical reaction is almost
instantaneous.  Energy deposition to a cell occurs very quickly, within 10-18 s, in a
random fashion [95].  Radiation causes ionization, the process by which a neutral atom
acquires a positive or negative charge.  The passage of an ionizing ray induces a series
of ionization in the atoms encountered along its trajectory.  Photon radiation is
indirectly ionizing since it is not charged and its activity depends on particles
encountered.  Electrons, protons, and alpha particles are directly ionizing: these
charged particles produce ionization by collision or repulsion within the matter [93,
94].
Following radiation indirect or direct interaction in a cell may occur [95].
Indirect interaction occurs when radiations interact with cellular water, resulting in a
hydrogen molecule and a hydroxyl free radical molecule.  If two hydroxyl molecules
recombine, they form a hydrogen peroxide. As this highly unstable molecule diffuses
throughout the cell, it may lose a hydrogen ion resulting in a peroxide hydroxyl
molecule which can combine with organic molecules, an enzyme for example, to form
a stable organic hydrogen peroxide molecule, impairing the molecule’s function [95].
These indirect interactions begin within seconds following irradiation.  On the other
hand, radiations may interact directly with cellular macromolecules such as DNA or
other proteins.  Many different types of DNA alterations may be induced within
minutes after radiation exposure such as single strand breaks, double strand breaks,
base damage of various types and DNA-protein cross-links [96].  Direct hits are
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mostly repaired with high fidelity since the undamaged strand of DNA with its
complementary base sequence can be used as a template for repair. However, the
probability of perfect repair reduces with increasing complexity or clustered damage
to DNA. Cellular damage might result in division delay and reproductive failure,
allowing time for repair of DNA [95].  Cell death may occur promptly or many
generations after IR exposure (Figure 14) [93].
Figure 14. Mechanisms of action of ionizing radiations.  Adapted from [93].
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Tissular alterations which result of cellular damage occur within a few days to
a few years after radiation exposure.  In addition to the intrinsic radiosensibility of the
tissue exposed to radiations, the length of the treatment and if it is fractionated
influence the occurrence of adverse effects.  Increasing the duration of the treatment
gives time to tissues with rapid renewal rates such as the skin or mucosa to repopulate
normal tissues and prevent acute reactions.  However, since tumors often behave like
rapidly renewing tissues they also have the opportunity to multiply.  Multiple fractions
of IR with at least 6hres between each treatment enables tissues with low renewal
rates, for example the brain, to repair the radio-induced lesions between treatments.
Most secondary effects occur in adjacent normal tissues after a certain dose of
radiation is administered (Table 6).  After this dose, the risk of developing secondary
effects due to IR increases with the total dose delivered [93].
Table 6. Total dose of irradiation tolerated by normal organs
Adapted from [93]
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1.5.2.1.3 Types of radiotherapy
Conventional, or fractionated, radiotherapy delivers a fraction of the complete
radiation dose to an involved field over many sessions.  A standard algorithm is 60 Gy
of external-beam radiotherapy delivered in 1.8 to 2.0 Gy fractions 5 times per week.
Conventional radiotherapy has been shown to prolong median survival for 6-10
months [10, 97].  Many studies have assessed the effect of dose intensification and
modified radiation profile such as hypofractionation and accelerated fractionation to
improve outcomes of patients with GBM, however results were equivalent to
conventional radiotherapy schemes [98].
Stereotactic radiosurgery (SRS) is a technique of external beam radiation that
uses convergent beams to deliver a high single dose of radiation to a small tumor
volume, limiting radiation exposure to surrounding brain.  SRS can be performed by
X-rays (linear accelerator), gamma radiation (gamma knife), and proton particles
(proton beam).  SRS followed by conventional radiotherapy and chemotherapy
(carmustine) did not improve survival of patients with GBM or quality-of life
measures [99].
Several experimental techniques are being evaluated.  Interstitial
brachytherapy, in which the radioactive source is implanted in the tumor bed, delivers
continuous low-dose radiation.  Boron Neutron capture therapy is based on the
selective uptake of boron-10, a non-radioactive isotope, by tumor cells, and the
subsequent irradiation of the area with an appropriate neutron beam.  The boron-10
desintegrates into densely ionizing particles that kill cells in proximity.
Radioimmunotherapy delivers tumor-associated radiolabelled monoclonal antibodies
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directly to the surgical cavity.  A recent study conducted in newly diagnosed patients
with malignant brain tumors treated with direct injections of (131)I-labeled anti-
tenascin monoclonal antibody into surgical cavity followed by conventional
radiotherapy and chemotherapy have shown an increase in the mean survival of GBM
patients [100].  More research is needed regarding these experimental radiotherapy
techniques.
1.5.2.2 Radiosensitivity and radioresistance
Tumors, as well as normal tissue, vary in their sensitivity to radiation.  In
addition to the intrinsic radiosensitivity of tumor cells, there are other factors that
influence a tumor’s response to radiation. Cellular oxygenation is an important factor.
Well oxygenated tumors show a greater response to radiotherapy than poorly
oxygenated tumors.  Theoretically, the oxygen can combine with free radicals formed
during ionization, producing new and toxic combinations [94].  The cell cycle also
influences response to radiation.  Quiescent cells are the most radioresistant and
proliferating cells, the most radiosensitive [93].  Increased fractionation of the total
dose protects tissues with slow renewal rate, enabling cell damage repair between
radiation sessions.  Spacing the treatments protects tissues with rapid renewal rate,
enabling cellular repopulation between sessions [93, 94].
An alternative approach involves identifying and targeting the mechanisms
responsible for tumour resistance.  Indeed, glioblastoma cells that escape the cytotoxic
effects of radiation may develop a radiation-induced resistant phenotype.  Recent
studies have proposed that GBMs’ recurrence following IR is partially mediated by an
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enhanced invasive character of radioresistant tumor cells, which makes them more
difficult to treat [101, 102].  Through radiation-induced proto-oncogene or a tumor
suppressor gene alterations, tumor cells may acquire a more malignant character.
Although DNA repair and DNA damage cell cycle checkpoint mechanisms constitute
the main defense systems for maintaining genetic integrity in the event of DNA
damage, failure of these processes can lead to destabilization of the genome with a
resultant enhancement of the rate with which deleterious modifications arise [103].
Until recently, the mechanisms underlying tumor radioresistance have
remained elusive.  Survivin, belonging to the family of inhibitor of apoptosis proteins,
has been proposed as a major factor for radioresistance in glioblastoma [104]. Its
expression has been associated with enhanced malignant potential of gliomas and
increased cell viability after IR exposure [105, 106].  Rho proteins,  more specifically,
farnesylated RhoB pathway, have been suggested as a key factor in glioblastoma
resistance to IR. Overexpression of RhoB in radiosensitive cells increased cell survival
after IR [107]. Conversely, inhibition of RhoB led to decreased glioma cell survival
[108].  Although studies have shown that the expression of RhoA and RhoB were
similar in brain tumors of grades II to IV [109], the specific role of RhoA, in
conjunction with Caveolin-1, a protein associating RhoA to endothelial caveolae-
enriched membrane domains [110, 111], had not been studied.
Recent data suggests that these high grade malignancies harbour a population
of glioma stem cells that are both radioresistant and capable of initiating tumour
regrowth.  Glioma stem cells contribute to radioresistance through preferential
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activation of the DNA damage checkpoint response and an increase in DNA repair
capacity [112].
1.5.3 Chemotherapy
1.5.3.1 Principles of CNS pharmacology and obstacles to chemotherapy
A first obstacle in chemotherapy for brain tumors is getting the drug to the
involved target, either tumor or tumor-associated endothelial cells.  Factors such as
route of administration, drug’s bioavailability, capability to cross the BBB and blood-
tumor barrier all limit the delivery of the cytotoxic drug to the brain tumor.  High-dose
chemotherapy has been tried to increase the delivery of chemotherapeutic agents but
resulted in increased systemic cytotoxicity. Infusion of chemotherapeutic agents
directly in the arterial supply of a tumor have shown encouraging responses [113].
BBB disruption achieved either with osmotic agents or modulation of specific
receptors of the BBB are experimental strategies used to circumvent the BBB [113].
A second problematic step is getting the agent to stay in the brain tumor cell
and exert its effect.  However, multiple mechanisms exist in malignant astrocytomas
to resist the effect of cytotoxic therapy.  The MDR1 (multidrug resistance) gene
encodes a protein, p-glycoprotein (Pgp), which acts as a transmembrane efflux pump
on the cytosolic membrane of neoplastic cells as well as endothelial cells of tumor
capillaries [114, 115].  Pgp in this special localization can exclude chemotherapeutic
agents from tumor cells that are located around the capillaries. This pump can actively
exclude a huge variety of lipophilic drugs from tumor cells located adjacent to
capillaries [114].
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A third obstacle is maintaining the induced damage.  The O6-methylguanine-
DNA methyltransferase (MGMT) gene codes for an excision repair enzyme removing
alkyl-groups from the O6-position of guanine, one of the targets of alkylating agents.
MGMT gene promoter is inactivated through methylation and the results in
suppression of MGMT activity.  Studies have shown that epigenetic silencing of the
MGMT gene by promoter methylation is an independent prognostic factor associated
with a significant response rate to temozolomide chemotherapy [116-118].
1.5.3.2 Description of frequently used agents
Chemotherapy is currently used either as an adjuvant, concurrent, or pre-
irradiation treatment for malignant gliomas.  The addition of standard cytotoxic
chemotherapy offers a minimal survival advantage [97, 119, 120].  Commonly used
agents can be grouped in three categories: alkalating agents, alkaloids, topoisomerase
inhibitors.
Of the alkalating agents, the nitroureas are the most frequently used and
studied agents in the treatment of malignant astrocytomas.  Carmustine and lomustine
are the two main drugs in this class.  They exert their cytotoxic effect by methylation
of DNA, generating different types of DNA adducts especially O6methylguanine, but
also N3-methylguanine and N7-methylguanine [121].  Interestingly, measuring the
level of DNA adducts following alkylation of the N7 guanine has been proposed as a
molecular dosimeter to evaluate the delivery of alkylating agents to brain tumors
[122].  Temozolomide (TMZ) is one of the newer alkylating agents that is recognized
for its complete bioavalability after oral intake and good BBB penetration [123].
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Temozolomide also generates different types of methyl adducts (70% N7-
methylguanine, 10% N3-methyladenine and 9% O6-methylguanine) [121].  Its
cytotoxic activity has been mainly attributed to the formation of O6-methylguanine
adducts.  Tumor cells’ chemosensitivity to TMZ is influenced by the functional status
of DNA repair systems, implicated either in the removal of methyl adducts from O6G
or in the apoptotic signaling triggered by O6-methylG:T mispairs [121].  Although
initially studied at GBM recurrence, a major phase III study was designed in which
newly diagnosed GBM patients were randomized to either radiotherapy alone or
radiotherapy and TMZ [124].  Median survival time was 14,6 months against 12,1
months in favor of patients receiving TMZ.  Two-year survival increased from 10,4 to
26,5% when on TMZ [124].  In view of these results, concurrent TMZ and radiation
therapy is now considered by many investigators as standard primary treatment for
newly diagnosed glioblastomas.
Of the alkaloid agents, vincristine is a cell-cycle specific agent binding to
tubulin during the S phase and inducing a metaphase arrest [2].  This agent has been
commonly administered to treat primary brain tumors, especially as part of multiagent
regimens such as PCV (Procarbazine – Lomustine – Vincristine).  However, a
randomized trial of radiotherapy alone or radiotherapy with PVC in newly diagnosed
anaplastic astrocytomas or glioblastomas failed to show significant survival benefit in
patients treated with radiotherapy and PVC [125].  Experimentally, it has been
demonstrated that vincristine has negligible penetration in normal rat brain or brain
tumor, despite intra-arterial delivery [126].  In the light of such data, some authors
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have proposed that vincristine should be withdrawn from the chemotherapeutic
options for high grade gliomas [126].
Of the topoisomerase inhibitor agents, etoposide is the most commonly used
agent.  It prevents the topoisomerase enzymes to detach from the DNA strand, which
leads to replication of defective DNA, arrest in the G2 phase and eventually apoptosis
[123].
When administered in cyclic high-dose, conventional cytotoxic
chemotherapeutic agents exert a negligible antiangionegic effect since endothelial
cells are provided enough time to repair induced damage [86].  A strategy combining
low-dose regimens of conventional chemotherapeutic agents and antiangiogenic
treatment recently showed in animal studies a marked decrease in tumor volume,
vascularity, and proliferative index, and an increased apoptosis [127].  Results of
clinical studies administering a chemotherapeutic drug, most often TMZ, and
antiangiogenic compounds such as thalidomide or interferon, seem promising [86].
53
1.6 Nutratherapy
1.6.1 Diet and cancer prevention
There are geographic and ethnic differences in the incidence of various cancers
around the world as well as trends for each population over time [128, 129].  Diet, a
modifiable factor, can play an important role either in precipitating or preventing
diseases such as cancer.  Indeed, diet-related factors are thought to account for about
30% of cancers in developed countries [129].  The association of different cancers
with diet is illustrated by the fact that the incidence patterns of cancers observed
among immigrants changes according to where they live [128].  Other environmental
and lifestyle factors such as cigarette smoking, alcohol, sun exposure, environmental
pollutants, infections, stress, obesity, and physical inactivity may also modify patterns
of cancers among immigrants [130].
Over the past 20 years, a large number of epidemiological studies, particularly
case-control and cohort studies, have been conducted to investigate the role of diet and
the risk of developing different types of cancer.  The concept of chemoprevention is to
control the occurrence of cancer by slowing, blocking, attacking, or reversing the
development of the disease by the administration of naturally occurring or synthetic
compounds [131, 132].  A review of over 200 studies found a significant protective
effect of fruit and vegetable intake against lung, colon, breast, cervix, oesophagus, oral
cavity, stomach, bladder, pancreas and ovary cancer [133].  For most cancer sites,
persons with low fruit and vegetable intake (at least the lower one-fourth of the
population) experience about twice the risk of cancer compared with those with high
intake [133].  Such observations are supported by convincing evidence of
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chemopreventive efficacy of specific dietary constituents in cellular and rodent models
of carcinogenesis.  The ultimate proof of efficacy of chemopreventive dietary
constituents will be provided through long-term phase III clinical studies.
1.6.2 Nutritional sciences
Nutratherapy, nutritional chemotherapy, is a type of chemotherapy that uses
the arsenal of anticancerous molecules naturally found in dietary constituents to
combat cancer cells.  Nutratherapy is a complementary approach that should be
integrated to the existing standard cancer treatments such as surgery, radiotherapy and
chemotherapy.
An incomplete list of some of the numerous food components that may be
important in modifying cancer risk and tumor behavior is provided in table 7 [132].
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Table 7. Partial list of bioactive food components that may influence cancer risk
and tumor behavior
Adapted from [132].
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It is probable that most bioactive food components simultaneously modify
multiple steps in the cancer process (Figure 15) [132].  Multiple variables influence
how cancer cells respond to bioactive food constituents: the fluctuations in the amount
of bioactive components in the diet, the variations in the ability of bioactive
constituents to reach or affect critical molecular targets, the presence of genetic
polymorphisms that can influence the absorption, metabolism, or sites of action of
bioactive components [132].
Figure 15.  Diet may influence genetic & epigenetic events associated with several cancer
processes.  Bioactive food components are known to influence multiple biological processes.
Determining which is most instrumental in bringing about a phenotypic change is critical to
the future of nutrition and health.  Adapted from [132].
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The advent of nutriproteomics which studies the interaction of bioactive
components with proteins [134] and nutrigenomics which studies the ability of
bioactive food constituents to modulate gene expression [135] will help better
understand how the bioactive components influence cancer.
1.6.3 Dietary polyphenolic phytochemicals
Plants interact with their environment by producing phenolic compounds as
secondary metabolites.  There are more than ten types of polyphenols, depending on
their chemical structure [136].  Flavonoids and phenolic acids account for 60% and
30% respectively of total dietary polyphenols [136].
1.6.3.1 Polyphenol catechins
Polyphenolic catechins are characterized by di- or trihydroxyl group
substitution of the B ring and meta5,7-dihydroxy substitution of the A ring of
flavanols [136].  Catechins contribute to the bitterness and astringency of food.  There
are many catechins in green tea: (-)epicatechin (EC), (-)epicatechin-3-gallate (ECG),
(-)epigallocatechin-3-gallate (EGCG), (+)catechin, and (-gallocatechin-) (GC) (Figure
16) [137].
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Figure 16. Structures of the major polyphenolic catechins present in green tea.  Reproduced
from [137].
Green tea has been shown to have many beneficial health properties.  Green tea
consumption seems to afford significant protection against Parkinson’s disease,
Alzheimer’s disease, ischemic insults [138] and cardiovascular diseases [139].  Green
tea has also shown anti-diabetic, anti-bacterial, anti-HIV, anti-aging and anti-
inflammatory activities [137].  Results of epidemiological studies assessing the effect
of green tea on chemoprevention have been inconsistent; some finding a reduced
cancer incidence and recurrence associated with green tea consumption and others
failing to show such an effect [140].  Results from in vitro and animal models have
been more convincing regarding the properties of green tea and its catechins [136].
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1.6.3.2 Epigallocatechin-3-gallate anticancerous properties
EGCG is the most abundant catechin in green tea, it accounts for 50-80% of
the total catechin content, representing 200-300 mg in a brewed cup of green tea
[141].  EGCG has been recognized as having many anticancerous properties verified
in several cell types including malignant primary brain tumors.  EGCG has exhibited
antiproliferative properties on brain tumor cells [142].  EGCG has been shown to
inhibit antiapoptotic Bcl-2-family proteins, Bcl-x(L) and Bcl-2 [143], induce apoptosis
through caspase-3 activation and poly(ADP)ribose polymerase-1 (PARP-1) cleavage
[144, 145] and induce cell cycle arrest through regulation of cyclin D1, cdk4, cdk6,
p21/WAF1/CIP1 and p27/KIP1 [145, 146].
EGCG inhibits cancer invasion and metastasis [147].  EGCG has been shown
to inhibit matrix metalloproteinases MMP-2 and MMP-9 in tumor and endothelial
cells, these enzymes play an important role in degrading the basement membrane and
facilitating cell invasion, metastasis and angiogenesis [145, 148].  Also, EGCG has
been found to inhibit the activity of urokinase-plasminogen activator (uPA), a protease
that can stimulate cell migration and angiogenesis and modulate cell adhesion [148,
149].
EGCG bears recognized antiangiogenic properties.  It can inhibit VEGF’s
promoter activity and cellular production of VEGF [150] as well as interfere with
VEGF receptor expression [151] and activity [152] in ECs.  EGCG can inhibit ECs
proliferation and induce their apoptosis, possibly by blocking VEGF induction [153].
Also, EGCG has been shown to inhibit ECs migration [154] and in vitro tubulogenesis
[152].
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EGCG has been recognized for its antioxydant properties.  Many mechanisms
have been proposed for this, including EGCG capacity to neutralize free radicals, act
as a metal chelator by binding transition metal ions such as copper and iron that would
otherwise catalyse free radical formation, and inhibit pro-oxidant enzymes with
peroxidase activity [155].  However, EGCG may in itself be pro-oxydant and induce
DNA damage [156].  EGCG exposure may induce differential oxidative environments
depending on the type of cell studied and the treatment dose [157].  It is proposed that
pathways activated by EGCG in normal epithelial versus tumor cells create different
oxidative environments, favoring either normal cell survival or tumor cell destruction
[158].  Table 8 summarizes the mechanistic findings of EGCG against tumor
development and progression [153].
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Table 8. Mechanistic findings of EGCG against tumor development and
progression
Adapted from [153].
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1.6.3.3 Mechanisms of action of EGCG
Until now, it is unknown through which cell signalling pathways EGCG exerts
its inhibitory effect on carcinogenesis.  The antitumor effects of EGCG may be due
either to binding to multiple cellular targets and subsequent inhibition of the activation
of downstream effectors or to direct targeting of intracellular signalling molecules
[131].  It has been shown that EGCG inhibits the activation of the EGFR and HER2
and multiple downstream signalling pathways such as Akt, ERK, and NFkB in various
tumors [131, 159].  Recent studies have shown that the inhibitory effect of EGCG on
tumor cell proliferation might be transduced through its binding to the 67-kDa laminin
receptor (67LR) overexpressed on the cell surface of various tumor cells [160].  More
studies are needed to better understand the cell signalling pathways and molecular
events leading to EGCG’s antitumor effect.
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1.7 Hypothesis, goals, and cellular models
1.7.1 Hypothesis
Unfortunately, even with the current standard of care management, GBM tend
to recur in proximity of the primary site in the majority of patients [161], possibly due
to the proliferation of cells that escaped the cytotoxic effects of radiotherapy.
Although the detailed mechanisms underlying GBM radioresistance remain unknown,
some molecular markers have attracted attention. Survivin, an intracellular molecule
with anti-apoptotic function, is widely expressed in human malignancies and its
expression correlates with radioresistance in several tumors, including GBM [104].
Rho proteins have been proposed to be involved in the radioresistance and IR-induced
invasiveness of primary GBM [107, 108].  Also, the use of anticancerous molecules
naturally found in dietary constituents as a complementary approach to conventional
treatment is appealing. EGCG has been recognized as having anticancerous properties
on malignant primary brain tumors.  It is possible that EGCG could sensitize GBMs’
response to radiation.  If EGCG’s radiosensitizing effect is documented on
glioblastoma U-87 cells, it might be mediated by mechanisms dependant on Survivin
and RhoA.
To verify these hypothesis, we will culture several cell lines of human high
grade astrocytoma and expose them to a single increasing IR dose.  Cell proliferation
will be analyzed by nuclear cell counting. In order to determine if IR induces a
caspase-medicated apoptotic cell death, we will perform a fluorimetric caspase-3
assay.  Our study will continue using the most radioresistant cell line of those tested
(U-87).  For the following assays, we will irradiate cells with the IR dose that will
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result in a significant decrease in cell proliferation without any caspase-3 activity.  To
assess if IR could modulate the protein expression of Survivin, RhoA and Caveolin-1,
we will perform western blot assays with cell lysates. If IR induces the expression of
Survivin, RhoA and Caveolin, we will partially mimic IR’s effect by transfecting U-87
cells with cDNA constructs encoding Survivin, RhoA and Caveolin-1.  To assess if the
overexpression of these proteins could alter U-87 cells’ sensitivity to IR exposure, we
will irradiate the transfected cells and assess their proliferation rate.  We will also
assess how EGCG influences mock and transfected cells’s proliferation.  To verify if
EGCG has the ability to modify the radioprotective effect of Survivin overexpression,
we will pretreat mock and Survivin-transfected cells with EGCG, irradiated them, and
assessed their proliferation rate.  We will assess by Western immunobloting the impact
of EGCG treatment and/or IR exposure on mock and Survivin-transfected cells to
elucidate and underlying relationship between RhoA and Survivin.
Until recently tumor cells have been recognized as the sole cellular target of
radiotherapy’s anti-cancerous effects.  However, studies have shown that ECs are also
targeted by radiotherapy [104].  Interestingly, both apoptosis and necrosis have been
documented in various cancer lines following IR exposure [104].  It is possible that
similar cell death mechanisms may be in part responsible for IR’s cytotoxic effect on
tumor-associated ECs.  Given the radiosensitizing effect of EGCG on tumor cells, this
anti-angiogenic nutrient might potentiate IR’s effect.
To verify these hypothesis we will assess HBMEC survival immediately and
48 hours after either IR with a single dose or EGCG treatment by nuclear cell counting
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and Trypan blue exclusion methods.  HBMEC survival will also be assessed 48 hours
after the combined EGCG/IR treatment.  In order to evaluate if the reduction of
HBMEC survival following the combined EGCG/IR treatment is due to a modification
of cell distribution throughout the cell cycle, we will perform a cell cycle assay by
flow cytometry.  Also, we will assess by Western immunoblotting the protein
expression of the cyclin inhibitors p21 and p27, both known to arrest cell cycle
progression, following EGCG +/- IR exposure.  To evaluate if the combined treatment
reduced cell survival by inducing apoptosis, we will analyse the pattern of DNA
fragmentation in the sub-G1 population by flow cytometry and measure the expression
of pro-apoptotic proteins caspase-3, caspase-9 and cytochrome C by Western
immunoblotting.  We will assess the relative importance of apoptosis and necrosis on
overall cell death following EGCG and/or IR treatment by flow cytometry following
annexin V-fluorescein isothiocyanate and propidium iodide.
The altered angiogenic functions and signalling pathways in radioresistant
tumor-associated ECs have not yet been investigated.  It is known that radioresistant
tumor cells present an altered malignant behavior such as an enhanced invasive
potential [104].  The Rho signalling pathway hase been proposed to be involved in IR-
induced invasiveness of primary GBM [104].  IR possibly alters resistant ECs’
capacity to migrate and form tubules.  This might be related to radioresistant ECs’
altered response to brain tumor-derived growth factors.  Modulations of the
RhoA/ROK pathway might be related to altered ECs functions.
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To verify these hypothesis, HBMEC survival will be assessed 48 hours after IR
with a single dose by nuclear cell counting and Trypan blue exclusion methods. Cell
death, including apoptosis and necrosis, will be evaluated by Annexin-V/PI staining.
Migration will be assessed in control and irradiated (10 Gy) HBMEC in response to
VEGF, S1P, or brain tumor-derived growth factors (U-87 GF).  We will examine if IR
modifies the protein expression of RhoA, ROK, and Caveolin-1 by Western
immunoblotting.  If the RhoA/ROK is activated following IR, we will partially mimic
IR’s effect by transfecting HBMEC with a cDNA construct encoding for RhoA.  We
will document migration in mock, IR, and RhoA-transfected cells in response to
agents that will have stimulated the most mock cells’ migration.  We will evaluate the
effect of inhibiting the RhoA/ROK pathway on HBMEC migration by adding to
previous conditions Y-27632, an inhibitor or ROK.  We will evaluate the capacity of
mock, IR, and RhoA-transfected cells to form capillary-like structure by Matrigel
assays.  The effect of inhibiting the RhoA/ROK on tubulogenesis will also be
assessed.
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1.7.2 Goals
The goals of this theses are:
1) To determine if EGCG, in synergy with radiotherapy, can sensitize
GBM’s response to radiation and whether specific molecular markers
are involved.
2) To characterize the impact of ionizing radiation on HBMEC survival
and to determine whether EGCG, also recognized for its anti-
angiogenic properties, could optimize this effect.
3) To investigate the effects of ionizing radiation on HBMEC angiogenic
responses, i.e. cell proliferation, migration in response to brain tumor-
derived growth factors, and capacity for tubulogenesis.
1.7.3 Cellular models used
1.7.3.1 Brain tumor-derived cell lines
The U-118, U-138, U-87 glioblastoma-derived cell lines were used as a
surrogate model for human glioblastomas.  The DAOY medulloblastoma-derived cell
line were used as a surrogate model for medulloblastoma.  The DAOY cell line was
derived from biopsy material taken from a tumor in the posterior fossa of a 4 year old
boy.  We chose to compare high grade astrocytomas response to radiotherapy with
DAOY’s given the recognized radiosensitivity of medulloblastomas[162].
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1.7.3.2 Brain-derived endothelial cell line
The HBMEC model is a surrogate model that approximates the most tumor-
derived ECs.  Although ECs have been isolated from GBM specimens [76, 163], the
primary cell cultures were found not to be suitable for long-term in vitro studies since
they de-differentiated in culture and had inherently limited proliferative potential
before senescence [164].  Although this model is not derived from glioma-associated
ECs, the HBMEC model is, to our knowledge, the closest in vitro model that can
approximate the human brain tumor-derived ECs phenotype in long term studies,
maintaining both morphological and functional characteristics of brain ECs [165].
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ABSTRACT
Introduction : Glioblastoma multiforme’s (GBM) aggressiveness is potentiated in
radioresistant tumor cells. The combination of radiotherapy and chemotherapy has
been envisioned as a therapeutic approach for GBM. The goal of this study is to
determine if epigallocatechin-3-gallate (EGCg), a green tea-derived anti-cancer
molecule, can modulate GBM’s response to ionizing radiation (IR) and whether this
involves mediators of intracellular signaling and inhibitors of apoptosis proteins.
Material and Methods : U-87 human GBM cells were cultured and transfected with
cDNAs encoding for Survivin, RhoA or Caveolin-1. Mock and transfected cells were
irradiated at sublethal single doses. Cell proliferation was analyzed by nuclear cell
counting. Apoptosis was detected using a fluorimetric caspase-3 assay. Analysis of
protein expression was accomplished by Western immunobloting.
Results : IR (10 Gy) reduced control U-87 cell proliferation by 40% through a
caspase-independent mechanism. The overexpression of Survivin induced a
cytoprotective effect against IR while the overexpression of RhoA conferred a
cytosensitizing effect upon IR. Control U-87 cells pretreated with EGCg exhibited a
dose-dependent decrease in their proliferation rate. The growth inhibitory effect of
EGCg was not antagonized by overexpressed Survivin. However, Survivin-transfected
cells pretreated with EGCg became sensitive to IR and their RhoA expression was
downregulated. A potential therapeutic effect of EGCg targeting the prosurvival
intracellular pathways of cancer cells is suggested to act synergistically with IR.
Conclusion : The radioresistance of GBM is possibly mediated by a mechanism
dependent on Survivin in conjunction with RhoA. The combination of natural anti-
71
cancerous molecules such as EGCg with radiotherapy could improve the efficacy of
IR treatments.
Abbreviations for this manuscript:
EGCg: Epigallocatechin-3-gallate
GBM: Glioblastoma multiforme
IR: Ionizing radiation
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INTRODUCTION
Glioblastoma multiforme (GBM) represents the most aggressive and invasive
primary cerebral neoplasm in the adult population. Median length of survival without
further therapy is usually less than one year from the time of diagnosis [18, 28]. When
surgical excision is considered, the goal should be gross total removal to prolong
quality survival [32]. However, the effect of surgical resection on the time to tumor
progression and the median length of survival can only be optimized when combined
with other therapies. For instance, conventional local field radiotherapy has been
shown by itself to prolong median survival for 6-8 months [23]. Unfortunately, 90% of
patients receiving radiation therapy following GBM resection still develop tumor
recurrence in the proximity of the primary site [30]. Neither whole brain irradiation
nor high focal radiation doses can decrease the incidence or change the location of
recurrences [45]. Ionizing radiation (IR)-induced alterations of the malignant behavior
are not unique to astrocytic tumors and are still poorly understood [40]. Recent studies
have reported that GBMs’ recurrence following IR is partially mediated by an
enhanced invasive character of radioresistant tumor cells, which makes them more
difficult to treat [17, 59].
Chemotherapy is thus used either as an adjuvant, concurrent, or pre-irradiation
treatment along with radiotherapy for malignant primary tumors. However, only
modest benefits in survival have been reported [23, 34, 44]. More recently the
combination of chemotherapeutic drugs such as temozolomide with molecules
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exhibiting an anti-angiogenic activity have been shown to be safe and more effective
with respect to survival than the administration of the chemotherapeutic agent alone
[9, 55]. Also attention has been focused on identifying naturally occurring substances
capable of inhibiting, retarding or reversing the multi-stage carcinogenesis process.
Recent reports have proposed that some phytochemicals can function as sensitizers,
augmenting the effectiveness of conventional radiotherapy [15, 25]. Epigallocatechin-
3-gallate (EGCg), a major anti-oxydative green tea polyphenol, has been recognized
for its anti-mutagenic and anti-carcinogenic properties [20, 48]. More recently, we
have shown that EGCg also possessed anti-angiogenic properties as it suppressed
vascular endothelial growth factor receptors functions in endothelial cells [33]. We
have also demonstrated that EGCg efficiently targeted endothelial cells that escaped
IR-induced apoptosis [6].  Whether this natural polyphenol can be used to target pro-
survival pathways involved in GBM radioresistant phenotype is unknown.
The identification of the molecular mechanisms underlying GBM
radioresistance thus becomes essential for the development of combination therapies
against this lethal condition. Survivin, along with other markers, has been proposed as
a major factor for radioresistance in glioblastoma [13]. Survivin, belonging to the
family of inhibitor of apoptosis proteins, is involved in the modulation of apoptosis [3,
16, 36, 46] in the regulation of cell growth [3, 49, 52], in the regulation of mitotic
events such as chromosomal segregation and cytokinesis [54, 57], and in the process
of angiogenesis [12, 39]. Its expression has been associated with enhanced malignant
potential of gliomas, increased cell viability after IR exposure and adverse clinical
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prognosis [14, 31]. Rho proteins, which belong to a family of small GTPases, are also
involved in the control of key cellular processes such as modulation of the
cytoskeleton, receptor internalization, or cell adhesion [7, 22, 58]. More specifically,
farnesylated RhoB pathway has been suggested as a key factor in glioblastoma
resistance to IR. Indeed, overexpression of RhoB in radiosensitive cells increased cell
survival after IR [2]. Conversely, inhibition of RhoB led to the appearance of
multinucleated cells and induced a post-mitotic cell death that led to decreased glioma
cell survival [1]. Interestingly, the same effect was observed in glioma cells
transduced with a p34cdc2 phosphorylation-defective SurvivinT34A, suggesting a link
between Survivin and Rho proteins [53]. Although studies have shown that the
expression of RhoA and RhoB were similar in brain tumors of grades II to IV [24], the
specific role of RhoA, in conjunction with Survivin, in glioma radioresistance remains
to be investigated. Caveolin-1, a protein associating RhoA to caveolae-enriched
membrane domains [26, 42], is proposed to participate in cell survival and
angiogenesis [37, 41]. The molecular implication of Caveolin-1 in glioma
radioresistance has also not yet been investigated. Hence, the goal of this study is to
determine whether EGCg can sensitize GBMs’ response to radiation and whether
specific molecular markers are involved.
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MATERIALS AND METHODS
Materials:  Agarose, (-)-epigallocatechin 3-gallate (EGCg), sodium
dodecylsulfate (SDS), gelatin, and bovine serum albumin (BSA) were purchased from
Sigma (Oakville, ON). FUGENE-6 transfection reagent was from Roche Diagnostics
Canada (Laval, QC). Mouse anti-Survivin monoclonal antibody was from Cell
Signaling Technology (Beverly, MA), mouse anti-RhoA monoclonal antibody was
from Santa Cruz Biotechnology (Santa Cruz, CA). The mouse anti-Caveolin-1
monoclonal antibody was from BD Pharmingen (Mississauga, ON) and mouse β-actin
monoclonal antibody was from Sigma. Horseradish peroxidase-conjugated donkey
anti-rabbit or anti-mouse IgG were obtained from Jackson Immunoresearch
Laboratories (West Grove, PA). BCA protein assay kit was purchased from Pierce
(Rockford, Il) and enhanced chemiluminescence (ECL)-Western blot kit from
Chemicon International (Temecula, CA). Products for electrophoresis were bought
from Bio-Rad (Mississauga, ON) and polyvinylidene difluoride (PVDF) membranes
from Boehringer Mannheim. Trypsin was from INVITROGEN (Burlington, ON).
Cell culture and cDNA transfection : The U-118, U-138, and U-87 human
glioblastoma cell lines were purchased from the American Type Culture Collection
(Manassas, VA) and were maintained in Eagle’s minimum essential medium (MEM)
containing 10% (v/v) fetal bovine serum (FBS) (HyClone Laboratories, Logan, UT), 2
mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin, and were cultured
at 37oC under a humidified atmosphere containing 5% CO2. U-87 cells were
transiently transfected with cDNA constructs using the non-liposomal FUGENE-6
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transfection reagent. The EGFP-tagged WT-Survivin cDNA construct has been
described previously [54]. The Myc-tagged WT-RhoA cDNA construct was provided
by Dr Allan Hall (London, UK). GFP-tagged WT-Caveolin-1 was provided by Dr
Sung-Soo Yoon (Sung Kyon Kwan University, Korea). Transfection efficiency was
analysed by Western blotting and fluorescent microscopy. All experiments involving
these cells were performed 36 hrs following transfection. Mock transfection of U-87
cultures with the empty pcDNA (3.1+) expression vector was used as controls.
EGCg and irradiation treatment: Cells were treated in serum-free MEM
supplemented (or not) with EGCg (3-30 µM) for 6 hours and were overlaid with
sufficient medium to subsequently provide efficient build up doses. Cells were
irradiated with a 6 MV photon beam from an Elekta SL75 linear accelerator. The
delivered radiation doses were measured using a thermoluminescence dosimetry
(TLD) system with an accuracy of 7%. After irradiation, MEM containing 20% FBS
was added and cultures were left to recuperate for 18 hours. Non-irradiated control
cells were handled similarly to the cells which were subjected to IR.
Cell proliferation assay : The extent of cell proliferation was assessed 18 hours
after irradiation. Cells were collected by gentle scraping and were resuspended in the
overlaying medium. From each probe, 150 µl homogenate was saved for nuclear cell
counting using an automatic nuclear counter and its specific reagents (New Brunswick
Scientific Co., Edison, NJ) and for cell number determination using Trypan blue for
exclusion of dead cells.
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Fluorimetric caspase-3 activity assay : U-87 cells were grown to about 60%
confluence and treated with EGGg or IR doses. Cells were collected and washed in
ice-cold PBS pH 7.0. Cells were subsequently lysed in Apo-Alert lysis buffer
(Clontech, Palo Alto, CA) for one hour at 4°C and the lysates were clarified by
centrifugation at 16,000g for 20 minutes. Caspase-3 activity was determined by
incubation with 50 µM of the caspase-3-specific fluorogenic peptide substrate acetyl-
Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin (Ac-DEVD-AFC) in assay
buffer [50 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 10% sucrose, 0,1% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate, 5 mM DTT and 1 mM
EDTA] in 96-well plates. The release of AFC was monitored for at least 30 minutes at
37 °C on a fluorescence plate reader (Molecular Dynamics) (λex= 400nm,
λem=505nm).
Immunoblotting procedures: Total protein lysates from control cells and
treated cells were separated by SDS–polyacrylamide gel electrophoresis (PAGE).
After electrophoresis, proteins were electrotransferred to polyvinylidene difluoride
membranes which were then blocked overnight at 4°C with 5% non-fat dry milk in
Tris-buffered saline (150 mM Tris, 20 mM Tris–HCl, pH 7.5) containing 0.3%
Tween-20 (TBST). Membranes were further washed in TBST and incubated with the
primary antibodies (1/1,000 dilution) in TBST containing 3% bovine serum albumin,
followed by a 1 hr incubation with horseradish peroxidase-conjugated anti-rabbit IgG
(1/10,000 dilution) in TBST containing 5% non-fat dry milk. The secondary
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antibodies were visualized by enhanced chemiluminescence and quantified by
densitometry.
Statistical data analysis : Data are representative of three or more independent
experiments. Statistical significance was assessed using Student’s unpaired t-test and
was used to compare the relative proliferation rates. Probability values of less than
0.05 were considered significant. In each figure statistically significant differences are
identified by an asterisk (*) for ECGg or IR treatment compared to control, while
double asterisk (**) is to show significance between combined EGCg/IR treatment
and either EGCg or IR treatment alone.
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RESULTS
Sublethal, low, single dose IR partially inhibits U-87 and DAOY cell
proliferation. We examined the proliferation rates of several human high grade
astrocytoma (U-138, U-118, U-87) and medulloblastoma (DAOY) cell lines in
response to increasing doses of IR (Fig.1). We observed a dose-dependent decrease of
the cell proliferation rate at increasing IR doses, up to 30 Gy. DAOY was the most
radiosensitive cell line, as the proliferation rate was decreased by 70% after 10 Gy and
by 95% after 30 Gy exposures. U-87 cells were the most radioresistant cell line when
compared to the other astrocytoma cell lines; their proliferation rate was decreased by
only 40% after 10 Gy and by 50% after 30 Gy exposures.
Sublethal, low, single dose IR inhibits U-87 cell proliferation by a caspase-
independent mechanism. In order to assess whether the decrease in cell proliferation
was due to IR-induced caspase-mediated apoptosis, we measured caspase-3 activity.
In all human astrocytoma cell lines analysed, radiation exposure up to 10 Gy did not
induce caspase-3 activity (Fig.2). However, at 30 Gy, the caspase-3 activity was
twofold increased in U-138 and U-118 cells, whereas in U-87 cells no significant
increase in caspase-3 activity was detectable. In contrast, IR induced significant
caspase-3 activity in DAOY cells even at doses as low as 3 Gy. These results
prompted us to further investigate the possible apoptosis-independent mechanisms
underlying the observed radioresistance of U-87 cells.
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Low dose IR induces the expression of prosurvival proteins in U-87 cells. We
investigated the protein expression of Survivin, RhoA, and Caveolin-1 in irradiated U-
87 cells. We selected 10 Gy as the delivered IR dose since it was associated with a
significant decrease in cell proliferation and absence of caspase-3 activity (Fig.1 and
2). After exposure to IR, Survivin expression in U-87 control cells increased 2-fold
over basal expression, while that of RhoA increased 4-fold (Fig.3a and 3b).
Interestingly, the expression of Caveolin-1, a protein regulating RhoA functions, also
increased by 4.5-fold in irradiated U-87 cells. β-actin and total Erk protein levels were
not affected by IR (Fig.3a).
Overexpression of Survivin and RhoA exhibit antagonistic effects on the
radioresistant phenotype of U-87 cells. U-87 cells were cultured to 50% confluence
and transfected with cDNA constructs encoding Survivin, RhoA, or Caveolin-1
proteins. Transfection efficiencies were assessed by the presence of GFP positive cells
in Survivin and Caveolin-1 transfectants (Fig.4a) and by immunodetection for ectopic
RhoA protein in RhoA-transfected cells (Fig.4b). Surprisingly, ectopic expression of
Survivin induced RhoA, whereas recombinant Caveolin-1 did not (Fig.4b). Mock-
transfected controls and cells either expressing Survivin, RhoA or Caveolin-1, were
then exposed to increasing doses of IR. In mock-transfected U-87 cells, we observed a
dose-dependent decrease in the cell proliferation rate (open circles) when cells were
irradiated with doses up to 30 Gy. Interestingly, the proliferation rate of U-87 cells
overexpressing Survivin (closed circles) did not decrease upon IR treatment, and
maintained a proliferation rate similar to non-irradiated cells (Fig.4c). This clearly
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demonstrates that Survivin confers resistance to irradiation. Strikingly, cells
overexpressing RhoA (closed squares) exhibited a significantly decreased cell
proliferation rate in comparison to mock U-87 cells (Fig.4c). Overexpression of RhoA
thus seems to render U-87 cells more sensitive to IR resulting in a decreased
proliferation capacity. Overexpression of Caveolin-1 (open squares) had no influence
on the U-87 cell proliferation rate (Fig 4c).
Survivin overexpression does not antagonize EGCg’s antiproliferative effect.
Recent studies have demonstrated that EGCg, a green tea-derived polyphenol, inhibits
the growth of various human cancer cell lines [8, 43, 51], particularly human
glioblastoma cells [61]. We further investigated the effect of EGCg on U-87 glioma
cell proliferation. We show that EGCg indeed inhibited cell proliferation in a dose-
dependent manner with an optimal inhibitory effect at 25 µM of more than 70%
(Fig.5a). Caspase-3 activity was measured in parallel and found not to be significantly
induced by EGCg (Fig.5a) suggesting that the inhibition in cell proliferation was not
due to apoptosis. Cells were cultured to 50% confluence and transfected with cDNAs
encoding for Survivin, RhoA, or Caveolin-1, treated with EGCg, and left to recuperate
overnight. Maximal inhibition of proliferation (35-40% of untreated cells) was
achieved with 25 µM EGCg (Fig.5b). The growth of U-87 cells overexpressing RhoA,
Survivin, and Caveolin-1 was also decreased by EGCg, similarly to the mock U-87
cells. We conclude that neither RhoA, Survivin, nor Caveolin-1 were able to fully
reverse EGCg’s antiproliferative effect. Individual, maximally inhibitory treatments
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with EGCg (25 µM) and IR (10 Gy) were also compared to show that only Survivin
was able to reverse the inhibitory effect that IR has on cell proliferation.
Effect of combined EGCg and low dose IR on U-87 glioma cells proliferation.
We studied the effect of a combined approach consisting of pre-treating U-87 cells
with EGCg followed by exposure to sublethal single IR doses on the protein
expression levels of Survivin, RhoA, and Caveolin-1. EGCg did not affect the steady
state protein levels of Survivin, RhoA and Caveolin-1 in non-irradiated cells (Fig.6a).
Interestingly, while IR induced the expression of Survivin, RhoA and Caveolin-1,
EGCg pre-treated cells showed a dose-dependent decrease in the IR-induced protein
expression of Survivin and of RhoA (Fig.6a). The protein expression levels of
Caveolin-1 were increased in cells treated with both EGCg and irradiation. The effect
of this combined treatment was further investigated with respect to RhoA expression.
U-87 cells were transfected with the Survivin cDNA, which induced RhoA expression
(Fig.4b and Fig.6b). Interestingly, this effect was reversed when Survivin-transfected
cells were treated with EGCg but not when they were exposed to IR (Fig.6b).
Consequently, the cytoprotective effect that Survivin has towards IR may, in part, be
caused by RhoA signalling, which is significantly abrogated when cells are treated
with EGCg. Most importantly, cell proliferation assays showed that the combined
EGCg/IR treatment was able to significantly decrease cell proliferation when
compared to individual EGCg or IR treatments (Fig.6c, left panel). Furthermore, the
combined EGCg/IR treatment in U-87 cells overexpressing recombinant Survivin was
able to reverse the cytoprotective effect that Survivin had towards IR (Fig.6c, right
83
panel). Prosurvival intracellular pathways might thus be targeted by EGCg, a
phytochemical that could be efficiently used as an adjunct to radiotherapy.
84
DISCUSSION
Glioblastomas multiforme (GBM) are highly invasive primary tumors of the
adult central nervous system. Although radiotherapy is routinely prescribed in the
management of high grade gliomas, its efficacy remains limited because of tumor cell
radioresistance, enhanced invasive character following radiation and resultant tumor
recurrence [17, 59]. In our study, we first analyzed the sensitivity of various human
high-grade astrocytoma- and medulloblastoma-derived cell lines to ionizing radiation
(IR). U-87 glioma cells were found to be the most radioresistant cell line, while
DAOY medulloblastoma cells were the most radiosensitive cell line tested. This is in
accordance with the reported radioresistance of glioblastoma cells [13, 17] and
radiosensibility of medulloblastoma cells [35]. Studies have indeed shown that p53-
mediated apoptosis is an important response of medulloblastomas to radiotherapy [19].
In contrast, p53 mutations are present in as much as 40-60% of GBMs [60],
suggesting that either pro-survival mechanisms or p53-independent events may
regulate their therapeutic response to IR [29].
In light of the emergence of several markers of glioma malignant progression,
the molecular characterization of GBMs’ radioresistance was next investigated.
Among these markers, Survivin has been recently related to the malignant phenotype
of gliomas as its expression is associated with glioma progression from low- to high-
grade [14, 31]. Furthermore, Survivin expression is well recognized as a predictor of
adverse clinical prognosis for patients with gliomas [14], as it increases survival of
primary GBM cell lines through its capacity to suppress caspase-mediated apoptosis
85
[13] by directly binding to caspase-9 or by interacting with smac-DIABLO [38, 47].
The effects of Survivin in our study support the lack of IR-induced growth inhibition
that we observed in GBM. Furthermore, Survivin is also implicated in the regulation
of cell division [3, 49] as it is localized in multiple components of the mitotic
apparatus and centrosomes and participates in cell cytokinesis [54, 57], a process that
involves RhoA [4]. Novel functions of Survivin have been proposed to emerge
following IR such as double-strand DNA break repair and enhancement of tumor cell
metabolism potentially mediating radioresistance [13]. In addition, some studies have
suggested that overexpression of Survivin may facilitate evasion from checkpoint
mechanisms of growth arrest and promote resistance to chemotherapeutic regiments
targeting the mitotic spindle [27]. Whether these mechanisms also regulate the
radioresistant phenotype of GBM remains to be confirmed.
Our study shows that IR exposure increases the basal expression of Survivin in
U-87 glioma cells, possibly through RhoA-mediated intracellular signaling, and that
this overexpression subsequently confers radioprotection against IR. Rho GTPases
function as molecular switches that modulate the activation of several enzymes
involved in different biological processes related to tumor progression, such as cell
growth, transcriptional regulation, and apoptosis [7, 22, 58]. Interestingly, RhoA-
induced apoptosis is independent of p53 but dependent on modulation of anti-
apoptotic proteins [21]. In our study, whether RhoA expression was induced by IR or
through cDNA cell transfection, a cytosensitizing effect was observed in U-87 cells
which resulted in a significant decrease in cell proliferation following IR. On the other
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hand, although the overexpression of recombinant Survivin also induced RhoA
expression, the resultant was rather a cytoprotective effect on cell proliferation
following IR. This paradoxal effect might be explained by post-transcriptional
modifications that would be induced by IR and that may alter RhoA’s function or
cellular distribution to specialized membrane domains. We previously reported that
RhoA is associated with caveolae-enriched membrane domains, possibly through
physical interaction with Caveolin-1 [26]. Although caveolae regulate cell survival
processes [37], we show that overexpression of Caveolin-1 induced either by IR or
cDNA cell transfection did not influence cell proliferation but may potentially have
regulated RhoA’s functions or localization. The interaction between RhoA and
Caveolin-1 in the context of IR is currently under investigation.
One of the major features characterizing high-grade radioresistant gliomas is
their infiltrating character. Recently, we showed that this phenotype might be linked to
RhoA/Rok-mediated CD44 cell surface shedding which could be targeted and
inhibited by EGCg, a green tea-derived polyphenol with anticancerous properties [5].
In light of this evidence and of recent studies which have shown that EGCg could
serve as an IR enhancer on cancer cell lines [8], we investigated whether EGCg
pretreatment prior to IR could reverse the cytoprotective effect of Survivin. We
observed that the combined EGCg/IR treatment was able to significantly decrease cell
proliferation when compared to individual EGCg or IR treatments. Furthermore, the
combined EGCg/IR treatment in U-87 cells overexpressing recombinant Survivin was
able to downregulate RhoA expression and reverse the cytoprotective effect that
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Survivin exhibited towards IR. Although the exact molecular mechanism of EGCg is
not completely understood, recent studies have shown that the inhibitory effect of
EGCg on tumor cell proliferation might be transduced through its binding to the 67-
kDa laminin receptor (67LR) [50], a protein whose expression is strongly correlated
with tumor aggressiveness [11]. Interestingly, studies have shown that through its
binding to the 67LR, EGCg may also reduce the phosphorylation of myosin II
regulatory light chain, resulting in an increase in cells in the G2/M phase of cell cycle
and ultimately in an inhibition of cell growth [56] possibly through increased cell
radiosensitivity [10].
In conclusion, we demonstrate that the growth inhibitory effect of EGCg
pretreatment efficiently antagonized both the IR-induced expression of Survivin, as
well as that of RhoA induced by overexpression of recombinant Survivin. A potential
therapeutic impact of EGCg in targeting pro-survival and RhoA-mediated intracellular
pathways in cancer cells is suggested to act synergistically with IR. We propose that
EGCg might potentiate IR’s inhibitory effect on tumor cell proliferation by increasing
the proportion of cells in a radiosensitive state. This natural phytochemical might thus
be an important molecule to consider in combined adjuvant chemotherapy and
radiotherapy.
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Fig.1 : Effects of ionizing radiation on the proliferation rates of malignant glioma
and medulloblastoma cell lines. Single dose ionizing radiation (IR) was
applied to subconfluent cells and cell proliferation rate was assessed 18 hours
after IR using an automatic nuclear counter and Trypan blue staining. Cell
proliferation is expressed as a percent of the non-irradiated (control) cell
proliferation.
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Fig.2 : Ionizing radiation effects on caspase-3 activity in malignant glioma and
medulloblastoma cell lines. Cells were grown to 60% confluence and were
exposed to a single dose of IR. A representative caspase-3 activity profile for
each cell line tested is presented and was assessed as described in the Methods
section.
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Fig.3 : Expression of prosurvival proteins in malignant glioma cells exposed to
ionizing radiation. U-87 cells were cultured and exposed to 10 Gy IR. Cell
lysates isolated from control and irradiated conditions were electrophoresed on
SDS-gels, and transferred to PVDF membranes. (A) Immunodetection of the
specific proteins was carried out as described in the Methods section. (B)
Quantification of protein expression was performed by scanning densitometry
of control, non-irradiated U-87 cells (white bars) and of irradiated cells (black
bars).
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Fig.4 : Effect of IR exposure on the proliferation rates of malignant glioma cells
transfected with proteins involved in radioresistance. U-87 cells were
transfected with cDNA constructs encoding for recombinant Survivin,
Caveolin-1 or RhoA. (A) Transfection efficiency was confirmed by fluorescent
microscopy in cells transfected with Survivin and Caveolin-1 and (B) by
Western blotting in cells transfected with RhoA. (C) A dose-dependent
decrease in the mock U-87 (open circles) proliferation rate is observed as cells
are irradiated with increasing sublethal doses. The proliferation rate of U-87
cells transfected with Survivin (closed circles), RhoA (closed squares), and
Caveolin-1 (open squares) is also shown.
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Fig.5 :Survivin overexpression does not antagonize EGCg’s antiproliferative
effect.  Subconfluent cells were exposed for 6 hours to increasing
concentrations of EGCg (0-30 µM) and cell proliferation rate (white circle) and
caspase-3 activity (black circle) were assessed following EGCg treatment as
described in the Methods section. Results are expressed as a percent of the
control untreated Mock cells (A). The proliferation rate was also assessed in U-
87 cells transfected with Survivin, RhoA or Caveolin-1 cDNAs and further
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exposed to IR (black bars) or EGCg treatment (grey bars). Cell proliferation
rate is expressed as a ratio of control untreated Mock cells (white bars).
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Fig.6 : Effect of combined EGCg and low dose IR on U-87 glioma cell
proliferation. U-87 cells were cultured and treated with EGCg (0-25 µM) for 6 hours
before IR (10 Gy) and left to recuperate overnight at 37°C. (A) Cell lysates of each
condition were electrophoresed on SDS-gels and immunodetection was carried out as
described in the Methods section. (B) Mock or Survivin-transfected U-87 cells were
also treated with either EGCg (upper panel) or IR (lower panel) and RhoA
immunodetection performed in cell lysates. (C) Cell proliferation was performed in
Mock and Survivin-transfected cells that were either treated with EGCg, irradiated
(IR), or which were submitted to combined EGCg/IR treatment.
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ABSTRACT
The microvasculature of brain tumors has been proposed as the primary target
for ionizing radiation (IR)-induced apoptosis. However, the contribution of low dose
IR-induced non-apoptotic cell death pathways has not been investigated. This study
aimed to characterize the effect of IR on human brain microvascular endothelial cells
(HBMEC) and to assess the combined effect of epigallocatechin-3-gallate (EGCg), a
green tea-derived anti-angiogenic molecule. HBMEC were treated with EGCg,
irradiated with a sublethal (≤10Gy) single dose. Cell survival was assessed 48 hours
later by nuclear cell counting and Trypan blue exclusion methods. Cell cycle
distribution and DNA fragmentation were evaluated by flow cytometry (FC), cell
death was assessed by fluorimetric caspase-3 activity, FC and immunoblotting for pro-
apoptotic proteins. While low IR doses alone reduced cell survival by 30%, IR
treatment was found more effective in EGCg pretreated-cells reaching 70% cell death.
Analysis of cell cycle revealed that IR induced cell accumulation in G2-phase.
Expression of cyclin-dependent kinase inhibitors p21(CIP/Waf1) and p27(Kip) were
increased by EGCg and IR. Although random DNA fragmentation increased by
approximately 40% following combined EGCg/IR treatments, the synergistic
reduction of cell survival was not related to increased pro-apoptotic caspase-3,
caspase-9 and cytochrome C proteins. Cell necrosis increased five-fold following
combined EGCg/IR treatments while no changes in early or late apoptosis were
observed. Our results suggest that the synergistic effects of combined EGCg/IR
treatments may be related to necrosis, a non-apoptotic cell death pathway. Strategies
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sensitizing brain tumor-derived EC to IR may enhance the efficacy of radiotherapy
and EGCg may represent such a potential agent.
Abbreviations for this manuscript:
EC: Endothelial cells
EGCg: epigallocatechin-3-gallate
GBM: Glioblastoma multiforme
HBMEC: Human brain microvascular endothelial cells
HUVEC: Human umbilical vein endothelial cells
IR: Ionizing radiation
VEGF: Vascular endothelial growth factor
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INTRODUCTION
Malignant gliomas, especially glioblastomas multiforme (GBM), are among
the tumors most resistant to radiotherapy and chemotherapy [1]. Even in the group
with the best prognosis, the median survival rarely passes 1 year [2, 3]. Malignant
gliomas are also amongst the most intensively vascularized solid tumors [4]. The
process of angiogenesis is essential for tumor progression from microscopic cell
clusters, receiving nutrients and oxygen by passive diffusion, to macroscopic foci
supplied by blood vessels [5]. Furthermore, malignant gliomas become more
angiogenic with increasing tumor grade, suggesting that the vascular component plays
an important role in their malignant progression [6]. Indeed, GBMs’ cell proliferation,
invasiveness and necrosis, three facets of gliomas’ malignant phenotype, are directly
related to brain tumor microvasculature [7].
Radiotherapy is a widely used adjuvant therapy for malignant brain tumors [1]
and is believed to exert its anti-cancerous effects by targeting tumor cells [8, 9].
However, recently, it has been proposed that IR might prevent tumor growth or cause
tumor regression by targeting tumor vasculature [10]. Indeed, studies have shown that
radiotherapy can selectively target endothelial cells (EC) and associated angiogenesis
of residual tumor [7]. Tumor-associated EC have a proliferation rate up to 20 times
greater than the proliferation rate of normal vasculature [11], rendering them more
radiosensitive than non-dividing cells [12]. In addition, EC are generally well
oxygenated, which makes them more radiosensitive than poorly oxygenated tumor
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cells because the oxygen present at the time of radiation may contribute to the
formation of cytotoxic molecules and prevent the reversal of some chemical changes
[12, 13]. Many investigators have found that IR exposure induces apoptosis in EC [14-
17], and that this event precedes tumor cell apoptosis [18]. The occurrence of EC
death following IR is a critical factor for both tumor survival following IR and for
tumor growth. While toxic insults or physical damage have been found to initiate
cellular necrosis [19], the impact of IR-induced cellular damage resulting in non-
apoptotic pathways such as necrosis has not been yet investigated in EC.
Targeting tumor-associated EC as part of cancer treatments is an appealing
prospect. Antiangiogenic agents have been used successfully in combination with IR
to increase the therapeutic efficacy of radiation exposure [20, 21]. Only recently have
the EC been considered not only the target of antiangiogenic agents but also of IR and
therefore a powerful new potential treatment target in highly vascularized tumours
such as glioblastoma [4]. Recent reports have proposed that some naturally occurring
phytochemicals can function as sensitizers, augmenting the effectiveness of
conventional radiotherary [22-24]. Epigallocatechin-3-gallate (EGCg), a green tea-
derived molecule, has been recognized as having many biochemical functions
including inhibition of tumor cell growth [8, 24], cell cycle arrest [25-27], induction of
apoptosis [24, 28, 29], inhibition of invasion and metastasis [30, 31] and inhibition of
angiogenesis [29, 32]. Moreover, we have shown that EGCg suppressed vascular
endothelial growth factor (VEGF) receptor function in EC [33] and that EGCg
efficiently targeted human EC that escaped IR-induced damage [34]. Whether this
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natural polyphenol can be used to potentiate IR effects on human brain EC is
unknown. Although the human brain microvascular endothelial cells (HBMEC)
model, used in this study, is a surrogate model that only approximates tumor-derived
EC, it is to our knowledge, the closest in vitro model that can approximate the human
brain tumor-derived EC phenotype in long term studies. The goal of this study is thus
to characterize the impact of irradiation on HBMEC and to determine whether EGCg
can optimize this effect.
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MATERIALS AND METHODS
Materials: (-)-epigallocatechin 3-gallate (EGCg), sodium dodecylsulfate (SDS)
and bovine serum albumin (BSA) were purchased from Sigma (Oakville, ON). Mouse
anti-p21 monoclonal antibody, rabbit anti-p27 polyclonal antibody and rabbit anti-
Caspase-9 polyclonal antibody were from Cell Signaling Technology (Beverly, MA),
rabbit anti-Caspase-3 polyclonal and mouse anti-cytochrome C monoclonal antibody
were from BD Pharmingen (Mississauga, ON) and mouse anti-GAPDH monoclonal
antibody was from Advanced Immunochemical Inc. (Long Beach, CA). Horseradish
peroxidase-conjugated donkey anti-rabbit or anti-mouse IgG were obtained from
Jackson Immunoresearch Laboratories (West Grove, PA). BCA protein assay kit was
purchased from Pierce (Rockford, IL) and enhanced chemiluminescence (ECL)-
Western blot kit from Chemicon International (Temecula, CA). Products for
electrophoresis were bought from Bio-Rad (Mississauga, ON) and polyvinylidene
difluoride (PVDF) membranes were from Boehringer Mannheim. Trypsin was from
Invitrogen (Burlington, ON).
Cell culture: Human brain microvascular endothelial cells (HBMEC) were
generated and characterized by Dr Kwang Sik Kim from the John Hopkins University
School of Medicine (Baltimore, MD). These cells were positive for factor VIII-Rag,
carbonic anhydrase IV, Ulex Europeus Agglutinin I, took up fluorescently labelled
acetylated low-density lipoprotein and expressed gamma glutamyl transpeptidase,
demonstrating their brain EC specific phenotype [35]. HBMEC were immortalized by
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transfection with simian virus 40 large T antigen and maintained their morphologic
and functional characteristics for at least 30 passages [36]. HBMEC were maintained
in RPMI 1640 (Gibco, Burlington, ON) supplemented with 10% (v/v) fetal bovine
serum (FBS) (HyClone Laboratories, Logan, UT), 10% (v/v) NuSerum (BD
Bioscience, Mountain View, CA), modified Eagle’s medium nonessential amino acids
(1%) and vitamins (1%) (Gibco), heparin (5 U/ml) (Gibco), sodium pyruvate (1 mM),
L-glutamine (2 mM) (Gibco), EC growth supplement (30 µg/ml), 100 units/ml
penicillin and 100 µg/ml streptomycin. Culture flasks were coated with 0.2% type-I
collagen to support the growth of HBMEC monolayers. Cells were cultured at 37oC
under a humidified atmosphere containing 5% CO2. All experiments were performed
using passages 15 to 28.
EGCg and irradiation treatment: Cells were treated in serum-free RPMI
supplemented (or not) with 3-30 µM EGCg for 6 hours and were overlaid with
medium. Cells were irradiated with a 6 MV photon beam from an Elekta SL75 linear
accelerator. The delivered radiation doses were measured using a thermoluminescence
dosimetry (TLD) system with an accuracy of 7%. After irradiation, serum free
medium was replaced by RPMI containing 10% FBS and 10% NuSerum and cultures
were left to recuperate for 48 hours. Non-irradiated control cells were handled
similarly to the cells which were subjected to EGCg and/or IR treatments.
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Cell survival assay: The extent of cell survival was assessed at either 1 or 48
hours after irradiation. Cells were collected by gentle scraping and were resuspended
in the overlaying medium. From each experimental sample, 150 µl homogenate were
reserved for nuclear cell counting using an automatic cell counter (New Brunswick
Scientific Co., Edison, NJ). Viable cell number determination was also assessed using
Trypan blue dye solution for exclusion of dead cells.
Analysis of cell cycle by flow cytometry: Distribution of HBMEC throughout
the cell cycle was assessed by flow cytometry 48 hours after EGCg and/or IR
treatments. No serum-fasting preparation was performed prior to analysis and
therefore the cell populations were asynchronous. Cells were harvested by gentle
scraping, pelleted by centrifugation, washed with ice-cold PBS + EDTA (5 mM), then
resuspended in 1 volume PBS/EDTA and fixed with 100% ethanol overnight. Three
volumes of staining solution, containing propidium iodide (50 µg/ml) (Sigma) and
DNAse-free RNAse (20 µg/ml), were added. The fraction of the population in each
phase of the cell cycle was determined as a function of the DNA content using a
Becton Dickinson FACS Calibur flow cytometer equipped with CellQuest Pro
software. In particular, the characteristics of cell distribution in the sub-G1 region
were studied on the DNA histogram.
Fluorimetric caspase-3 activity assay: HBMECs were grown to 60%
confluence and treated with EGGg and/or exposed to IR. Cells were collected and
washed in ice-cold PBS pH 7.0. Cells were subsequently lysed in Apo-Alert lysis
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buffer (Clontech, Palo Alto, CA) for one hour at 4°C and the lysates were clarified by
centrifugation at 16,000g for 20 minutes. Caspase-3 activity was determined by
incubation with 50 µM of the caspase-3-specific fluorogenic peptide substrate acetyl-
Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin (Ac-DEVD-AFC) in assay
buffer [50 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 10% sucrose, 0,1% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate, 5 mM DTT and 1 mM
EDTA] in 96-well plates. The release of AFC was monitored for at least 30 minutes at
37°C on a fluorescence plate reader (Molecular Dynamics) (λex= 400nm, λem=505nm).
Immunoblotting procedures: Cell lysates were separated by
SDS–polyacrylamide gel electrophoresis (PAGE). After electrophoresis, proteins were
electrotransferred onto polyvinylidene difluoride membranes which were then blocked
overnight at 4°C with 5% non-fat dry milk in Tris-buffered saline (150 mM Tris, 20
mM Tris–HCl, pH 7.5) containing 0.3% Tween-20 (TBST). Membranes were then
washed in TBST and incubated with the primary antibodies (1/1,000 dilution) in
TBST containing 3% bovine serum albumin, followed by a 1 hr incubation with
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (1/2500 dilution) in
TBST containing 5% non-fat dry milk. The secondary antibodies were visualized by
ECL and quantified by densitometry.
Analysis of apoptosis by flow cytometry: Cell death was assessed 48 hours after
irradiation by flow cytometry. Cells floating in the supernatant and adherent cells
harvested by trypsin solution were gathered to produce a single cell suspension. The
116
cells were pelleted by centrifugation and washed with PBS. Then, 2x105 cells were
pelleted and suspended in 200 µL of buffer solution and stained with annexin V-
fluorescein isothiocyanate (FITC) and propidium iodide (PI) as described by the
manufacturer (BD Bioscience). The cells were diluted by adding 300 µL of buffer
solution and processed for data acquisition and analysis on a Becton Dickinson FACS
Calibur flow cytometer using CellQuest Pro software. The X- and Y-axes indicated
the fluorescence of annexin-V and PI respectively. It was possible to detect and
quantitatively compare the percentages of gated populations in all of the four regions
delineated. In the early stages of apoptosis, phosphatidylserine is translocated to the
outer surface of the plasma membrane, which still remains physically intact. As
annexin-V binds to phosphatidylserine but not to PI, and the die is incapable of
passing the plasma membrane, it is excluded in early apoptosis (annexin-V+/PI-). Cells
in late apoptosis are stained with annexin-V and PI (annexin-V+/PI+). Necrotic cells
have lost the integrity of their plasma membrane and are predominantly stained with
PI (annexin-V-/PI+).
Statistical data analysis: Data are representative of three or more independent
experiments. Statistical significance was assessed using Student’s unpaired t-test and
was used to compare the relative proliferation rates. Probability values of less than
0.05 were considered significant. In each figure the statistically significant differences
are identified by an asterisk (*) for EGCg or IR treatment compared to control, while a
double asterisk (**) shows significance between combined EGCg/IR treatment and
either EGCg or IR treatment alone.
117
RESULTS
Combined EGCg treatment and ionizing radiation exposure reduce HBMEC
survival. We examined HBMEC survival in response to either EGCg treatment or IR
exposure. Cell survival was assessed immediately after EGCg treatment or 48 hours
after recuperation in medium with serum. Immediately after EGCg treatment, there
was a dose-dependent decrease in cell survival with increasing EGCg concentrations,
reaching a maximum effect of 30% decrease at 30 µM EGCg (Fig.1A, left panel,
white circles). In contrast, 48 hours after treatment, cells had recovered from the
EGCg treatment and no effect could be observed at this time on cell survival (Fig.1A,
left panel, black circles). HBMEC survival was also assessed after exposure to single
IR doses, either immediately or after 48 hours recovery. We found that low IR doses
had no effect on cell survival assessed 1 hour after IR (Fig.1A, right panel, white
circles). On the contrary, 48 hours after IR exposure, cell survival was reduced by
30% at 10 Gy and by 40% at 30 Gy (Fig.1A, right panel, black circles). Interestingly,
HBMEC pretreated with 10 µM EGCg and exposed to a 10 Gy single IR dose showed
a 70% reduction in cell survival 48 hours after IR exposure (Fig.1B). Therefore,
combined EGCg/IR treatments synergistically reduced cell survival.
The reduction of HBMEC survival following combined EGCg/IR treatment is
not due to changes in cell cycle phases. Cell cycle distribution was assessed in
HBMEC which had been treated with 10 µM EGCg and/or irradiated at single low
doses (≤ 10 Gy) and then left to recuperate in medium with serum for 48 hours. We
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employed a 10 µM EGCg treatment concentration and used 10 Gy as the delivered IR
dose since the combination of these treatment levels was associated with a synergistic
decrease in cell survival 48 hours after treatments (Fig.1B). Discrete modulations of
cell cycle phase distribution were observed in cells pretreated for 6 hours with low
concentrations of EGCg (Fig.2, lower left panel). On the opposite, cell cycle phase
analysis of irradiated HBMEC showed a significant accumulation of cells in G2M
phase (Fig.2, upper right panel) and identical results were found when cells were
treated with combined EGCg/IR (Fig.2, lower right panel).
Expression of the cyclin kinase inhibitors p21 and p27 is separately induced by
EGCg and IR treatments. We investigated the protein expression of the cyclin kinase
inhibitors p21(CIP/Waf1) and p27(Kip), known to arrest cell cycle progression by
inhibiting G1-S and G2-M transitions [37-39] (Fig. 3A and B). IR exposure (10 Gy)
increased the expression of cyclin kinase inhibitors p21 and p27 2.4-fold over basal
expression (Fig.3B). In addition, 10 µM EGCg treatments also induced a 2.4-fold
increase in the p21 and p27 proteins (Fig.3B). However, the combination of EGCg/IR
treatments did not further modulate p21 and p27 expression. GAPDH protein levels
were not affected by EGCg treatment and/or IR exposure (Fig.3A).
IR-induced DNA random fragmentation increases following combined
EGCg/IR treatment. Forty-eight hours after treatment with EGCg and/or IR, we
assessed cell cycle distribution in HBMEC. The characteristics of cell distribution in
the sub-G1 region were studied on the DNA histogram obtained by flow cytometry
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(Fig.2). Instead of observing only a distinct peak in the sub-G1 region representing
apoptotic cells, we found an increase evenly distributed across the same region,
suggesting the presence of randomly degraded DNA, a phenomenon representative of
necrosis as established in the literature [40]. Quantification of the gated population
found in the sub-G1 region revealed that IR and combined EGCg/IR treatments
induced a 2-fold and almost 3.5-fold increase, respectively, in the sub-G1 population
as characterized above (Fig.4). These results prompted us to further investigate
whether apoptosis might contribute to the decrease in cell survival.
IR-induced caspase-dependant mechanisms are not increased by EGCg
pretreatment. In order to assess whether the decrease in cell survival was due to
increased cell death through apoptosis, we measured the expression of pro-apoptotic
proteins caspase-3, caspase-9 and cytochrome C. No significant increases in the
expression of these pro-apoptotic proteins or in that of the housekeeping protein
GAPDH were observed following combined EGCg/IR treatments as compared to
basal expression (Fig.5A). We also assessed apoptosis by measuring caspase-3 activity
48 hours after EGCg treatment and/or IR exposure. Although exposure to EGCg
slightly induced caspase-3 activity at 10 µM, IR induced a significant dose-dependent
increase in caspase-3 activity (Fig.5B, left panel). EGCg pre-treatment did not
modulate the IR-induced caspase-3 activity (Fig.5B, right panel). We next examined
whether the decrease in cell survival was rather due to increased cell death through
necrosis.
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Combined EGCg/IR treatments increase HBMEC necrosis. HBMEC treated
with EGCg and/or IR and left to recuperate for 48 hours were harvested and stained
with annexin-V and propidium iodide as described in the Methods section.
Quantification of the population distribution throughout the four areas revealed that no
significant increase occurred in early (Fig.6A, lower right quadrant) or late apoptosis
(Fig.6A, upper right quadrant) in EGCg-treated, irradiated cells as compared to control
cells. However, cell necrosis (Fig.6A, upper left quadrant) increased 5-fold following
combined EGCg/IR treatments (Fig.6B). These results suggest that non-apoptotic
pathways such as necrosis might contribute to the decrease in cell survival following
combined EGCg/IR treatments and could explain the decrease in HBMEC survival.
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DISCUSSION
We have recently shown that IR decreases in vitro cell proliferation of
malignant glioma cells derived from highly vascularized brain tumors [8].
Furthermore, we also demonstrated that EGCg can enhance the effects of IR on these
same cells by potentiating the decrease in cell proliferation [8]. Interestingly,
malignant gliomas’ proliferation, invasiveness and necrosis are directly related to their
microvasculature [7]. Therefore tumor-associated EC represent a potential new
treatment target. IR is capable of inducing cellular injuries to EC in vitro and in vivo
[10, 14-16, 34]. However, little is known about EC injury occurring after radiation
exposure and even less is known regarding EGCg’s capacity to enhance the effects of
IR on HBMEC. In the present study, we therefore characterized the impact of IR on
HBMEC and tested whether EGCg could optimize this effect.
The HBMEC model used in this study is a surrogate model that approximates
tumor-derived EC. Although one must recognize that this model does not represent
glioma-derived EC, it is to our knowledge the closest in vitro model that can
approximate the human brain tumor-derived EC phenotype in long term studies. Until
recently, molecular impacts on brain microvasculature functions were in fact
extrapolated from studies mostly performed on human umbilical vein EC (HUVEC)
[34] or bovine aortic EC (BAEC) [41]. However, microvascular EC, such as brain EC,
display a selective phenotype which differs from macrovascular EC [35]. Recently,
isolation of human EC from glioblastoma specimens was achieved [42, 43].
122
Unfortunately, primary cell cultures were found not to be suitable for long-term in
vitro studies since they de-differentiated in culture and had inherently limited
proliferative potential before senescence [44]. The HBMEC model thus represents a
stable in vitro model since they maintain both morphological and functional
characteristics of brain EC, as well as an increased proliferation rate due to their
transformation with the simian virus 40 large T antigen [36]. Noteworthy, HUVEC
immortalized with SV40 antigens and the catalytic subunit of human telomerase
overexpress the tumor endothelial marker-1/endosialin which is regarded as the most
differentially expressed molecule in tumor-derived endothelium versus normal-derived
endothelium [45]. Therefore the fact that HBMEC were immortalized by transfection
with SV40 allows us to further approximate the molecular impact of our study to those
cells that would have acquired some transformed phenotype in the GBM tumor
microenvironment.
To investigate the mechanism responsible for the synergistic EGCg/IR
decrease in cell survival we first assessed changes in the cell cycle. It has been firmly
established that IR results in prolongation of the cell cycle, including delays or arrests
in the G1, S and G2 phases[46-49], and induction of cyclin inhibitor p21(cip/waf)
[37]. Interestingly, p21(cip/waf) and p27(kip) have also been recognized as effectors
of cell cycle arrest at the G1-S and G2-M phases of the cell cycle [37-39]. Similarly,
EGCg has been shown capable of inducing G1-phase arrest of cell cycle in many cell
lines [25-27], depending on the concentration and the duration of treatment. Several
studies have indeed recognized that EGCg treatment induces p21 [25-27] and p27
123
expression [26, 50]. Interestingly, p21 may exhibit an antiapoptotic or proapoptotic
effect depending on the conditions inducing its expression [51]. In our study, pre-
treatment with low concentrations of EGCg (≤ 10 µM) during a short period of time (≤
6 hours) did not affect the IR-induced G2-M and G1-S transition arrests nor the
overexpression of cyclin kinase inhibitor proteins. Therefore the cell cycle changes
cannot account for the synergistic survival decrease of cells pretreated with EGCg and
subsequently irradiated.
Recently, a study of total body irradiation in mice showed that the proportion
of EC undergoing apoptosis in a population of cells was 20% after 12 hours [16]. In
light of these findings, we sought to determine whether apoptosis-mediated cell death,
a late event which eliminates cells with irreparable DNA damage, could account for
the synergistic EGCg/IR effect. We showed that low dose IR induced only moderate
caspase-3 activity, and that HBMEC exposure to EGCg did not induce significant
caspase-3 activity nor did it modulate IR-induced, caspase-dependent mechanisms.
Although the late stage of apoptosis is associated with secondary necrotic cell death,
primary necrotic cell death may occur in the absence of apoptotic parameters [52]. The
possible contribution of non-apoptotic pathways, such as necrosis, was next
investigated. We found that random DNA fragmentation, assessed by sub-G1 cell
distribution, increased significantly following IR exposure and, more importantly, this
effect was enhanced by combined EGCg/IR treatments. Although no significant
increase in cell necrosis was observed in HBMEC treated with either EGCg or IR, the
combined treatments did increase cell necrosis. These results suggest that the cell
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death pathways leading to necrosis may explain the synergistic effect of EGCg/IR
treatments.
It is well recognized that IR is capable of inducing both apoptosis and necrosis
in various tumor cell lines [52, 53]. Many factors may influence the importance of
necrosis following IR. Studies have shown that necrosis is induced in tumor cells
following exposure to high irradiation doses [53-55]. However, it has also been shown
that human promyeloctytic leukemia cells, irradiated with 50 Gy, died early, primarily
by apoptosis while cells irradiated with 10 Gy died later, predominantly by necrosis
[56]. The effect of time after radiation is controversial and probably depends on many
additional factors. Some authors report that rapid cell death occurs primarily through a
non-apoptotic pathway [57, 58] while others observe a dose-related increase in
necrosis with some delay after exposure [23]. Furthermore, human lymphocytes
exposed to X-rays for up to 20 Gy displayed no necrosis at 4 hours post-IR. Although
cell death was explained through apoptosis in short-term culture (4 hours), the
proportion of apoptotic cells did not match the increase in cell death with increasing
radiation. The authors explained this discrepancy as being due to prolongation of the
apoptotic process [59]. In long-term cultures, a combination of apoptosis and necrosis
was apparent and explained the decrease in viability [59]. The kinetics of appearance
of both apoptotic and necrotic cells in irradiated tumors is most probably influenced
by cell cycle progression and by cell loss. In addition, treatment of cancer cells with
chemotherapeutic agents and IR resulted in an increase in the necrotic component of
cell death [60]. For example, combined treatment of a melanoma human cell line with
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radiation and with camptothecin, a topoisomerase I inhibitor with significant
anticancer activities, induced significantly more necrotic than apoptotic cell death
[60]. Interestingly, simultaneous exposure of a human leukaemic cell line, EOL-1, to
high concentrations of EGCg (50 µM) and IR (0-8 Gy) resulted in a synergistic
decrease in cell proliferation and a synergistic increase in apoptosis and necrosis[23].
Interestingly, EGCg bears recognized antiangiogenic properties. Many
mechanisms have been proposed for this, including decreased production of VEGF by
tumor cells, interfering with VEGF receptor activity [33] and expression [32], and
altering endothelial morphogenesis and cellular functions [33]. Therefore, VEGF
survival signalling might be inhibited by EGCG, which could partially explain the
enhanced results of combining radiotherapy and antiangiogenesis agents [61].
Furthermore, EGCg has been shown to sensitize various tumor cell lines to radiation
and to augment the effectiveness of radiotherapy [8, 23, 24]. EGCg has also been
shown to induce apoptosis in a variety of cell lines including EC lines, but at doses
ranging from 20-100 µM over various time periods [29, 34, 62]. In our study, because
EGCg pre-treatment did not, by itself, induce apoptosis or potentiate IR-induced
apoptosis, increased apoptosis cannot explain the synergistic EGCg/IR decrease in cell
survival.
In summary, brain tumor-associated EC represent a powerful cancer treatment
target especially in highly vascularized tumors such as GBM [4]. Although the
HBMEC model used in the present study does not represent glioma-derived EC, it is
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to our knowledge the closest in vitro model that can approximate the human brain
tumor-derived EC phenotype in long term studies. The combination of EGCg and IR
treatments resulted in a synergistic delayed anti-survival effect that could be accounted
for by an increase in necrosis. It can be envisioned that strategies sensitizing brain
tumor vasculature to low dose IR may thus enhance the efficacy of radiotherapy.
Therefore, EGCg represents a potential agent for sensitizing brain EC to radiotherapy,
possibly by potentiating IR’s necrotic effect.
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Fig.1 : Effects of EGCg treatment or ionizing radiation exposure on HBMECs’
survival. A) Subconfluent HBMEC were either treated with EGCg for 6 hours
in serum-free medium or exposed to a single dose of ionizing radiation (IR).
Cell survival was assessed immediately after (white circles) and 48 hours after
(black circles) individual treatments using an automatic nuclear cell counter
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and Trypan blue staining. Cell survival is expressed as percent of the non-
treated and non-irradiated (control) cell survival. B) HBMEC survival assessed
48 hours after combined EGCg (10 µM)/IR (10 Gy) treatments. Probability
values of less than 0.05 were considered significant, and an asterisk (*)
identifies such significance against untreated control. A double asterisk (**)
identifies significant probability values of less than 0.05 in irradiated
conditions.
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Fig.2 : Ionizing radiation’s influence on HBMEC cell cycle phase distribution is
not modulated by EGCg pre-treatment. Cells were harvested 48 hours
following 10 _M EGCg and/or 10 Gy IR treatments and cell cycle was
analyzed by flow cytometry as described in the Methods section.
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Fig.3 : Induction of cyclin kinase inhibitors p21 and p27 by EGCg treatment and
IR. A) Subconfluent HBMEC were treated with EGCg (10 _M) and/or
irradiated at 10 Gy, left to recuperate at 37°C for 48 hours and then harvested.
Cell lysates of each condition were electrophoresed on SDS-gels and
immunodetection was carried out as described in the Methods section. B)
Results from a representative experiment were normalized to GAPDH
expression. Quantification of p21 and p27 protein expression was performed
by scanning densitometry of samples from control cells and from HBMEC
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treated with EGCg and/or IR. Probability values of less than 0.05 were
considered significant, and an asterisk (*) identifies such significance against
untreated control.
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Fig.4 :Combined EGCg and ionizing radiation treatements increased sub-G1
population. Forty-eight hours after EGCg and/or IR treatments, cell cycle was
assessed by flow cytometry, with specific attention to the sub-G1 region.
Although IR (10 Gy) treatment induced 2.25-fold induction of the sub-G1
region content, combined EGCg (10 _M)/IR (10 Gy) treatments induced a
3.25-fold induction, suggesting that cell death is increased. Probability values
of less than 0.05 were considered significant, and an asterisk (*) identifies such
significance against the respective non-irradiated conditions. A double asterisk
(**) identifies significant probability values of less than 0.05 in irradiated
conditions.
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Fig.5 : IR-induced caspase-dependant mechanisms are not increased by EGCg
pre-treatment. A) HBMEC were treated with 10 _M EGCg and/or exposed to
a single 10 Gy IR dose. Cells were left to recuperate for 48 hours and were
harvested. Cell lysates were electrophoresed on SDS-gels and
immunodetection was carried out for caspase-3, caspase-9, and cytochrome C
as described in the Methods section. B) In the left panel, caspase-3 activity was
measured as described in the Methods section, on harvested cells after EGCg
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treatment (black circles) or single radiation exposure (white circles). In the
right panel, caspase-3 activity is shown for cells treated with various doses of
EGCg and then followed (white circles) or not (black circles), with 10 Gy IR
exposure.
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Fig.6 : Cell necrosis significantly increases following EGCg/IR combined
treatments. Cell apoptosis and necrosis were analyzed, 48 hours after 10 µM EGCg
and/or 10 Gy IR treatments, by flow cytometry after double staining with Annexin V
and propidium iodide as described in the Methods section. A) Lower left quadrant
represents viable cells; lower right quadrant, early apoptosis; upper right quadrant, late
apoptosis; upper left quadrant, necrosis. B) Bar graph illustrates the quantification
performed on each quadrant from A). Probability values of less than 0.05 were
considered significant, and an asterisk (*) identifies such significance against
untreated control. A double asterisk (**) identifies significant probability values of
less than 0.05 in irradiated conditions.
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ABSTRACT
Introduction: Radioresistant brain tumor vasculature is thought to hamper the
efficiency of adjuvant cancer therapies. However, little is known regarding the
signalling pathways involved in the angiogenic response to brain tumor-derived
growth factors in irradiated human brain microvascular endothelial cells (HBMEC).
The goal of this study is to assess the effect of ionizing radiation (IR) on HBMEC
survival, migration and tubulogenesis.
Methods: HBMEC were cultured and irradiated at sublethal single doses. Cell
survival was assessed by nuclear cell counting and flow cytometry. HBMEC
migration in response to brain tumor-derived growth factors (U-87 GF) and
tubulogenesis were assayed using modified Boyden chambers and Matrigel,
respectively.
Results: We observed that single administration of 3-10 Gy IR doses only reduced
cell survival by 30%. Radioresistant HBMEC overexpressed RhoA, a small GTPase
protein regulating cellular adhesion and migration, and Rho-kinase (ROK), a serine-
threonine protein kinase and one of RhoA’s major targets. HBMEC migration was
induced by vascular endothelial growth factor (VEGF), but even more so in response
to sphingosine-1-phosphate (S1P) and to U-87 GF. Following IR exposure, HBMEC
basal migration increased more than two-fold, whereas the response to S1P and to U-
87 GF was significantly diminished. Similarly, the inhibitor of ROK Y-27632
decreased HBMEC migration in response to S1P and U-87 GF. Overexpression of
RhoA decreased tubulogenesis, an effect also observed in irradiated HBMEC.
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Conclusion: Our results suggest that radioresistant HBMEC migration response to
tumor-secreted growth factors and tubulogenesis are altered following IR. The
RhoA/ROK signalling pathway is involved in the IR-altered angiogenic functions and
may represent a potential molecular target for enhancing the impact of radiotherapy on
tumor-associated endothelial cells.
Abbreviations for this manuscript:
EC: Endothelial cells;
GBM: Glioblastoma multiforme
HBMEC: Human brain microvascular endothelial cells
HUVEC: Human umbilical vein endothelial cells
IR: Ionizing radiation
PDGF: Platelet-derived growth factor
ROK: Rho-kinase
S1P: Sphingosine-1-phosphate
U-87 GF: Brain tumor-secreted growth factors
VEGF: Vascular endothelial growth factor
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INTRODUCTION
Glioblastoma multiform (GBM) represents the most common but also the most
lethal primary cerebral neoplasm in the adult population.1 In fact, median length of
survival rarely exceeds one year after diagnosis.1,2 From the highly cellular rim of
viable tumor which surrounds the necrotic core, GBM cells infiltrate the adjacent
cerebral tissue.3 Although single invasive glioma cells do not solely depend on tumor-
associated angiogenesis, the growth of primary GBM and the development of a
recurrent mass critically depends on neovascularisation. This explains why malignant
gliomas are amongst the most intensively vascularized solid tumors.4
The process of tumor angiogenesis begins with increased vessel permeability
via degradation of basement membrane by proteases secreted by activated endothelial
cells (EC), which migrate and proliferate, leading to the formation of solid EC sprouts
into the stroma.5,6 This process is regulated by a host of growth factors such as the
vascular endothelial growth factor (VEGF) or the platelet-derived growth factor
(PDGF). These are produced either by the tumor itself or by infiltrating inflammatory
cells.5,7,8 It is noteworthy that several studies have recently defined platelet
phospholipids as potential angiogenic factors, most notably sphingosine-1-phosphate
(S1P), which is released by activated platelets as well as by glioblastoma cells9 and
which is a very potent EC chemoattractant.10,11
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Radiotherapy is generally believed to exert its anti-cancerous effects by
targeting tumor cells.12 To this end, we have shown that ionizing radiation (IR)
decreases in vitro cell proliferation of malignant glioma cells.13 Paradoxically, the
glioma cells that resist the acute cytotoxic effects of radiation may acquire an
increased migratory potential and enhanced invasiveness.14,15 It was recently
suggested that IR prevents tumor growth by directly targeting tumor vasculature and
inducing pro-apoptotic and necrotic processes.16-20 It is recognized that both single-
dose and fractionated radiotherapy induce EC damage.21 Interestingly, endothelial
apoptosis and microvascular dysfunction contribute more significantly to tumor cell
lethality by the single-dose approach (8-10 Gy) than the low-dose exposures to
fractionated therapy (1-3 Gy) since adaptive responses are simultaneously induced in
the latter regiment.21 Surprisingly, EC can also survive single radiation exposure
similarly to cancer cells, in part due to of the tumor-derived microenvironment in
which the phenotypic and functional properties of the EC differ from those of normal
brain EC.22 The signaling pathways and altered angiogenic functions in radioresistant
human brain EC have not yet been investigated.
The Rho signalling pathway has been proposed to be involved in the
radioresistance and IR-induced invasiveness of primary GBM.13,23,24 Rho GTPase
proteins function as molecular switches that modulate the activation of enzymes
involved in different biological processes related to tumor progression, such as cell
proliferation, apoptosis, cytoarchitecture, adhesion, migration, cell polarity, and
transcriptional regulation.25,26 The roles of Rho proteins in the cell motility and cell
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morphology of EC have only recently begun to be uncovered.26,27 The role(s) of this
pathway in the functional properties of radioresistant EC has not yet been assessed. To
our knowledge the human brain microvascular endothelial cell (HBMEC) model used
in this study is the closest in vitro model for approximating the human brain tumor-
derived EC phenotype in long term studies.
The goal of our study is to investigate the effects of IR on HBMEC angiogenic
responses, i.e. cell survival, 3D tubulogenesis, and migration in response to VEGF,
S1P and to human glioblastoma cell-derived growth factors. The RhoA/ROK
signalling pathway was also investigated in relation to the adaptive properties of
radioresistant HBMEC.
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MATERIALS AND METHODS
Materials: Sodium dodecyl sulfate (SDS), bovine serum albumin (BSA) and
S1P were purchased from Sigma (Oakville, ON). Lipofectamine-2000 transfection
reagent and trypsin were from Invitrogen (Burlington, ON). Mouse anti-RhoA and
anti-ROK monoclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA), mouse anti-Caveolin-1 monoclonal antibody was from BD Pharmingen
(Mississauga, ON) and mouse anti-GAPDH monoclonal antibody was from Advanced
Immunochemical (Long Beach, CA). Horseradish peroxidase-conjugated anti-mouse
IgG was obtained from Jackson Immunoresearch Laboratories (West Grove, PA).
BCA protein assay kit was purchased from Pierce (Rockford, IL) and enhanced
chemiluminescence (ECL)-Western blot kit from Chemicon International (Temecula,
CA). Products for electrophoresis were obtained from Bio-Rad (Mississauga, ON) and
polyvinylidene difluoride (PVDF) membranes were from Boehringer Mannheim
(Laval, QC). Human recombinant VEGF (isoform 165) was produced and purified as
previously described.28 Y-27632 was purchased from Calbiochem (San Diego, CA).
Cell culture and cDNA transfection method: Human brain microvascular
endothelial cells (HBMEC) were obtained from Dr Kwang Sik Kim (John Hopkins
University School of Medicine, Baltimore, MD).  These cells were positive for factor
VIII-Rag, carbonic anhydrase IV, Ulex Europeus Agglutinin I, took up fluorescently
labelled, acetylated low-density lipoprotein and expressed gamma glutamyl
transpeptidase, demonstrating their brain EC specific phenotype.29 HBMEC were
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immortalized by transfection with simian virus 40 large T antigen and maintained their
morphological and functional characteristics for at least 30 passages.30 HBMEC were
maintained in RPMI 1640 (Gibco, Burlington, ON) supplemented with 10% (v/v) fetal
bovine serum (FBS) (HyClone Laboratories, Logan, UT), 10% (v/v) NuSerum (BD
Bioscience, Mountain View, CA), modified Eagle’s medium nonessential amino acids
(1%) and vitamins (1%), heparin (5 U/ml), sodium pyruvate (1 mM), L-glutamine (2
mM), EC growth supplement (30 µg/ml), 100 units/ml penicillin and 100 µg/ml
streptomycin.  Culture flasks were coated with 0.2 % type-I collagen to support the
growth of HBMEC monolayers. Cells were cultured at 37oC under a humidified
atmosphere containing 5% CO2. All experiments were performed between cell
passages 16 and 28. HBMEC were transiently transfected with the Myc-tagged WT-
RhoA cDNA construct generously provided by Dr. Allan Hall (University College
London, London, UK). All experiments involving these cells were performed 36 hours
following transfection. Mock transfection of HBMEC cultures with empty pcDNA
(3.1+) expression vector was used as a control.
Irradiation treatment: Cells were irradiated with a 6 MV photon beam from an
Elekta SL75 linear accelerator. The delivered radiation doses were measured using a
thermoluminescence dosimetry (TLD) system with an accuracy of 7%. During
irradiation, cells were in RPMI containing 10% FBS and 10% NuSerum.
Radioresistant cells were allowed to recuperate for 48 hours. Non-irradiated control
cells were handled similarly to those which were subjected to IR treatment.
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Cell survival assay: Cells were collected by gentle scraping and were
resuspended in the overlaying medium. From each experimental sample, 150 µl of cell
suspension were saved for nuclear cell counting using an automatic cell counter (New
Brunswick Scientific Co., Edison, NJ). Viable cell number determination was also
assessed using Trypan blue dye exclusion. Cells stained dark blue were not considered
viable. Cell survival data are expressed as a mean value for at least four independent
experiments.
Analysis of apoptosis/necrosis by flow cytometry: Cell death was assessed 48
hours after irradiation by flow cytometry. Cells floating in the supernatant and
adherent cells harvested by trypsin solution were gathered to produce a single cell
suspension. The cells were pelleted by centrifugation and washed with PBS. Then,
2x105 cells were pelleted and suspended in 200 µL of buffer solution and stained with
annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) as described
by the manufacturer (BD Bioscience). The cells were diluted by adding 300 µL of
buffer solution and processed for data acquisition and analysis on a Becton Dickinson
FACS Calibur flow cytometer using CellQuest Pro software. The X- and Y-axes
indicated the fluorescence of annexin-V and PI respectively. It was possible to detect
and quantitatively compare the percentages of gated populations in all of the four
regions delineated. In the early stages of apoptosis, phosphatidylserine is translocated
to the outer surface of the plasma membrane, which still remains physically intact. As
annexin-V binds to phosphatidylserine but not to PI, and the die is incapable of
passing the plasma membrane, it is excluded in early apoptosis (annexin-V+/PI-). Cells
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in late apoptosis are stained with annexin-V and PI (annexin-V+/PI+). Necrotic cells
have lost the integrity of their plasma membrane and are predominantly stained with
PI (annexin-V-/PI+).
Analysis of HBMEC migration:  HBMEC migration was assessed using
modified Boyden chambers. The lower surfaces of Transwells (8-_m pore size; Costar,
Acton, MA) were pre-coated with 0.2% type-I collagen for 2 hours at 37°C. The
Transwells were then assembled in a 24-well plate (Fisher Scientific Ltd, Nepean,
ON). The lower chamber was filled with serum-free HBMEC medium or growth
factor-enriched conditioned medium isolated from 48 hours serum starved-U-87
human glioblastoma cells (U-87 GF). Control HBMEC or cells exposed to IR were
collected by trypsinization, washed and resuspended in serum-free medium at a
concentration of 106 cells/ml and 105 cells were then inoculated onto the upper side of
each modified Boyden chamber. The plates were placed at 37°C in 5% CO2/95% air
for 30 minutes after which VEGF (50 ng/ml), S1P (10 µM), or Y-27632 (10 µM) (an
inhibitor of Rho-kinase (ROK)) were added to the lower chambers of the Transwells.
Migration then proceeded for 20 hours at 37°C in 5% CO2/95% air. Cells that had
migrated to the lower surface of the filters were fixed with 10% formalin phosphate
and stained with 0.1% crystal violet-20% methanol (v/v). Images of at least five
random fields per filter were digitized (100X magnification). The average number of
migrating cells per field was quantified using Northern Eclipse software (Empix
Imaging Inc., Mississauga, ON). Migration data are expressed as a mean value of at
least four independent experiments.
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Endothelial cell morphogenesis assay: Tubulogenesis was assessed using
Matrigel aliquots of 50 _L, plated into individual wells of 96-well tissue culture plates
(Costar, Amherst, MA) and allowed to polymerize at 37°C for 30 minutes. After brief
trypsination, control or irradiated HBMEC were washed and resuspended at a
concentration of 106 cells/ml in serum-free medium. Next, 25 _L of cell suspension
(25,000 cells/well) and 75 _L of serum with medium were added into each culture
well. Cells were allowed to form capillary-like tubes at 37°C in 5% CO2/95% air for
20 hours. The structures formed within the Matrigel were digitized and quantified
(100X magnification). For each experiment, four randomly chosen areas were
quantified by counting the number of tubes formed. Tubulogenesis data are expressed
as a mean value of at least three independent experiments.
Immunoblotting procedures: Cell lysates were separated by
SDS–polyacrylamide gel electrophoresis (PAGE). After electrophoresis, proteins were
electrotransferred onto polyvinylidene difluoride membranes which were then blocked
overnight at 4°C with 5 % non-fat dry milk in Tris-buffered saline (150 mM NaCl, 20
mM Tris–HCl, pH 7.5) containing 0.3 % Tween-20 (TBST). Membranes were then
washed in TBST and incubated with the primary antibodies (1/1,000 dilution) in
TBST containing 3 % BSA, followed by a 1 hr incubation with horseradish
peroxidase-conjugated anti-mouse IgG (1/2,500 dilution) in TBST containing 5 %
non-fat dry milk. The secondary antibodies were visualized by ECL and quantified by
densitometry.
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Statistical data analysis: Data are representative of three or more independent
experiments. Statistical significance was assessed using Student’s unpaired t-test and
was used to compare migration and extent of capillary-like structure formation to
mock non-irradiated HBMEC migration and tube formation. Probability values of less
than 0.05 were considered significant and are indicated by an asterisk (*).
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RESULTS
Ionizing radiation reduces HBMEC survival. HBMEC survival to increasing
doses of IR was first examined. Subconfluent cells were exposed to single doses of IR
and the cell survival was assessed 48 hours after exposure to IR using flow cytometry
(Fig.1A) and trypan blue dye exclusion (Fig.1B). We observed a dose-dependent
decrease in cell survival (lower left quandrants in Fig.1A) that was quantified by up to
40% at 30 Gy. (Fig.1B, left panel). Induction of significant cell death was also
observed with increasing IR doses, as 10-30 Gy induced a combined
necrosis/apoptosis of 4-10-fold over control (Fig.1B, right panel). The appearance of a
heterogeneous cellular morphology (100X magnification) was also apparent at 10-30
Gy confirming some cell death (Fig.1C). These observations suggest that
approximately 60-70% cells escaped the IR-induced cytotoxic effect and potentially
exhibited some radioresistant phenotype. This sub-population was further analyzed for
the rest of our study.
HBMEC migration in response to pro-angiogenic factors is diminished in
radioresistant cells. EC migration in response to pro-angiogenic stimuli is a feature of
angiogenesis. Several reports have previously shown that both tumor-derived VEGF
and the angiogenic, platelet–derived S1P stimulated brain EC migration.9,31,32
Therefore we assessed cell migration of control and irradiated HBMEC. A single 10
Gy radiation dose was found to trigger a significant 2.15-fold increase in HBMEC
migration (Fig.2). As expected, basal migration of control HBMEC was increased by
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1.75-fold in response to VEGF (50 ng/ml), 2.5-fold with S1P (10 µM) and 4.4-fold
with U-87 GF. Interestingly, the pro-migratory effect of S1P tended to decrease in
irradiated HBMEC, while it was significantly abrogated in response to U-87 GF
(Fig.2).
Single dose IR induces the expression of RhoA, ROK and Caveolin-1. We
previously found that a single IR dose induced the expression of RhoA, a small
GTPase protein regulating cellular adhesion, migration and invasion,25 in
radioresistant U-87 malignant glioma cells.13 Therefore we examined, in irradiated
HBMEC, expression of the RhoA protein, expression of ROK (a serine-threonine
protein kinase known to be one of RhoA’s major targets) and the expression of
Caveolin-1, a protein associating RhoA to endothelial caveolin-enriched membrane
domains33, which are proposed to participate in cell survival and angiogenesis.34 After
exposure to 10 Gy IR, a 2-fold increase was observed in RhoA expression, while that
of ROK increased by 1.5-fold (Fig.3A&B). Interestingly, the expression of caveolin-1
also significantly increased by 1.6-fold after IR, while that of the house-keeping
protein GAPDH remained unaffected.
Inhibition of RhoA signalling pathway diminishes HBMECs’ response to pro-
angiogenic factors. In order to partially mimic the RhoA/ROK-activated signalling
pathway of irradiated cells, HBMEC were transfected with the cDNA construct
encoding for RhoA protein. Transfection efficiency was confirmed by
immunodetection for ectopic RhoA protein in RhoA-transfected cells (Fig.4A). Mock,
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irradiated and RhoA-transfected HBMEC were inoculated onto the upper side of each
Transwell and migration proceeded as described in the Methods section. Both IR and
overexpression of RhoA significantly increased basal HBMEC migration by 1.75-fold
and 2.6-fold, respectively (Fig.4B). We further studied the migration of RhoA-
transfected HBMEC in the presence of the two most potent pro-angiogenic conditions
used, namely, S1P and U-87 GF. The migration of HBMEC which overexpressed
recombinant RhoA increased respectively 3.2-fold and 6.4-fold in response to S1P and
U-87 GF (Fig.4B, black bars), relatively to mock cells in the absence of added
stimulatory agent. Whereas RhoA-transfected HBMEC exhibit increased migration, as
reflected with a RhoA-transfected/Mock ratio of 2.6, their migration response was
lower showing a ratio of 1.26 for S1P and 1.46 for U-87 GF. Indeed, RhoA-
transfected HBMEC present a weaker migration response to pro-angiogenic agents but
irradiated HBMEC’s migration response is abrogated. (Fig.2 and 4). This suggests that
other signalling pathways, in addition to the RhoA pathway, may be implicated in
mediating the altered angiogenic functions of radioresistant HBMEC. We also
assessed the effect of inhibiting the RhoA/ROK signalling pathway on HBMEC
migration. The addition of Y-27632, an inhibitor of ROK, into the lower chamber of
the Transwells did not affect the migration of control HBMEC but significantly
decreased that of RhoA-transfected cells as well as decrease the migration of
irradiated HBMEC as compared to cells untreated with the ROK inhibitor. The
addition of Y-27632 to S1P and CM U-87 significantly inhibited mock, irradiated and
RhoA-transfected HBMECs’ migration response to these angiogenic agents.
162
IR and RhoA overexpression decrease HBMEC in vitro tubulogenesis. We next
investigated HBMEC’s capacity to form tube-like structures on Matrigel. Matrigel is a
reconstituted basement membrane containing various growth factors including basis
fibroblast growth factor, platelet-derived growth factor, transforming growth factor
beta, epidermal growth factor and insulin-like growth factor 1.35 In a first series of
experiments, irradiated and RhoA-transfected HBMEC were seeded on Matrigel and
allowed to form capillary-like tubes. While non-irradiated HBMEC were capable of
forming an extensive network of thin tubules (Fig.5A), these capillary-like structures
were decreased in irradiated and RhoA-transfected HBMEC by 50% and 42%,
respectively (Fig.5B). Tubules formed under these conditions presented aggregated
cells with heterogeneous tubule thickness and diameter (Fig.5A). Therefore HBMEC
that overexpress RhoA or that survive IR present a decreased tubulogenesis potential.
Moreover, we assessed the inhibitor of ROK, Y-27632, on tubulogenesis. Mock,
irradiated and RhoA-transfected HBMEC were resuspended in medium containing Y-
27632 and were seeded on Matrigel. In the presence of Y-27632, mock HBMEC’s
capacity to form tubes was completely abolished (Fig.5A&B). Furthermore, although
the inhibitor of RhoA/ROK pathway completely disrupted the abnormal tubes formed
by radioresistant HBMEC, it partially reversed the abnormal appearance of tubes
formed by RhoA-transfected HBMEC (Fig.5A&B). Indeed, small diameter tube-like
structures were observed in HBMEC overexpressing recombinant RhoA and treated
with the RhoA/ROK inhibitor (Fig.5A&B).
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DISCUSSION
Until recently, research on the effects of IR on malignant gliomas was
primarily focused on the cancer cells themselves. Although IR suppressed neoplastic
glial cell proliferation,13,36,37 inhibited cell cycle progression36 and triggered cell
death,38 radiotherapy not only still fails to eradicate all tumour cells, but paradoxically
enhances glioblastoma cells invasive potential.14,15 On the other hand, the effects of IR
on the cerebral vascular compartment have been far less documented. It has been
suggested that the microvascular damage induced by IR might regulate the tumor
response to further radiation and therefore mediate the sensitivity of tissues to
radiotherapy, especially in single-dose regiments.21,39 In fact, IR is thought to exert
antiangiogenic effects on EC of various origins such as human umbilical vein EC
(HUVEC).19,40,41 It should be noted that HUVEC immortalized with SV40 antigens
and the catalytic subunit of human telomerase overexpress the tumor endothelial
marker-1/endosialin, which is regarded as the most differentially expressed molecule
in tumor-derived endothelium versus normal endothelium.42 Therefore, the fact that
HBMEC were immortalized by transfection with SV40 allows us to further
approximate the molecular impact of our study on cells that would have acquired some
transformed phenotype in the GBM tumor microenvironment. The HBMEC model
used in this study is a surrogate model that approximates tumor-derived EC. To our
knowledge, it is the closest in vitro model that can approximate the human brain
tumor-derived EC phenotype in long term studies.20
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We have recently shown that IR decreases in vitro HBMEC cell survival
through altered cell cycle progression and induction of apoptosis and necrosis.20 In
fact, that study was the first to report a dose response to IR in HBMEC.20 Although
EC dysfunction has been observed following fractionated 1-3 Gy therapy, the
endothelial damage induced by single 8-10 Gy dose radiotherapy has been reported to
induce greater tumor cell lethality.21 Given the variability of radiation regiments
applied in clinical practice, one can envision EC to be exposed to different total
radiation doses administered in a single or multiple fractions.43 Noteworthy, EC
response to IR in mouse and human tumor specimens displayed an apparent threshold
at 8-10 Gy21 supporting the doses range of our current study. Therefore, the ability of
IR to damage HBMEC at doses relevant to clinical radiotherapy suggests that
targeting EC may contribute to the overall anti-cancerous effect of radiotherapy.16-20
Since each tumor capillary vascularizes hundreds of tumor cells, targeting
tumor vasculature should potentiate the anti-tumorigenic effect of radiation. However,
similar to tumour cells, EC can escape IR effects. The signalling pathways through
which EC are protected against IR have only begun to be investigated and the
activation of the phosphoinositide-3-kinase (PI3-K)-Akt-Bcl-2 survival pathway has
been recently suggested.44,45 The impact of IR exposure on the angiogenic functions of
surviving human brain tumor-derived EC has not previously been investigated.
Here we investigated the specific impact of IR on HBMEC, which approximate
human brain tumor-derived EC, with a focus on migration and tubulogenesis. Initial
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characterization of HBMEC migration revealed induction by VEGF and S1P.
However, the strong migration response induced by S1P, in comparison to VEGF,
suggests that this factor induces agonist-specific regulation of EC angiogenic
responses.46 The HBMEC migration response was even greater in the presence of U-
87 GF, which contains numerous pro-angiogenic growth factors and cytokines
secreted by malignant brain tumors. Radioresistant HBMEC had an increased basal
migration potential in comparison to non-irradiated HBMEC consistent with our
previous observations on irradiated HUVEC.19 The IR-induced migration of HBMEC
correlates with their increased expression of RhoA and caveolin-1, both known to
regulate EC migration.19,47
Interestingly, although radioresistant HBMEC have an increased migration
potential, their response to angiogenic factors, including VEGF, S1P and U-87 GF,
was attenuated, especially in the presence of U-87 GF. Furthermore, tubulogenesis
capacity was also decreased in irradiated HBMEC. The reported effects of IR on
tubulogenesis vary widely as some studies reported that IR increased tube formation19,
while others reported decreased tube formation.40,48 This discrepancy may reflect cell
type specificity and differences in experimental conditions, notably the maximum IR
dose and the time elapsed from radiation to the time that tubulogenesis was assessed.
It is established that tumors can regulate the responsiveness of their associated
EC by secreting growth factors, cytokines and mitogens.39 The induction of
angiogenic factors has also been proposed to be part of the tumors-associated EC
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response to IR-induced stress.49,50 It has been documented that IR of the tumor cell
compartment may induce the co-expression of VEGF40,51,52 and of its receptors51 and
stimulate the expression of PDGF.53 Irradiated HUVEC and human dermal
microvascular EC showed up-regulation of VEGF receptor-2.40 IR may also result in
increased phosphorylation of tyrosine residues in the cytoplasmic domain of receptor
tyrosine kinases, which serve as docking sites for signalling entities of downstream
pathways.54,55 Therefore, radioresistant HBMEC angiogenic functions, namely
migration response to chemoattractants and tubulogenesis, may be attenuated due to
alterations in downstream signaling pathways. Although some EC escape radiation’s
cytotoxicity, they respond weakly to growth factors required for tumor expansion and
angiogenesis. This probably contributes to IR’s capacity to stabilize or reduce tumor
cell burden.
The Rho signalling pathway has been reported to be involved in the
radioresistance of glioblastomas.13,23,24 Rho, Rac and Cdc42 have been shown, in vitro,
to affect multiple aspects of cell behavior relevant to tumorigenicity.25 RhoGTPases
are critical not only for tumor cells but also for EC shape changes and for the adhesion
dynamics that drive migration.26,56,57 Although the RhoA/ROK signaling pathway may
be activated in radioresistant HBMEC, a balance in the RhoA/ROK pathway may be
crucial in regulating EC functions.27,57 Tubulogenesis in control and irradiated
HBMEC may be diminished by ROK inhibitors if the resultant balance of RhoA/ROK
expression is negative. However, tube formation of RhoA-transfected cells may be
partially re-established by RhoA/ROK inhibitors if the balance tends toward
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equilibrium. Other pathways may also be involved in mediating the altered angiogenic
functions of radioresistant HBMEC as one can acknowledge the limitations of the well
characterized and specific pharmacological inhibitors used in our study. Specific gene
silencing using siRNA, combined to dominant negative molecule approaches, will
ultimately provide further evidence on the alternate pathways involved. Our data
however strongly suggest that the RhoA/ROK signaling pathway plays an important
role in the response of tumor-associated EC to IR.
Collectively, our data suggest that IR significantly alters crucial steps of
angiogenesis, namely cell proliferation, migration and tubulogenesis in radioresistant
HBMEC. Response to growth factors important for tumor expansion and angiogenesis
is significantly attenuated in radioresistant HBMEC. These functional alterations
probably contribute to IR’s capacity to stabilize or reduce tumor cell burden. We
propose that the RhoA/ROK signalling pathway may be involved in mediating the IR-
induced altered angiogenic functions. This pathway might represent a potential
molecular target for enhancing the impact of radiotherapy on tumor-associated EC.
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Fig.1 : Ionizing radiation decreases HBMEC survival. Subconfluent HBMEC were
exposed to single doses of ionizing radiation of different strengths (IR). A)
Cell survival was assessed 48 hours after IR exposure by using Annexin-V/PI
staining and trypan blue exclusion (B) as described in the Methods section.
Cell survival data are expressed as a mean value of at least three independent
experiments. Error bars represent standard deviation of values. C) Pictures of
adherent HBMEC were taken 48 hours after IR.
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Fig.2 : Ionizing radiation inhibits HBMECs’ migratory response to brain tumor-
derived growth factors. Control and irradiated (10 Gy) HBMEC were seeded
on type-1 collagen-coated filters, allowed to adhere for 30 min and migration
performed as described in the Methods section in the presence or absence of
VEGF (50 ng/ml), S1P (10 µM), or U-87 GF. Migration data are expressed as
a mean value for the relative migration rate from at least four independent
experiments. Error bars represent standard deviation of values.
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Fig.3 :Ionizing radiation induces RhoA, ROK and Caveolin-1 expression in
radioresistant HBMEC. Subconfluent HBMEC were irradiated at 10 Gy, left
to recuperate at 37°C for 48 hours and then radioresistant cells were harvested.
Cell lysates from each condition were electrophoresed on SDS gels and (A)
immunodetection was carried out as described in the Methods section. B)
Quantification of RhoA, ROK and Caveolin-1 protein expression was
performed by scanning densitometry of samples from control and from
irradiated HBMEC. Protein expressions were normalized to GAPDH
expression.
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Fig.4 :  Inhibition of RhoA/ROK signalling pathway produces similar diminution
in migration responses of RhoA-transfected and of irradiated HBMEC. A)
HBMEC cultured at 70% confluence were transfected with the Myc-tagged
WT-RhoA cDNA construct. The transfection efficiency was confirmed by
Western blotting and immunodetection for anti-RhoA as described in the
Methods. Endogenous RhoA was detected after a 30 second exposition and
recombinant RhoA after a 2 minute exposition. B) RhoA-transfected (RhoA
Tx) and irradiated (IR, 10 Gy) HBMEC were seeded on type-1 collagen-coated
filters and allowed to adhere for 30 min. Migration was performed for 20 hours
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in the presence or absence of S1P (10 µM), U-87 GF or Y-27632 (10 µM).
Migration data are expressed as a mean value of at least four independent
experiments. Error bars represent standard deviation of values.
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Fig.5 : Ionizing radiation and RhoA overexpression decrease HBMEC capacity to
form tubes in vitro. HBMEC were seeded on Matrigel and allowed to form
capillary-like tubes at 37°C for 20 hours in the presence or absence of Y-27632
(10 µM). A) The formation of capillary-like structures was examined
microscopically and pictures (100X magnification) were taken. A
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representative experiment is presented. B) Capillary-like structures were
quantified as described in the Methods section. For each experiment, four
randomly chosen areas were quantified by counting the total number of well
formed tubes. Tubulogenesis data are expressed as a mean value of at least
three independent experiments. Error bars represent standard deviation of
values. (*) represents statistical significance with respect to untreated mock
cells, while (**) statistical significance between untreated and Y-27632-treated
cells in mock, IR-treated cells, and in RhoA-transfected cells.
CHAPTER V. DISCUSSION
5.1 Summary
In chapter II, we documented that IR induced the expression of Survivin and
RhoA in U-87 human glioblastoma cells.  U-87 cells transfected with the Survivin
cDNA induced a cytoprotective effect against IR and induced RhoA expression.
However, when Survivin-transfected cells were treated with EGCG, cells were
rendered sensitive to IR and their RhoA expression was downregulated.  The
radioresistance of GBM may in part be mediated by a mechanism dependent on
Survivin in conjunction with RhoA, which is abrogated with EGCG treatment.
In chapter III, we showed that although IR could reduce cell survival of
HBMEC, radiation exposure was most effective in EGCG pre-treated cells.  The
synergistic effects of combined EGCG/IR treatments were related to increased cell
necrosis, a non-apoptotic cell death mechanism.  In chapter IV, we demonstrated that
IR induced the expression of RhoA/ROK pathway in HBMEC.  Irradiated or RhoA-
transfected HBMEC presented an increased migration capacity.  However, their
response to angiogenic factors was decreased, especially in irradiated cells suggesting
that other pathways, in addition to the RhoA/ROK pathway, may contribute to altered
functions of radioresistant ECs.  Regarding tubulogenesis, IR and RhoA-transfected
cells presented a decreased capacity to form tubules.  The decreased tubulogenesis was
partially overcome in RhoA-transfected cells treated with Y-27632, an inhibitor of the
RhoA-ROK pathway.  This also suggests that other pathways possibly contribute to
defective tubulogenesis following IR.  Therefore, radioresistant HBMEC present
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altered angiogenic functions and the RhoA-ROK pathway equilibrium may be
involved in ECs’ response to IR.
5.2 Discussion
5.2.1 Radioresistance of cells
Radiotherapy is routinely administered in the management of GBMs.
However, its efficiency remains poor mostly because of tumor cell radioresistance,
acquired enhanced invasive character following radiation and resultant tumor
recurrence [101, 102].  Numerous signalling pathways have been proposed to
contribute to GBM’s radioresistance.  Our studies showed that radioresistance of
GBM may in part be mediated by a mechanism dependent on Survivin in conjunction
with RhoA signalling.  Following IR, Survivin and RhoA expression increased in U-
87 cells.  Rho proteins have been identified as an immediate-early gene activated
following DNA damage [166]. Authors have documented a biphasic activation of the
RhoA/ROK signalling pathway following IR [167].  The initial burst accounts for the
rapid cytoskeletal remodelling.  The second peak corresponds to the sustained
contractile cell phenotype [167].  Activation of Rho proteins may be mediated through
ligand interactions with growth factor or integrin receptors.  Therefore, IR may induce
RhoA by enhancing the production of growth factor [168, 169].  Rho signalling
pathway may also be activated through IR-induced ROS that trigger signal
transduction pathways leading to the activation of transcription factors [166].  Indeed,
it has been documented that IR can activate the stress-activated protein kinases or c-
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Jun N-terminal kinase (SAPK/JNK) and p38 mitogen-activated protein kinases
(MAPK) through non-tyrosine kinase pathways [170].
RhoA has been recognized as a key regulator of cytosqueletal reorganization,
cell motility, cell-cell and cell-extracellular matrix adhesion, cell cycle progression by
promoting entry into G1 and progression to S phase, gene expression and regulator of
apoptosis [171, 172].  RhoA may modulate Survivin’s activity through various ways.
RhoA may regulate Survivin’s activity by acting on its promoter activity or on its cell
cycle-regulated gene transcription.  Also, RhoA pathways may modulate Survivin’s
function by altering its nuclear exportation which is dependent on Crm-1, a nuclear
export receptor that is regulated by small GTPases [173].  Survivin has been found to
directly interact with Ran-GTP, a small GTPase, in S phase and during mitosis [174].
Furthermore, Rho proteins, through their downstream pathways, may influence
Survivin’s intracellular regulation pathways including sequential
ubiquitylation/deubiquitylation and multiple steps of phosphorylation [174].
Therefore, RhoA and Survivin probably interact at many levels given the extent of
their cellular functions.
It has been shown that Rho proteins as well as Survivin may contribute to
radioresistance.  Overexpression of RhoB in radiosensitive cells increased cell survival
after radiation exposure.  The expression of RhoBN19, an inducible dominant negative
form of Rho, as well as the treatment with farnesyltransferase inhibitors, led to the
appearance of multinucleated cells and induced post-mitotic cell death in
radiosensitive cells transfected with basic fibroblast growth factor-2 (bFGF-2).
Therefore, it was proposed that RhoB, but not RhoA, might control the FGF-2-
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induced radioresistance by protecting cells against radiation-induced post-mitotic cell
death [107].  Farnesyltransferase inhibitors have had similar radiosensitizing effects on
U-87 glioblastoma radioresistant cells [175].  Expression of RhoBN19 in U-87 cells
induced a more important radiosensitizer effect in vivo than in vitro, due, according to
the authors, to the control by Rho pathways of the tumor oxygenation and
angiogenesis [108].  Also, it has been recently proposed that RhoA may be involved it
the radiation-induced invasion [176].  Activation of RhoA may be mediated by EGFR
and insulin-like growth factor-1 receptor (IGFR-1) through PI3K [176].  The extent of
RhoA’s implication in glioma radioresistance remains to be investigated.  Survivin
may also contribute to glioma radioresistance.  Survivin may mediate double-strand
DNA break repair and enhancement of tumor cell metabolism [104].  Recently, it was
shown that suppression of Survivin by siRNA in p53 mutant malignant glioma cells
enhanced tumor cells’ radiosensitivity [177].  This supports that Survivin inhibition
might be an attractive therapeutic target to overcome GBM’s radioresistance.
Many other mechanisms have been proposed to contribute to glioblastomas’
radioresistance.  Potential radioresistance mechanisms may be grouped into three
broad categories including extracellular growth factors or growth factor receptors,
signal transduction cascades, and control of cell cycle.  ErbBR have been identified as
immediate early response gene products that are activated by IR as well as by their
physiological growth factor ligands.  However, the magnitude of activation following
IR is much more significant than by growth factor ligand interaction.  Activation of
ErbBR induces a secondary stimulation of cytoplasmic protein kinase cascades
leading to radioresistance by stimulating proliferation of surviving cells and by
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inhibiting cell death [178].  Indeed, numerous reports suggest that antagonizing EGFR
in irradiated cells induces a significant radiosensitizing effect [179].  However, not all
EGFR-expressing GBMs are amenable to anti-EGFR radiosensitization [180].
Resistant GBM cells had an increased IGFR-1 expression and downstream signalling
through PI3K-Akt was sustained [180].
The PI3K/Akt/mTOR pathway is a proposed mechanism for radioresistance.
Ionizing radiation has been found to induce Akt in U-87 cells, which stimulates
mammalian target of rapamycin (mTOR).  mTOR inhibits autophagy, a programmed
cell death, by activating p70S6K, a cytoprotective molecule.  Inhibiting PI3K, Akt or
mTOR may increase radiation response by enhancing autophagy.  Furthermore, Akt is
inactivated by PTEN.  Authors have shown in PTEN-deficient cells that inhibition of
PI3K/Akt signalling by treatment with a PI3K inhibitor or by conditional PTEN
expression may lead to radiosensitization through the persistence of unrepaired DNA
damage.  These results suggest that PI3K/Akt may also modulate radioresistance by
modulating response to radiation-induced DNA damage [181].  Since the PI3K/Akt
pathway is implicated in many downstream pathways contributing to tumor formation
and progression [40], their inhibition may possibly have many cellular effects
influencing radioresistance.
Another pathway proposed to be implicated in GBMs’ radioresistance is p53, a
transcription factor that is induced in response to DNA damage.  It can either induce
cell cycle arrest and orchestrate DNA repair or promote apoptosis.  When present and
activated, p53 may induce arrest of cells in the G1 phase of cell cycle and inhibit cell
division.  However, loss of p14/ARF, amplification of MDM2, or loss of p53 releases
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cell cycle control and cell division from inhibition.  IR cells lacking p53 may continue
to replicated and accumulate additional oncogenic genetic alterations, contributing to
radioresistance.  However, if proapoptotic p53 targets are also induced with p53
activation, then apoptosis will occur [182].  Since approximately 30-60% of GBMs
have inactivated p53 pathways, the lack of p53-mediated apoptosis may in itself
contribute to GBMs’ radioresistance.
Most probably, biological therapies trying to favourably modulate GBMs’
radioresistance will have to be individualized to each patient given the marked genetic
heterogeneity of GBMs and adjusted to the modifications occurring throughout
radiotherapy.
Another important aspect when studying radioresistance is which cell within
the tumor microenvironment is responsible for the tumor’s radioresistance?  Most
studies have assessed the tumor cells’ implication in radioresistance.  More recently, it
has been well documented that tumor cells may modulate their response to IR by
stimulating angiogenesis through the release of numerous growth factors such as
VEGF and SCF [62, 183-185], to assure their supply in oxygen and nutrients.
Interestingly, this paracrine relationship may be modulated by radiation exposure
[168, 169, 186].  Indeed, IR elicits a stress response in malignant cells which induces
an up-regulation of VEGF-A expression [186].  IR has been found to significantly
enhance the secretion of VEGF as well as hepatocyte growth factor (HGF), both
growth factors are known to be implicated in malignant tumor cells’ proliferation,
invasion and angiogenesis [168, 169].  Therefore, IR-enhanced secretion of VEGF
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may contribute to the protection of tumor blood vessels from IR-mediated cytotoxicity
and thereby prevent tumor cell death [186].  However, because tumor vasculature is
abnormal and because heterogeneous hypoxic regions are spread throughout the
tumor, it is difficult to predict how tumor vasculature responds to radiation therapy in
a given tumor.  Interestingly, it has been documented that ECs can be directly targeted
by IR.  Investigators have found that IR exposure can induce apoptosis in ECs [187-
190], even prior to tumor cell apoptosis [191].  On the other hand, ECs can also escape
the cytotoxic effects of IR and survive single radiation exposure similarly to cancer
cells.  We demonstrate in the present thesis that the angiogenic properties of these
radioresistant ECs in response to tumor-derived growth factors were altered.  The
signalling pathways through which ECs are protected against IR have only begun to be
investigated and the activation of the PI3K-Akt-Bcl-2 survival pathway has been
recently suggested [192, 193].  The impact of IR exposure on the angiogenic functions
of surviving human brain tumor-derived ECs had not previously been investigated.
Our results suggest that radioresistant HBMEC migration response to tumor-secreted
growth factors and tubulogenesis are altered following IR.  It is possible that these
dysfunctional ECs contribute to the persistence of hypoxic microenvironments and
subsequent radioresistance.
Recently, tumor stem cells within malignant gliomas have been proposed as
the mediator of radioresistance.  Bao and colleague showed that cancer stem cells
expressing CD133, a marker for both neural stem cells and brain cancer stem cells,
isolated from both human glioma xenografts and primary patient glioblastoma
specimens preferentially activate the DNA damage checkpoint in response to
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radiation, and repair radiation-induced DNA damage more effectively than CD133-
negative tumor cells [194].  These results suggest that CD133-positive tumor cells
may represent the cellular population that mediates glioma radioresistance.  In
addition, the radioresistance of CD133-positive glioma stem cells could be reversed
with a specific inhibitor of Chk1 and Chk2 checkpoint kinases [194].  Therefore, DNA
damage checkpoint response in cancer stem cells may be an interesting target to
overcome GBM radioresistance.
In summary, resistance of GBM to radiotherapy implicates many players
namely the tumor cells, the tumor-associated endothelial cells, and more recently
recognized the brain tumor stem cells.  This way of conceiving radioresistance also
implies that new players in a complex phenomenon will need to be taken into
consideration if tumor eradication is seeked.
5.2.2 Tumor-associated endothelial cells as a therapeutic target
Only recently have the ECs been considered a powerful new potential
treatment target in highly vascularized tumors such as glioblastoma [2]. Tumor-
associated ECs have a proliferation rate up to 20 times greater than the proliferation
rate of normal vasculature [195], rendering them more radiosensitive than non-
dividing cells [95].  ECs are generally well oxygenated, which makes them more
radiosensitive than poorly oxygenated tumor cells because the oxygen present at the
time of radiation may contribute to the formation of cytotoxic molecules which may
prevent the reversal of some IR-induced changes [95, 196].
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Tumor-associated ECs disruption and death following radiation exposure
modifies the tumor vasculature.  Consequently, oxygen and nutrient supply to tumor
cells is altered.  Following IR, tumor burden decreases, tumor vasculature reorganizes
itself and the proportion of hypoxic tumor is decreased.  This leads to a
radiosensitization for subsequent treatment.  Also, the generation of a more hypoxic
tumor microenvironment after vessel disruption might subsequently induce death of
tumor cells.  On the other hand, this hypoxic microenvironment can also establish the
conditions needed for selecting tumor cells that are more able to survive and grow in
hypoxic environments and are less susceptible to apoptosis and eventually more
radioresistant [197].  These observations suggest that a multimodal approach is
necessary to optimize radiation efficiency and prevent the occurrence of highly
resistant cells.
More recently, antiangiogenic agents have been successfully used in
combination with IR to increase the therapeutic effectiveness of radiation exposure
[124, 198].  Tumor-associated endothelial cells are an advantageous target regarding
many aspects.  Endothelial cells represent a homogeneous non-neoplastic cell
compartment that is less likely to be subject to resistance.  They are easily accessible
for circulating agents.  They proliferate rapidly which makes them vulnerable to
radiation and cytotoxic agents.  Furthermore, tumor-associated ECs can be
distinguished from the resting vasculature, enabling a target specific treatment [199].
Many targets have been explored and the VEGF/VEGFR-2 signaling pathway
has been suggested as an important target [199].  VEGF expression has been found
predominantly in palissading cells adjacent to necrotic areas and in clusters of tumor
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cells without obvious adjacent necrosis [200].  The areas of most pronounced
angiogenesis and most rapid glioma growth within a malignant glioma is the invading
border and this area corresponds to the highest SCF expression [62].  Recently, the
SCF/c-kit pathway has been found to play an important role in tumor- and normal host
cell-induced angiogenesis within the brain [62].  Therefore, it is possible that pro-
angiogenic factors have complementary roles given their predominant effect in various
regions of the tumor.  Targeting multiple angiogenic signaling pathways by polyvalent
inhibitors or combining antiangiogenic agents with distinct antiangiogenic properties
might offer the best chance for clinical success.
The addition of a chemotherapeutic agent with antiangiogenic properties often
has additive or synergistic effect when used in combination with IR or cytotoxic
chemotherapy.  Many hypotheses have been proposed to explain this sensitizing
effect. Administration of an antiangiogenic agent can transiently "normalize" the
altered structure and function of tumor vasculature to make it more efficient for
oxygen and drug delivery.  These agents can alleviate hypoxia and increase the
efficiency of conventional therapies [201].  However, not all tumor cells are dependent
on tumor vasculature and therefore remain unresponsive to antiangiogenic therapies.
Tumor cells that have migrated away from the tumor bulk to form tumor cell islands
probably receive adequate oxygen and nutrients either by passive diffusion or by
normal blood vessels [202].  These cells are not targeted by any adjuvant therapies
since radiotherapy is directed at the primary tumor site and angiogenic agents do not
target normal brain vessels from which tumor clusters supply.  Also, some viable
tumor cells might be located in a microenvironment at low oxygen tensions.  These
194
cells are radioresistant but also highly angiogenic given the hypoxic condition and are
potentially resistant to antiangiogenic strategies [203].  Therefore, some tumor clusters
at distance or within the primary tumor site constitute eligible candidates for recurrent
GBM.
In addition to being in interaction with tumor cells, ECs have been identified as
a critical component of the neural stem cell niche.  Brain tumor stem cells may also
rely on signalling interaction with nearby tumor vasculature to maintain their stem-like
state.  Folkins and collaborators have shown that only the combined treatment with
antiangiogenic and cytotoxic drugs induced a reduction in sphere-forming units in the
tumor xenografts [204].  They hypothesized that the synergetic effect of combined
treatment may be due to a preferential eradication of tumor brain stem cell by the
combined regiment.  The angiogenic therapies might disrupt the glioma tumor brain
stem cell vascular niche resulting in a reduction or loss of stem cell characteristics
[204].
To assess basic mechanisms of angiogenesis in gliomas as well as the efficacy
of antiangiogenic treatments, a variety of in vitro and in vivo models have been
developed.  In vitro systems using established EC lines have been shown to be
reproducible and reliable.  Until recently, most studies on brain microvasculature were
extrapolated from assays performed on human umbilical vein endothelial cells
(HUVEC) [154] or bovine aortic endothelial cells (BAEC) [205].  However, EC lines
isolated from large vessels do not adequately reflect the phenotype of microvascular
ECs [206].  Furthermore microvascular ECs vary from organ to organ and present
species-specificity.  Therefore, isolation and characterization of human cerebral
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microvascular ECs was essential for the study of brain microvasculature.  HBMEC
have been isolated from a brain biopsy of a woman with epilepsy.  The HBMEC were
positive for factor VIII-Rag, carbonic anhydrase IV, Ulex Europeus Agglutinin I, took
up fluorescently labeled acetylated low density lipoprotein and expressed gamma
glutamyl transpeptidase, demonstrating their brain endothelial cell characteristics
[206].  Their replicative senescence was bypassed by transformation with the viral
oncogene SV40LT [165].  The major limitation of using HBMEC as a surrogate
model surrogate model to approximate tumor-derived ECs resides in the fact that the
microvascular endothelium of malignant gliomas has been shown to differ from
normal brain endothelium.  Recently, ECs have been isolated from glioblastoma
specimens [76, 163].  Throughout the isolation process, different subfractions of EC
have been separated depending on their antigen expression pattern [80].  This suggests
the existence of different EC populations within the tumor, possibly each having
specific functional properties.  Isolated ECs adhered difficultly on culture plates, failed
to proliferate easily in vitro and were sensitive to passaging [80].  Interestingly,
authors also reported that cell culture and passaging influenced VE-cadherin, vWF and
CD31 expression in EC isolated from gliomas [80].  Given the dynamic phenotype of
isolated tumor ECs and their inherently limited proliferation potential, it has been
recommended to use freshly isolated tumor EC rather than repeated passages [80].
This model may not be suitable for long-term in vitro studies requiring a homogeneous
population from passage to passage to reproduce results.
Concerning in vivo models, no currently available animal model exactly
simulates human brain tumor growth and angiogenesis. Orthotopic models have the
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potential to give experimental intracerebral tumors that resemble glioblastoma
invasion and angiogenesis.  To date, no rat glioma model is an optimal model since the
9L cell line is not a glioma but rather a gliosarcoma and the C6 model has the
unfortunate tendency to evoke a strong alloimmunogenic response, limiting rat
survival [207].  Another option is xenografting human glioblastoma cells into
immunocompromized hosts such as thymectomized, SCID, or nu/nu animals. In such
models, the use of immunocompromized animals leads to a partially artificial
proliferation and angiogenesis pattern, given the absence of tumor-host immunologic
interaction.  Furthermore, not all human glioma cells inoculated in animal cerebral
parenchyma result in a tumor with glioblastomas’ phenotype.  The U-87 human
glioblastoma cell line, for example, gives rise to tumors that develop a perivascular
infiltration but not white matter infiltration as GBMs usually do [208].  Finally,
models of spontaneous tumor formation in genetically engineered mice offer the
opportunity to examine the pathophysiology of gliomas in immunocompetent models
in vivo.  However, in brain tumor modeling, authors have found that these tumor
models are complicated by poor reproducibility, low tumor penetrance, prolonged
tumor formation latency, and a need for in vivo imaging techniques [209]
Depending on the study’s objectives, different model systems might be more or
less suitable.  Questions regarding EC cellular functions may be best answered by in
vitro models.  In the chapters III and IV, the HBMEC model has been used as a
surrogate model to approximate tumor-derived ECs.  The HBMEC model represents a
stable and reliable in vitro model, maintaining both morphological and functional
characteristics of brain ECs, as well as an increased proliferation rate due to their
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transformation with the SV40-LT antigen [165].  Interestingly, transfection of tumor
cell lines with SV40-LT has lead to the repression of tumor suppressor genes such as
p53 and Rb.  Also, VEGF expression was increased in SV40-LT transfected cells
[210].  These modifications could contribute to regulate cellular proliferation and
tumorigenesis [210].  Therefore, HBMEC immortalized with SV40-LT may have
acquired a phenotype and genotype ressembling tumor-derived ECs. However, this
specific comparison has not yet been performed.
Although one recognizes that this model does not exactly represent glioma-
derived EC, it is to our knowledge the closest in vitro model that could approximate
brain tumor-derived ECs for long term studies requiring phenotypically stable cell
throughout the same passage and between passages.  Depending on the experimental
protocol, ECs might have been transfected and treated with EGCG +/-IR, and then
submitted to various assays such as proliferation, cell cycle assays by FACS,
migration, tubulogenesis.  Endothelial cells isolated from the glioblastoma resected
from a human or an animal in an orthotopic model might not be ideal for such research
protocols given their difficulty to adhere, their limited proliferation rate and early
senescence in vitro, and their heterogeneity as a whole and dynamic phenotype [80].
The conclusions of chapters II and III must be put into perspective given the inherent
limitation of the HBMEC model as surrogate for tumor-derived EC and the absence of
other flawless existing models.
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5.2.3 Necrosis, an important goal of adjuvant therapies
In most cases, adjuvant therapies aim to kill residual tumor cells not resected
during surgery.  In response to a given toxic insult or physical damage there is often a
continuum of apoptotic and non-apoptotic cell death mechanisms.
Apoptosis is described as a caspase-dependent active or programmed cell death
characterized by nuclear condensation and fragmentation, membrane blebbing and
formation of apoptotic bodies (Figure 1).  Apoptotic cells can be cleared from the
organism in the absence of inflammatory response.  The late stage of apoptosis may be
associated with secondary necrotic cell death [211].
Non-apoptotic cell death includes necrosis, mitotic cell death, autophagy and
senescence [211].  Necrosis was initially considered as an unprogrammed default form
of cell death but should be regarded as a regulated event displaying aspects of non-
apoptotic programmed cellular suicide.  Necrosis allows cells to actively recruit either
a defensive or reparative response to damage.  As such, programmed cell necrosis
allows systems to give a warning that the integrity of the system as a whole is
menaced.  To do so, various proteins are released into the extracellular environment to
trigger a host response.  When the integrity of the plasma membrane is lost by damage
to membrane lipids or loss of function of ion channels/pumps, the cells swell and
rupture, releasing intracellular content in the microenvironment and subsequently
inducing an inflammatory and immune response (Figure 1).
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Figure 1.  Differences between necrosis and apoptosis
Mitotic catastrophe refers to an aberrant mitosis which occurs when the cell
cycle checkpoints are defective and cells enter mitosis prematurely before DNA
damage has been repaired.  This mode of cell death is preferentially seen in tumors
with suppressed apoptotic pathways treated with DNA damaging treatments.  Other
than identification of multinucleated cells on histology, no specific in vitro or in vivo
assays are available to document mitotic catastrophe [212].
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Autophagy occurs in numerous stress conditions to degrade and recycle
organelles and cytoplasmic proteins by lysosomal hydrolases.  In periods of starvation,
autophagy may enable cell survival by providing energy.  When extreme situations
exist, autophagy becomes a suicide mechanism by inducing digestion of essential
cellular proteins and structures.  In tumor cells, autophagy, as a cell death mechanism,
may occur either in combination with or as a back-up of other deficient pathways,
such as apoptosis. Autophagy is detected in tissues by electron microscopy, by
immunoblotting-precipitation-fluorescence detection of microtubule-associated
protein 1A/1B-light chain 3 on autophagosomes [212, 213] and by flow cytometry
[214].
Senescence refers to a state of permanent loss of proliferative capacity.
Replicative senescence is associated with aging and results from a progressive
shortening of telomeres during cell division.  Cells may also respond to certain types
of DNA damaging stimuli by adopting a senescent phenotype [212].  Senescent cells
undergo irreversible growth arrest and loose clonogenic potential, possibly
representing an important component of tumor response to therapy [215].  Senescence
is dectected in tissues by electron microscopy, by detecting the senescence-associated
β-galactosidase by histochemical staining and by growth arrest assays [212].
IR is capable of activating numerous cell death pathways in numerous types of
tumors [211, 216, 217].  Many factors may influence the balance between these
mechanisms of cell death such as the radiation dose and timing of analysis after
irradiation.  Some authors report that rapid cell death occurs primarily through a non-
apoptotic pathway [218] while others observe a dose-related increase in necrosis with
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some delay after exposure [219].  The kinetics of appearance of both apoptotic and
necrotic cells in irradiated tumors is most probably influenced by cell cycle
progression and by cell death.  In addition, combined treatment of cancer cells with
chemotherapeutic agents and IR has resulted in an increase in the necrotic component
of cell death [220].  For example, combined treatment of a melanoma human cell line
with radiation and camptothecin, a topoisomerase I inhibitor with significant
anticancer activities, induced significantly more necrotic than apoptotic cell death
[220].
The development of resistance to apoptosis is an important step in
carcinogenesis. Glioma cells present both important proliferation and neoangiogenesis
processes and can actively migrate relatively long distances away from the tumor’s
primary site.  Invasive malignant glioma cells show a decrease in their proliferation
rates and a relative resistance to apoptosis compared to the highly cellular center of the
tumor [221].  Reducing tumor cell’s migration results in an increase of these cells’
sensitivity to proapoptotic drugs [222].  Inhibiting the molecular pathways involved in
apoptosis resistance and overexpressed in gliomas is an option to overcome malignant
gliomas’ resistance.  Also, inducing other non-apoptotic cell death mechanisms such
as necrosis or autophagy to kill tumor cells might be an appealing strategy to bypass
the relative resistance to apoptosis [222].
Of the non-apoptotic cell death mechanisms, necrosis may be beneficial since
it leads to a pro-inflammatory response.  Depending on the activated signal-
transduction pathway, tumor cells can express 'danger' and 'eat me' signals on the cell
surface such as heat shock proteins or can release immunostimulatory factors such as
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cytokines and high-mobility group box 1 to stimulate immune effectors [223].
Dexamethasone (DXM), a synthetic glucocorticoid, is commonly administered to
reduce the vasogenic oedema and inflammatory reaction surrounding the glioblastoma
[224].  DXM has also been reported to make GBM cells resistant to IR and
chemotherapeutic agents that otherwise cause DNA damage [225, 226].  Most recently
it has been found that pre-treatment of U87 cells with DXM blocked the
temozolomide-induced apoptosis [227].  The exact mechanism of DXM mediated
protection of glioblastoma cells from apoptosis remains unclear.
Therefore, should effective anticancer regiments be able to induce or potentiate
non-apoptotic cell death pathways?  For example, following IR exposure and
administration of DNA-alkylating agents, DNA damage occurs to some extent.  In the
presence of moderate amounts of DNA damage, PARP-1 is thought to participate in
the DNA repair process [228].  However, repair through poly (ADP-ribosyl)ation is an
energetically expensive process.  It results in a depletion of b-nicotinamide adenine
dinucleotide (NAD) [229], failure of ATP production and, eventually, cell death [230].
Therefore PARP-1 activation by DNA-alkylating agents might induce necrosis by
inducing energy failure [230].  Interestingly, in response to oxidative stress, PARP is
also able to elicit ROS-induced autophagy that plays a prosurvival function.  Indeed,
autophagy induced in nutrient depletion or oxidative stress could produce the
metabolic subtrates required to meet to the cells particular bioenergetic needs and
prevent cell death [231].  However, induction of autophagy does not inevitably have a
prosurvival function.  Overexpression of autophagic proteins or radiation-induced
inactivation of the mTOR pathway can lead to increased sensitivity to IR exposure
203
[232].  Therefore, tumor cells that have defective apoptotic mechanisms may respond
to anticancer regiments by activating alternative non-apoptotic cell death mechanisms
[232].  Treatments targeting tumor cells through alternative cell death mechanisms
offer promising avenues to overcome cancer.
5.2.4 Nutritherapy as a complementary therapeutic modality
Population-based studies have suggested that green tea consumption is
associated with reduced risk of several human malignancies [128, 233].  Indeed, green
tea polyphenols’ chemopreventive properties have been demonstrated in numerous
target organs such as oesophagus, duodenum, large intestin, colon, liver, lung,
mammary glands [233].  Of these, EGCG has been recognized as having many
anticancer properties including inhibition of tumor cell growth [142, 234], cell cycle
arrest [146, 235], induction of apoptosis [144, 234, 236], inhibition of invasion and
metastasis [147] and inhibition of angiogenesis [151].  EGCG has been shown to
sensitize various tumor cell lines and endothelial cell lines to radiation and to augment
the effectiveness of radiotherapy [142, 219, 234].  EGCG has been recognized to have
anti-inflammatory properties.  Studies have shown that EGCG can regulate
inflammatory cells’ recrutement to damages or inflamed tissues [237], migration [238]
and subsequently their infiltration into the sites of inflammation [239].  Also EGCG
can down-regulate cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase
(iNOS), two important enzymes that mediate inflammatory processes, through the
suppression of NFkB activation [240].  However, the anti-inflammatory properties of
EGCG have not been directly tested in vivo in gliomas given the relative protection of
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the CNS from the immune system throughout the blood brain barrier.  EGCG has also
been recognized for antioxidant properties.  It has been demonstrate that at low
concentrations of EGCG, activation of MAPK leads to antioxydant-response element-
mediated gene expression including detoxifying enzymes.  At higher concentrations
EGCG may induce a sustained activation of MAPKs such as JNK leading to apoptosis
[241].  Others have demonstrated that at low concentrations, reactive oxygen species
(ROS) scavenging activity of EGCG might predominate over its reducing power and
lead to its protective effect on DNA. However, at higher concentrations, the relatively
higher reductive power of EGCG may gradually predominate over its ROS scavenging
activity and result in a pro-oxidant effect of EGCG on DNA [242].  The numerous
anticancer and antiangiogenic effects of EGCG occur at variable doses, depending on
the period of treatment with EGCG, concurrent treatments, and cells studied.  In our
experiences EGCG seemed to potentiate the cytotoxic effect of IR on malignant
glioma and brain endothelial cells, maybe through its pro-oxidant effect or through
other anticancer properties such as cell death.
Multiple signalling pathways have been found to be regulated by EGCG
including: expression of VEGF, MMPs, uPA, EGFR, cell cycle regulatory proteins,
NFkB, PI3-K/Akt, and Ras/Raf/MAPK.  However, the exact molecular mechanism of
EGCG is not completely understood.  Studies have shown that the inhibitory effect of
EGCG on tumor cell proliferation might be transduced through its binding to the 67-
kDa laminin receptor (67LR) [160], a protein whose expression is strongly correlated
with tumor aggressiveness [243].  Interestingly, studies have shown that through its
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binding to the 67LR, EGCG may also reduce the phosphorylation of myosin II
regulatory light chain, resulting in an increase in cells in the G2/M phase of cell cycle
and ultimately in an inhibition of cell growth [244].  More studies are required
however.
Until now, the best way of assuring a regular intake of green tea polyphenols,
especially EGCG, is through its daily consummation in tea.  Although good habits are
worth working for, it is recognized that chronic habits are difficult to change.  Also,
the quantity of EGCG extracted after infusion is dependent on numerous and difficult
to control variables.  A Phase 1 pharmacokynetic study has been conducted to
determine the systemic availability of green tea catechins after single oral dose
administration of EGCG and Polyphenon E, a decaffeinated green tea catechin
mixture.  Authors found that the two catechin formulations resulted in similar plasma
EGCG levels and that the systemic availability of EGCG increased at higher doses,
possibly due to saturable presystemic elimination of orally administered green tea
polyphenols [233].  Importantly, there is evidence in animal models that EGCG is
capable of penetrating through the blood brain barrier, although its brain distribution is
less than the plasmatic distribution [245].  Another step towards human studies was
the need for biomarkers representing green tea consumption.  Wang et al analyzed
green tea polyphenol components in plasma and urine samples collected from a phase
II intervention trial carried out in 124 healthy adults receiving 500- or 1000-mg green
tea polyphenols or placebo for 3 months [246].  A significant dose-dependent
elevation was found for ECG and EGCG concentrations in plasma at both 1-month
and 3-months after intervention with green tea polyphenols, rendering them reliable
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biomarkers for green tea consumption at the population level [246].  Results of the
interventional trial are not yet published however.
Another promising avenue is the possible combination of nutrients to optimize
their individual anticancer properties.  Since EGCG pretreatment potentiates IR
effects’ on glioblastoma cells, could adding nutrients with anticancerous properties
optimize the effectiveness of this combined treatment?  U-87 human glioblastoma
cells were treated with EGCg (10µM) and/or Curcumin (1µM) for 6 hours.  Irradiated
cells were exposed to a single 3 Gy treatment with a linear accelerator.  After
irradiation, MEM containing 20% FBS was added and cells were left to recuperate for
18 hours.  Non-treated control cells were handled similarly to the cells subjected to
EGCG and/or Curcumin and/or IR.  Cell death was assessed 18 hours after treatments
and cell growth was assessed after 48 hours as described in the methodology section
of chapters II, III and IV.  EGCG and Curcumin individually induced U-87 cell death
(Figure 2) [246].  Furthermore, the combined pretreatment with EGCG and Curcumin
followed by IR significantly decreased growth of cancerous cells.  Therefore,
pretreatment with a combination of nutrients might enable lowering IR doses without
compromising the anticancerous effect of treatment.  There is promise that by
integrating nutritherapy in the global management of cancer that we might succeed in
decreasing treatment regiments that are less tolerated by patients, improve their quality
of life by decreasing adverse effects, and above all, increase their survival.
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Figure 2. Reproduced from [247].
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5.3 Conclusion
The first goal of this doctoral project was to determine if EGCG, in synergy
with radiotherapy, can sensitize GBM’s response to radiation and whether specific
molecular markers are involved.  We documented that U-87 cells were relatively
radioresistant and that Survivin, in conjunction with RhoA signaling, may be
implicated in GBM’s radioresistance.  Also we found that pre-treatment of U-87
cells with EGCG could overcome the cytoprotective effect of Survivin
overexpression and potentiate the cytoreductive effect of IR.
The second goal was to characterize the impact of IR on HBMEC survival and
to determine whether EGCG, also recognized for its anti-angiogenic properties, could
optimize this effect.  We found that although EGCG treatment and IR individually
decreased HBMEC survival, the combined treatment synergistically reduced survival.
We documented that the combined treatment increased cell death, more specifically
necrosis.
The third goal was to investigate impact of IR exposure on the angiogenic
functions i.e. cell proliferation, migration in response to brain tumor-derived growth
factors, and capacity for tubulogenesis of surviving human brain tumor-derived ECs.
The Rho signalling pathway was also investigated in relation to the functional
properties of radioresistant HBMEC.  Our data suggest that IR significantly alters
crucial steps of angiogenesis, namely cell proliferation, migration and tubulogenesis in
radioresistant HBMEC.  Response to growth factors important for tumor expansion
and angiogenesis is significantly attenuated in radioresistant HBMEC.
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In conclusion, this doctoral project confirmed IR’s cytoreductive properties on
malignant gliomas and proposed a novel mechanism to explain GBMs’
radioresistance.  The thesis documented for the first time IR’s cytotoxic effect in
human brain endothelial cells.  It also described the existence of radioresistant
HBMEC and characterized their altered angiogenic functions.  The thesis documented
that the combination of natural anti-cancerous and antiangiogenic molecules such as
EGCG with radiotherapy could improve IR’s effect on human malignant glioma cells
and tumor-derived ECs, especially through increased necrosis for HBMEC.  The
present thesis supports integrating nutrients with anticancerous and antiangiogenic
properties, such as EGCG, in the management of gliomas to sensitize tumor cells and
tumor-associated endothelial cells to conventional therapies.
CHAPTER VI BIBLIOGRAPHY
1. Martin, J.H., ed. Neuroanatomy - Text and Atlas. Second edition ed. 1996,
Appleton & Lange: Stamford. 578.
2. Winn, H.R., ed. Youmans Neurological Surgery. Fifth edition ed. Oncology,
ed. H.a.S.R. Brem. Vol. 1. 2004, Saunders: Philadelphia. 1457.
3. Oldendorf, W.H. and E.M. Cornford, A comparison of total body and local
spinal cord irradiation in experimental allergic encephalomyelitis. J
Neuropathol Exp Neurol, 1977. 36(1): p. 50-61.
4. Surawicz, T.S., et al., Descriptive epidemiology of primary brain and CNS
tumors: results from the Central Brain Tumor Registry of the United States,
1990-1994. Neuro Oncol, 1999. 1(1): p. 14-25.
5. Yates, A.J., An overview of principles for classifying brain tumors. Mol Chem
Neuropathol, 1992. 17(2): p. 103-20.
6. Louis, D.N., et al., The 2007 WHO classification of tumours of the central
nervous system. Acta Neuropathol, 2007. 114(2): p. 97-109.
7. Collins, V.P., Brain tumours: classification and genes. J Neurol Neurosurg
Psychiatry, 2004. 75 Suppl 2: p. ii2-11.
211
8. Daumas-Duport, C., et al., Grading of astrocytomas. A simple and
reproducible method. Cancer, 1988. 62(10): p. 2152-65.
9. Ellison D, L.S., ed. Neuropathology - A reference text of CNS pathology. First
edition ed. 1998, Mosby: Barcelona.
10. Norden, A.D. and P.Y. Wen, Glioma therapy in adults. Neurologist, 2006.
12(6): p. 279-92.
11. Kraus, J.A., et al., Shared allelic losses on chromosomes 1p and 19q suggest a
common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol
Exp Neurol, 1995. 54(1): p. 91-5.
12. Biernat, W., et al., Identical mutations of the p53 tumor suppressor gene in the
gliomatous and the sarcomatous components of gliosarcomas suggest a
common origin from glial cells. J Neuropathol Exp Neurol, 1995. 54(5): p.
651-6.
13. Li, L. and T. Xie, Stem cell niche: structure and function. Annu Rev Cell Dev
Biol, 2005. 21: p. 605-31.
14. Li, L. and W.B. Neaves, Normal stem cells and cancer stem cells: the niche
matters. Cancer Res, 2006. 66(9): p. 4553-7.
15. Singh, S. and P.B. Dirks, Brain tumor stem cells: identification and concepts.
Neurosurg Clin N Am, 2007. 18(1): p. 31-8, viii.
212
16. Yuan, X., et al., Isolation of cancer stem cells from adult glioblastoma
multiforme. Oncogene, 2004. 23(58): p. 9392-400.
17. Beier, D., et al., CD133(+) and CD133(-) glioblastoma-derived cancer stem
cells show differential growth characteristics and molecular profiles. Cancer
Res, 2007. 67(9): p. 4010-5.
18. Hunter, K.E. and M.E. Hatten, Radial glial cell transformation to astrocytes is
bidirectional: regulation by a diffusible factor in embryonic forebrain. Proc
Natl Acad Sci U S A, 1995. 92(6): p. 2061-5.
19. Jemal, A., et al., Cancer statistics, 2002. CA Cancer J Clin, 2002. 52(1): p. 23-
47.
20. Wrensch, M., et al., Epidemiology of primary brain tumors: current concepts
and review of the literature. Neuro Oncol, 2002. 4(4): p. 278-99.
21. Grossman, S.A., et al., Central nervous system cancers in first-degree relatives
and spouses. Cancer Invest, 1999. 17(5): p. 299-308.
22. Sanson M, T.S., Données générales de neuro-oncogenèse. Encyclopédie
Médico-Chirurgicale, 2004. 17(205): p. 1-10.
23. Hodges, L.C., et al., Prevalence of glioblastoma multiforme in subjects with
prior therapeutic radiation. J Neurosci Nurs, 1992. 24(2): p. 79-83.
213
24. Brat, D.J., et al., Molecular genetic alterations in radiation-induced
astrocytomas. Am J Pathol, 1999. 154(5): p. 1431-8.
25. Simmons, N.E. and E.R. Laws, Jr., Glioma occurrence after sellar irradiation:
case report and review. Neurosurgery, 1998. 42(1): p. 172-8.
26. Sankaranarayanan, K. and R. Chakraborty, Impact of cancer predisposition
and radiosensitivity on the population risk of radiation-induced cancers.
Radiat Res, 2001. 156(5 Pt 2): p. 648-56.
27. Wrensch, M., et al., Are prior head injuries or diagnostic X-rays associated
with glioma in adults? The effects of control selection bias.
Neuroepidemiology, 2000. 19(5): p. 234-44.
28. Tortosa, A., et al., Prognostic implication of clinical, radiologic, and
pathologic features in patients with anaplastic gliomas. Cancer, 2003. 97(4): p.
1063-71.
29. Price, A.C., et al., Primary glioma: diagnosis with magnetic resonance
imaging. J Comput Tomogr, 1986. 10(4): p. 325-34.
30. Kelly, P.J., et al., Imaging-based stereotaxic serial biopsies in untreated
intracranial glial neoplasms. J Neurosurg, 1987. 66(6): p. 865-74.
31. Osborn, A., ed. Diagnostic Imaging - Brain. ed. S.K. Blaser SI, Katzman GL,
Provenzale J, Castillo M, Hedlund GL, Illner A, Harnsberger HR, Cooper JA,
Jones BV, Hamilton BE 2004, Amirsys: Altona.
214
32. Bagley, L.J., et al., Gliomas: correlation of magnetic susceptibility artifact
with histologic grade. Radiology, 1997. 202(2): p. 511-6.
33. Watanabe, M., R. Tanaka, and N. Takeda, Magnetic resonance imaging and
histopathology of cerebral gliomas. Neuroradiology, 1992. 34(6): p. 463-9.
34. Earnest, F.t., et al., Cerebral astrocytomas: histopathologic correlation of MR
and CT contrast enhancement with stereotactic biopsy. Radiology, 1988.
166(3): p. 823-7.
35. Kleihues, P. and H. Ohgaki, Primary and secondary glioblastomas: from
concept to clinical diagnosis. Neuro Oncol, 1999. 1(1): p. 44-51.
36. Watanabe, K., et al., Overexpression of the EGF receptor and p53 mutations
are mutually exclusive in the evolution of primary and secondary
glioblastomas. Brain Pathol, 1996. 6(3): p. 217-23; discussion 23-4.
37. Ohgaki, H. and P. Kleihues, Genetic pathways to primary and secondary
glioblastoma. Am J Pathol, 2007. 170(5): p. 1445-53.
38. Reardon, D.A. and P.Y. Wen, Therapeutic advances in the treatment of
glioblastoma: rationale and potential role of targeted agents. Oncologist,
2006. 11(2): p. 152-64.
39. Lassman, A.B., Molecular biology of gliomas. Curr Neurol Neurosci Rep,
2004. 4(3): p. 228-33.
215
40. Hlobilkova, A., et al., Could changes in the regulation of the PI3K/PKB/Akt
signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis
and progression? Neoplasma, 2007. 54(4): p. 334-41.
41. Yahanda, A.M., et al., Astrocytes derived from p53-deficient mice provide a
multistep in vitro model for development of malignant gliomas. Mol Cell Biol,
1995. 15(8): p. 4249-59.
42. Altieri, D.C., Survivin, versatile modulation of cell division and apoptosis in
cancer. Oncogene, 2003. 22(53): p. 8581-9.
43. Shin, S., et al., An anti-apoptotic protein human survivin is a direct inhibitor of
caspase-3 and -7. Biochemistry, 2001. 40(4): p. 1117-23.
44. Conway, E.M., et al., Three differentially expressed survivin cDNA variants
encode proteins with distinct antiapoptotic functions. Blood, 2000. 95(4): p.
1435-42.
45. Tamm, I., et al., IAP-family protein survivin inhibits caspase activity and
apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.
Cancer Res, 1998. 58(23): p. 5315-20.
46. Grossman, D., et al., Transgenic expression of survivin in keratinocytes
counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin
Invest, 2001. 108(7): p. 991-9.
216
47. Croci, D.O., et al., Silencing survivin gene expression promotes apoptosis of
human breast cancer cells through a caspase-independent pathway. J Cell
Biochem, 2008.
48. Kang, D.W., et al., Ciglitazone induces caspase-independent apoptosis
through down-regulation of XIAP and survivin in human glioma cells.
Neurochem Res, 2008. 33(3): p. 551-61.
49. Li, F., et al., Control of apoptosis and mitotic spindle checkpoint by survivin.
Nature, 1998. 396(6711): p. 580-4.
50. Temme, A., et al., Localization, dynamics, and function of survivin revealed by
expression of functional survivinDsRed fusion proteins in the living cell. Mol
Biol Cell, 2003. 14(1): p. 78-92.
51. Wheatley, S.P., et al., INCENP is required for proper targeting of Survivin to
the centromeres and the anaphase spindle during mitosis. Curr Biol, 2001.
11(11): p. 886-90.
52. Blanc-Brude, O.P., et al., Therapeutic targeting of the survivin pathway in
cancer: initiation of mitochondrial apoptosis and suppression of tumor-
associated angiogenesis. Clin Cancer Res, 2003. 9(7): p. 2683-92.
53. O'Connor, D.S., et al., Control of apoptosis during angiogenesis by survivin
expression in endothelial cells. Am J Pathol, 2000. 156(2): p. 393-8.
217
54. Ricci, M.S. and W.X. Zong, Chemotherapeutic approaches for targeting cell
death pathways. Oncologist, 2006. 11(4): p. 342-57.
55. Chaudhry, I.H., et al., Vascular endothelial growth factor expression
correlates with tumour grade and vascularity in gliomas. Histopathology,
2001. 39(4): p. 409-15.
56. Zadeh, G. and A. Guha, Angiogenesis in nervous system disorders.
Neurosurgery, 2003. 53(6): p. 1362-74; discussion 1374-6.
57. Bergers, G. and L.E. Benjamin, Tumorigenesis and the angiogenic switch. Nat
Rev Cancer, 2003. 3(6): p. 401-10.
58. Hristov, M. and C. Weber, Endothelial progenitor cells in vascular repair and
remodeling. Pharmacol Res, 2008.
59. Asahara, T. and A. Kawamoto, Endothelial progenitor cells for postnatal
vasculogenesis. Am J Physiol Cell Physiol, 2004. 287(3): p. C572-9.
60. Holash, J., et al., Vessel cooption, regression, and growth in tumors mediated
by angiopoietins and VEGF. Science, 1999. 284(5422): p. 1994-8.
61. Kaur, B., et al., Hypoxia and the hypoxia-inducible-factor pathway in glioma
growth and angiogenesis. Neuro Oncol, 2005. 7(2): p. 134-53.
62. Sun, L., et al., Neuronal and glioma-derived stem cell factor induces
angiogenesis within the brain. Cancer Cell, 2006. 9(4): p. 287-300.
218
63. Folkman, J., The role of angiogenesis in tumor growth. Semin Cancer Biol,
1992. 3(2): p. 65-71.
64. Waeber, C., N. Blondeau, and S. Salomone, Vascular sphingosine-1-phosphate
S1P1 and S1P3 receptors. Drug News Perspect, 2004. 17(6): p. 365-82.
65. Auguste, P., et al., Molecular mechanisms of tumor vascularization. Crit Rev
Oncol Hematol, 2005. 54(1): p. 53-61.
66. Dome, B., et al., Alternative vascularization mechanisms in cancer: Pathology
and therapeutic implications. Am J Pathol, 2007. 170(1): p. 1-15.
67. Hendrix, M.J., et al., Vasculogenic mimicry and tumour-cell plasticity: lessons
from melanoma. Nat Rev Cancer, 2003. 3(6): p. 411-21.
68. Maniotis, A.J., et al., Vascular channel formation by human melanoma cells in
vivo and in vitro: vasculogenic mimicry. Am J Pathol, 1999. 155(3): p. 739-52.
69. Rojiani, A.M. and K. Dorovini-Zis, Glomeruloid vascular structures in
glioblastoma multiforme: an immunohistochemical and ultrastructural study. J
Neurosurg, 1996. 85(6): p. 1078-84.
70. Brat, D.J. and E.G. Van Meir, Glomeruloid microvascular proliferation
orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J
Pathol, 2001. 158(3): p. 789-96.
219
71. Preusser, M., P. Birner, and J.A. Hainfellner, Algorithm for the standardized
assessment of vascular patterns in glioblastoma specimens. Clin Neuropathol,
2004. 23(5): p. 238-40.
72. Sharma, S., et al., Angiogenic patterns and their quantitation in high grade
astrocytic tumors. J Neurooncol, 2006. 79(1): p. 19-30.
73. Less, J.R., et al., Microvascular architecture in a mammary carcinoma:
branching patterns and vessel dimensions. Cancer Res, 1991. 51(1): p. 265-73.
74. Papadopoulos, M.C., et al., Emerging molecular mechanisms of brain tumour
oedema. Br J Neurosurg, 2001. 15(2): p. 101-8.
75. Charalambous, C., T.C. Chen, and F.M. Hofman, Characteristics of tumor-
associated endothelial cells derived from glioblastoma multiforme. Neurosurg
Focus, 2006. 20(4): p. E22.
76. Charalambous, C., F.M. Hofman, and T.C. Chen, Functional and phenotypic
differences between glioblastoma multiforme-derived and normal human brain
endothelial cells. J Neurosurg, 2005. 102(4): p. 699-705.
77. Birner, P., et al., Vascular patterns in glioblastoma influence clinical outcome
and associate with variable expression of angiogenic proteins: evidence for
distinct angiogenic subtypes. Brain Pathol, 2003. 13(2): p. 133-43.
220
78. Preusser, M., et al., Histopathologic assessment of hot-spot microvessel density
and vascular patterns in glioblastoma: Poor observer agreement limits clinical
utility as prognostic factors: a translational research project of the European
Organization for Research and Treatment of Cancer Brain Tumor Group.
Cancer, 2006. 107(1): p. 162-70.
79. Leon, S.P., R.D. Folkerth, and P.M. Black, Microvessel density is a prognostic
indicator for patients with astroglial brain tumors. Cancer, 1996. 77(2): p.
362-72.
80. Miebach, S., et al., Isolation and culture of microvascular endothelial cells
from gliomas of different WHO grades. J Neurooncol, 2006. 76(1): p. 39-48.
81. Papadopoulos, M.C., et al., Occludin expression in microvessels of neoplastic
and non-neoplastic human brain. Neuropathol Appl Neurobiol, 2001. 27(5): p.
384-95.
82. Giese, A., et al., Dichotomy of astrocytoma migration and proliferation. Int J
Cancer, 1996. 67(2): p. 275-82.
83. Charalambous, C., et al., Interleukin-8 differentially regulates migration of
tumor-associated and normal human brain endothelial cells. Cancer Res,
2005. 65(22): p. 10347-54.
221
84. Alessandri, G., et al., Phenotypic and functional characteristics of tumour-
derived microvascular endothelial cells. Clin Exp Metastasis, 1999. 17(8): p.
655-62.
85. Tozer, G.M., C. Kanthou, and B.C. Baguley, Disrupting tumour blood vessels.
Nat Rev Cancer, 2005. 5(6): p. 423-35.
86. Tuettenberg, J., C. Friedel, and P. Vajkoczy, Angiogenesis in malignant
glioma--a target for antitumor therapy? Crit Rev Oncol Hematol, 2006. 59(3):
p. 181-93.
87. Scott, J.N., et al., How often are nonenhancing supratentorial gliomas
malignant? A population study. Neurology, 2002. 59(6): p. 947-9.
88. Brandes, A.A., State-of-the-art treatment of high-grade brain tumors. Semin
Oncol, 2003. 30(6 Suppl 19): p. 4-9.
89. Willems, P.W., et al., Effectiveness of neuronavigation in resecting solitary
intracerebral contrast-enhancing tumors: a randomized controlled trial. J
Neurosurg, 2006. 104(3): p. 360-8.
90. Wood, J.R., S.B. Green, and W.R. Shapiro, The prognostic importance of
tumor size in malignant gliomas: a computed tomographic scan study by the
Brain Tumor Cooperative Group. J Clin Oncol, 1988. 6(2): p. 338-43.
222
91. Keles, G.E., et al., Volume of residual disease as a predictor of outcome in
adult patients with recurrent supratentorial glioblastomas multiforme who are
undergoing chemotherapy. J Neurosurg, 2004. 100(1): p. 41-6.
92. Crocker, I.R. and Y. Popowski, Basic physics and biology of radiation
therapy. Semin Interv Cardiol, 1997. 2(2): p. 89-94.
93. Bernard, A. and J. Bourhis, [Radiotherapy. Radiobiological aspects, principal
secondary effects]. Rev Prat, 2001. 51(11): p. 1265-71.
94. Dunne-Daly, C.F., Principles of radiotherapy and radiobiology. Semin Oncol
Nurs, 1999. 15(4): p. 250-9.
95. Bolus, N.E., Basic review of radiation biology and terminology. J Nucl Med
Technol, 2001. 29(2): p. 67-73; test 76-7.
96. Hill, M.A., Radiation damage to DNA: the importance of track structure.
Radiat Meas, 1999. 31(1-6): p. 15-23.
97. Fine, H.A., et al., Meta-analysis of radiation therapy with and without
adjuvant chemotherapy for malignant gliomas in adults. Cancer, 1993. 71(8):
p. 2585-97.
98. Gupta, T. and K. Dinshaw, Modified optimal fractionation for poor prognosis
malignant gliomas: an elusive search. Acta Oncol, 2005. 44(2): p. 105-13.
223
99. Souhami, L., et al., Randomized comparison of stereotactic radiosurgery
followed by conventional radiotherapy with carmustine to conventional
radiotherapy with carmustine for patients with glioblastoma multiforme:
report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat
Oncol Biol Phys, 2004. 60(3): p. 853-60.
100. Akabani, G., et al., Dosimetry and radiographic analysis of 131I-labeled anti-
tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with
malignant gliomas: a phase II study. J Nucl Med, 2005. 46(6): p. 1042-51.
101. Wild-Bode, C., et al., Sublethal irradiation promotes migration and
invasiveness of glioma cells: implications for radiotherapy of human
glioblastoma. Cancer Res, 2001. 61(6): p. 2744-50.
102. Cordes, N., et al., Irradiation differentially affects substratum-dependent
survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer, 2003.
89(11): p. 2122-32.
103. Little, J.B., Genomic instability and bystander effects: a historical perspective.
Oncogene, 2003. 22(45): p. 6978-87.
104. Chakravarti, A., et al., Survivin enhances radiation resistance in primary
human glioblastoma cells via caspase-independent mechanisms. Oncogene,
2004. 23(45): p. 7494-506.
224
105. Kajiwara, Y., et al., Expression of survivin in astrocytic tumors: correlation
with malignant grade and prognosis. Cancer, 2003. 97(4): p. 1077-83.
106. Chakravarti, A., et al., Quantitatively determined survivin expression levels are
of prognostic value in human gliomas. J Clin Oncol, 2002. 20(4): p. 1063-8.
107. Ader, I., et al., RhoB controls the 24 kDa FGF-2-induced radioresistance in
HeLa cells by preventing post-mitotic cell death. Oncogene, 2002. 21(39): p.
5998-6006.
108. Ader, I., et al., Inhibition of Rho pathways induces radiosensitization and
oxygenation in human glioblastoma xenografts. Oncogene, 2003. 22(55): p.
8861-9.
109. Forget, M.A., et al., The expression of rho proteins decreases with human
brain tumor progression: potential tumor markers. Clin Exp Metastasis, 2002.
19(1): p. 9-15.
110. Gingras, D., et al., Localization of RhoA GTPase to endothelial caveolae-
enriched membrane domains. Biochem Biophys Res Commun, 1998. 247(3):
p. 888-93.
111. Regina, A., et al., Down-regulation of caveolin-1 in glioma vasculature:
modulation by radiotherapy. J Neurosci Res, 2004. 75(2): p. 291-9.
112. Chalmers, A.J., Radioresistant glioma stem cells--therapeutic obstacle or
promising target? DNA Repair (Amst), 2007. 6(9): p. 1391-4.
225
113. Fortin, D., et al., Enhanced chemotherapy delivery by intraarterial infusion
and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke
experience. Cancer, 2005. 103(12): p. 2606-15.
114. Toth, K., et al., MDR1 P-glycoprotein is expressed by endothelial cells of
newly formed capillaries in human gliomas but is not expressed in the
neovasculature of other primary tumors. Am J Pathol, 1996. 149(3): p. 853-8.
115. Demeule, M., et al., Brain endothelial cells as pharmacological targets in
brain tumors. Mol Neurobiol, 2004. 30(2): p. 157-83.
116. Hegi, M.E., et al., MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med, 2005. 352(10): p. 997-1003.
117. Hegi, M.E., et al., Clinical trial substantiates the predictive value of O-6-
methylguanine-DNA methyltransferase promoter methylation in glioblastoma
patients treated with temozolomide. Clin Cancer Res, 2004. 10(6): p. 1871-4.
118. Esteller, M., et al., Inactivation of the DNA-repair gene MGMT and the
clinical response of gliomas to alkylating agents. N Engl J Med, 2000.
343(19): p. 1350-4.
119. Lanzetta, G., et al., Temozolomide in radio-chemotherapy combined treatment
for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Anticancer Res, 2003. 23(6D): p. 5159-64.
226
120. Scott, J.N., et al., Which glioblastoma multiforme patient will become a long-
term survivor? A population-based study. Ann Neurol, 1999. 46(2): p. 183-8.
121. Tentori, L. and G. Graziani, Pharmacological strategies to increase the
antitumor activity of methylating agents. Curr Med Chem, 2002. 9(13): p.
1285-301.
122. Bodell, W.J., et al., Levels of N7-(2-hydroxyethyl)guanine as a molecular
dosimeter of drug delivery to human brain tumors. Neuro Oncol, 2001. 3(4): p.
241-5.
123. Mathieu, D. and D. Fortin, The role of chemotherapy in the treatment of
malignant astrocytomas. Can J Neurol Sci, 2006. 33(2): p. 127-40.
124. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96.
125. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant
treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin
Oncol, 2001. 19(2): p. 509-18.
126. Boyle, F.M., S.L. Eller, and S.A. Grossman, Penetration of intra-arterially
administered vincristine in experimental brain tumor. Neuro Oncol, 2004.
6(4): p. 300-5.
227
127. Bello, L., et al., Low-dose chemotherapy combined with an antiangiogenic
drug reduces human glioma growth in vivo. Cancer Res, 2001. 61(20): p.
7501-6.
128. Doll, R. and R. Peto, The causes of cancer: quantitative estimates of avoidable
risks of cancer in the United States today. J Natl Cancer Inst, 1981. 66(6): p.
1191-308.
129. Key, T.J., et al., The effect of diet on risk of cancer. Lancet, 2002. 360(9336):
p. 861-8.
130. Anand, P., et al., Cancer is a preventable disease that requires major lifestyle
changes. Pharm Res, 2008. 25(9): p. 2097-116.
131. Khan, N., et al., Targeting multiple signaling pathways by green tea
polyphenol (-)-epigallocatechin-3-gallate. Cancer Res, 2006. 66(5): p. 2500-5.
132. Milner, J.A., Molecular targets for bioactive food components. J Nutr, 2004.
134(9): p. 2492S-2498S.
133. Block, G., B. Patterson, and A. Subar, Fruit, vegetables, and cancer
prevention: a review of the epidemiological evidence. Nutr Cancer, 1992.
18(1): p. 1-29.
134. Schweigert, F.J., Nutritional proteomics: methods and concepts for research in
nutritional science. Ann Nutr Metab, 2007. 51(2): p. 99-107.
228
135. Afman, L. and M. Muller, Nutrigenomics: from molecular nutrition to
prevention of disease. J Am Diet Assoc, 2006. 106(4): p. 569-76.
136. Nichenametla, S.N., et al., A review of the effects and mechanisms of
polyphenolics in cancer. Crit Rev Food Sci Nutr, 2006. 46(2): p. 161-83.
137. Zaveri, N.T., Green tea and its polyphenolic catechins: medicinal uses in
cancer and noncancer applications. Life Sci, 2006. 78(18): p. 2073-80.
138. Mandel, S. and M.B. Youdim, Catechin polyphenols: neurodegeneration and
neuroprotection in neurodegenerative diseases. Free Radic Biol Med, 2004.
37(3): p. 304-17.
139. Sano, J., et al., Effects of green tea intake on the development of coronary
artery disease. Circ J, 2004. 68(7): p. 665-70.
140. Carlson, J.R., et al., Reading the tea leaves: anticarcinogenic properties of (-)-
epigallocatechin-3-gallate. Mayo Clin Proc, 2007. 82(6): p. 725-32.
141. Demeule, M., et al., Green tea catechins as novel antitumor and
antiangiogenic compounds. Curr Med Chem Anticancer Agents, 2002. 2(4): p.
441-63.
142. McLaughlin, N., et al., The Survivin-mediated radioresistant phenotype of
glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol
(-)-epigallocatechin-3-gallate. Brain Res, 2006. 1071(1): p. 1-9.
229
143. Leone, M., et al., Cancer prevention by tea polyphenols is linked to their direct
inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res, 2003. 63(23): p.
8118-21.
144. Yokoyama, S., et al., Inhibitory effect of epigallocatechin-gallate on brain
tumor cell lines in vitro. Neuro Oncol, 2001. 3(1): p. 22-8.
145. Shankar, S., G. Suthakar, and R.K. Srivastava, Epigallocatechin-3-gallate
inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci,
2007. 12: p. 5039-51.
146. Gupta, S., T. Hussain, and H. Mukhtar, Molecular pathway for (-)-
epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human
prostate carcinoma cells. Arch Biochem Biophys, 2003. 410(1): p. 177-85.
147. Annabi, B., et al., Probing the infiltrating character of brain tumors: inhibition
of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the
green tea catechin EGCg. J Neurochem, 2005. 94(4): p. 906-16.
148. Ho, Y.C., et al., Epigallocatechin-3-gallate inhibits the invasion of human oral
cancer cells and decreases the productions of matrix metalloproteinases and
urokinase-plasminogen activator. J Oral Pathol Med, 2007. 36(10): p. 588-93.
149. Tosetti, F., et al., Angioprevention': angiogenesis is a common and key target
for cancer chemopreventive agents. FASEB J, 2002. 16(1): p. 2-14.
230
150. Masuda, M., et al., Epigallocatechin-3-gallate decreases VEGF production in
head and neck and breast carcinoma cells by inhibiting EGFR-related
pathways of signal transduction. J Exp Ther Oncol, 2002. 2(6): p. 350-9.
151. Kojima-Yuasa, A., et al., Green tea extract inhibits angiogenesis of human
umbilical vein endothelial cells through reduction of expression of VEGF
receptors. Life Sci, 2003. 73(10): p. 1299-313.
152. Lamy, S., D. Gingras, and R. Beliveau, Green tea catechins inhibit vascular
endothelial growth factor receptor phosphorylation. Cancer Res, 2002. 62(2):
p. 381-5.
153. Jung, Y.D., et al., EGCG, a major component of green tea, inhibits tumour
growth by inhibiting VEGF induction in human colon carcinoma cells. Br J
Cancer, 2001. 84(6): p. 844-50.
154. Annabi, B., et al., Radiation induced-tubulogenesis in endothelial cells is
antagonized by the antiangiogenic properties of green tea polyphenol (-)
epigallocatechin-3-gallate. Cancer Biol Ther, 2003. 2(6): p. 642-9.
155. Frei, B. and J.V. Higdon, Antioxidant activity of tea polyphenols in vivo:
evidence from animal studies. J Nutr, 2003. 133(10): p. 3275S-84S.
156. Azam, S., et al., Prooxidant property of green tea polyphenols epicatechin and
epigallocatechin-3-gallate: implications for anticancer properties. Toxicol In
Vitro, 2004. 18(5): p. 555-61.
231
157. Kanadzu, M., Y. Lu, and K. Morimoto, Dual function of (--)-epigallocatechin
gallate (EGCG) in healthy human lymphocytes. Cancer Lett, 2006. 241(2): p.
250-5.
158. Yamamoto, T., et al., Green tea polyphenol causes differential oxidative
environments in tumor versus normal epithelial cells. J Pharmacol Exp Ther,
2003. 307(1): p. 230-6.
159. Liang, Y.C., et al., Suppression of extracellular signals and cell proliferation
through EGF receptor binding by (-)-epigallocatechin gallate in human A431
epidermoid carcinoma cells. J Cell Biochem, 1997. 67(1): p. 55-65.
160. Tachibana, H., et al., A receptor for green tea polyphenol EGCG. Nat Struct
Mol Biol, 2004. 11(4): p. 380-1.
161. Hess, C.F., et al., Malignant glioma: patterns of failure following individually
tailored limited volume irradiation. Radiother Oncol, 1994. 30(2): p. 146-9.
162. Leith, J.T., et al., Intrinsic and extrinsic characteristics of human tumors
relevant to radiosurgery: comparative cellular radiosensitivity and hypoxic
percentages. Acta Neurochir Suppl, 1994. 62: p. 18-27.
163. Bian, X.W., et al., Increased angiogenic capabilities of endothelial cells from
microvessels of malignant human gliomas. Int Immunopharmacol, 2006. 6(1):
p. 90-9.
232
164. Bian, C., et al., Immortalization of human umbilical vein endothelial cells with
telomerase reverse transcriptase and simian virus 40 large T antigen. J
Zhejiang Univ Sci B, 2005. 6(7): p. 631-6.
165. Greiffenberg, L., et al., Interaction of Listeria monocytogenes with human
brain microvascular endothelial cells: InlB-dependent invasion, long-term
intracellular growth, and spread from macrophages to endothelial cells. Infect
Immun, 1998. 66(11): p. 5260-7.
166. Fritz, G., B. Kaina, and K. Aktories, The ras-related small GTP-binding
protein RhoB is immediate-early inducible by DNA damaging treatments. J
Biol Chem, 1995. 270(42): p. 25172-7.
167. Gabrys, D., et al., Radiation effects on the cytoskeleton of endothelial cells and
endothelial monolayer permeability. Int J Radiat Oncol Biol Phys, 2007. 69(5):
p. 1553-62.
168. Hovinga, K.E., et al., Radiation-enhanced vascular endothelial growth factor
(VEGF) secretion in glioblastoma multiforme cell lines--a clue to
radioresistance? J Neurooncol, 2005. 74(2): p. 99-103.
169. Sheng-Hua, C., et al., Radiation-enhanced hepatocyte growth factor secretion
in malignant glioma cell lines. Surg Neurol, 2007. 68(6): p. 610-3; discussion
613-4.
233
170. Kumar, P., A.I. Miller, and P.J. Polverini, p38 MAPK mediates gamma-
irradiation-induced endothelial cell apoptosis, and vascular endothelial
growth factor protects endothelial cells through the phosphoinositide 3-kinase-
Akt-Bcl-2 pathway. J Biol Chem, 2004. 279(41): p. 43352-60.
171. Aznar, S. and J.C. Lacal, Rho signals to cell growth and apoptosis. Cancer
Lett, 2001. 165(1): p. 1-10.
172. Etienne-Manneville, S. and A. Hall, Rho GTPases in cell biology. Nature,
2002. 420(6916): p. 629-35.
173. Knauer, S.K., W. Mann, and R.H. Stauber, Survivin's dual role: an export's
view. Cell Cycle, 2007. 6(5): p. 518-21.
174. Altieri, D.C., New wirings in the survivin networks. Oncogene, 2008. 27(48):
p. 6276-84.
175. Delmas, C., et al., Farnesyltransferase inhibitor, R115777, reverses the
resistance of human glioma cell lines to ionizing radiation. Int J Cancer, 2002.
100(1): p. 43-8.
176. Zhai, G.G., et al., Radiation enhances the invasive potential of primary
glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol,
2006. 76(3): p. 227-37.
234
177. Saito, T., et al., Centrosome amplification induced by survivin suppression
enhances both chromosome instability and radiosensitivity in glioma cells. Br
J Cancer, 2008. 98(2): p. 345-55.
178. Schmidt-Ullrich, R.K., et al., ERBB receptor tyrosine kinases and cellular
radiation responses. Oncogene, 2003. 22(37): p. 5855-65.
179. Chakravarti, A., A. Dicker, and M. Mehta, The contribution of epidermal
growth factor receptor (EGFR) signaling pathway to radioresistance in human
gliomas: a review of preclinical and correlative clinical data. Int J Radiat
Oncol Biol Phys, 2004. 58(3): p. 927-31.
180. Chakravarti, A., J.S. Loeffler, and N.J. Dyson, Insulin-like growth factor
receptor I mediates resistance to anti-epidermal growth factor receptor
therapy in primary human glioblastoma cells through continued activation of
phosphoinositide 3-kinase signaling. Cancer Res, 2002. 62(1): p. 200-7.
181. Kao, G.D., et al., Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling
impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol
Chem, 2007. 282(29): p. 21206-12.
182. Shu, H.K., et al., The intrinsic radioresistance of glioblastoma-derived cell
lines is associated with a failure of p53 to induce p21(BAX) expression. Proc
Natl Acad Sci U S A, 1998. 95(24): p. 14453-8.
235
183. Harrigan, M.R., Angiogenic factors in the central nervous system.
Neurosurgery, 2003. 53(3): p. 639-60; discussion 660-1.
184. Ferrara, N., Vascular endothelial growth factor as a target for anticancer
therapy. Oncologist, 2004. 9 Suppl 1: p. 2-10.
185. Aonuma, M., et al., Tumorigenicity depends on angiogenic potential of tumor
cells: dominant role of vascular endothelial growth factor and/or fibroblast
growth factors produced by tumor cells. Angiogenesis, 1998. 2(1): p. 57-66.
186. Gorski, D.H., et al., Blockage of the vascular endothelial growth factor stress
response increases the antitumor effects of ionizing radiation. Cancer Res,
1999. 59(14): p. 3374-8.
187. Maj, J.G., et al., Microvascular function regulates intestinal crypt response to
radiation. Cancer Res, 2003. 63(15): p. 4338-41.
188. Fuks, Z., et al., Basic fibroblast growth factor protects endothelial cells
against radiation-induced programmed cell death in vitro and in vivo. Cancer
Res, 1994. 54(10): p. 2582-90.
189. Pena, L.A., Z. Fuks, and R.N. Kolesnick, Radiation-induced apoptosis of
endothelial cells in the murine central nervous system: protection by fibroblast
growth factor and sphingomyelinase deficiency. Cancer Res, 2000. 60(2): p.
321-7.
236
190. Paris, F., et al., Endothelial apoptosis as the primary lesion initiating intestinal
radiation damage in mice. Science, 2001. 293(5528): p. 293-7.
191. Browder, T., et al., Antiangiogenic scheduling of chemotherapy improves
efficacy against experimental drug-resistant cancer. Cancer Res, 2000. 60(7):
p. 1878-86.
192. Tan, J. and D.E. Hallahan, Growth factor-independent activation of protein
kinase B contributes to the inherent resistance of vascular endothelium to
radiation-induced apoptotic response. Cancer Res, 2003. 63(22): p. 7663-7.
193. Kumar, P., et al., Combination treatment significantly enhances the efficacy of
antitumor therapy by preferentially targeting angiogenesis. Lab Invest, 2005.
85(6): p. 756-67.
194. Bao, S., et al., Glioma stem cells promote radioresistance by preferential
activation of the DNA damage response. Nature, 2006. 444(7120): p. 756-60.
195. Denekamp, J., Endothelial cell proliferation as a novel approach to targeting
tumour therapy. Br J Cancer, 1982. 45(1): p. 136-9.
196. Coleman, C.N., Hypoxia in tumors: a paradigm for the approach to
biochemical and physiologic heterogeneity. J Natl Cancer Inst, 1988. 80(5): p.
310-7.
237
197. Yu, J.L., B.L. Coomber, and R.S. Kerbel, A paradigm for therapy-induced
microenvironmental changes in solid tumors leading to drug resistance.
Differentiation, 2002. 70(9-10): p. 599-609.
198. Schuuring, J., et al., Irradiation combined with SU5416: microvascular
changes and growth delay in a human xenograft glioblastoma tumor line. Int J
Radiat Oncol Biol Phys, 2005. 61(2): p. 529-34.
199. Kirsch, M., G. Schackert, and P.M. Black, Anti-angiogenic treatment
strategies for malignant brain tumors. J Neurooncol, 2000. 50(1-2): p. 149-63.
200. Plate, K.H., et al., Vascular endothelial growth factor is a potential tumour
angiogenesis factor in human gliomas in vivo. Nature, 1992. 359(6398): p.
845-8.
201. Jain, R.K., Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science, 2005. 307(5706): p. 58-62.
202. Thorsen, F. and B.B. Tysnes, Brain tumor cell invasion, anatomical and
biological considerations. Anticancer Res, 1997. 17(6B): p. 4121-6.
203. Sutherland, R.M. and A.J. Franko, On the nature of the radiobiologically
hypoxic fraction in tumors. Int J Radiat Oncol Biol Phys, 1980. 6(1): p. 117-
20.
238
204. Folkins, C., et al., Anticancer therapies combining antiangiogenic and tumor
cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma
xenograft tumors. Cancer Res, 2007. 67(8): p. 3560-4.
205. Tanaka, T., Effect of adenoviral-mediated thymidine kinase transduction and
ganciclovir therapy on tumor-associated endothelial cells. Neurol Med Chir
(Tokyo), 1997. 37(10): p. 730-7; discussion 737-8.
206. Stins, M.F., F. Gilles, and K.S. Kim, Selective expression of adhesion
molecules on human brain microvascular endothelial cells. J Neuroimmunol,
1997. 76(1-2): p. 81-90.
207. Goldbrunner, R.H., et al., Models for assessment of angiogenesis in gliomas. J
Neurooncol, 2000. 50(1-2): p. 53-62.
208. Claes, A., et al., Phenotypic and genotypic characterization of orthotopic
human glioma models and its relevance for the study of anti-glioma therapy.
Brain Pathol, 2008. 18(3): p. 423-33.
209. Fomchenko, E.I. and E.C. Holland, Mouse models of brain tumors and their
applications in preclinical trials. Clin Cancer Res, 2006. 12(18): p. 5288-97.
210. Catalano, A., et al., Enhanced expression of vascular endothelial growth factor
(VEGF) plays a critical role in the tumor progression potential induced by
simian virus 40 large T antigen. Oncogene, 2002. 21(18): p. 2896-900.
239
211. Vanden Berghe, T., et al., More than one way to die: methods to determine
TNF-induced apoptosis and necrosis. Methods Mol Med, 2004. 98: p. 101-26.
212. Verheij, M., Clinical biomarkers and imaging for radiotherapy-induced cell
death. Cancer Metastasis Rev, 2008. 27(3): p. 471-80.
213. Tanida, I., T. Ueno, and E. Kominami, LC3 and Autophagy. Methods Mol
Biol, 2008. 445: p. 77-88.
214. Shvets, E., E. Fass, and Z. Elazar, Utilizing flow cytometry to monitor
autophagy in living mammalian cells. Autophagy, 2008. 4(5): p. 621-8.
215. Roninson, I.B., Tumor cell senescence in cancer treatment. Cancer Res, 2003.
63(11): p. 2705-15.
216. Rainaldi, G., et al., Induction of apoptosis or necrosis by ionizing radiation is
dose-dependent in MG-63 osteosarcoma multicellular spheroids. Anticancer
Res, 2003. 23(3B): p. 2505-18.
217. Shimamura, H., et al., Irradiated pancreatic cancer cells undergo both
apoptosis and necrosis, and could be phagocytized by dendritic cells. Eur Surg
Res, 2005. 37(4): p. 228-34.
218. Kurita, H., et al., Early effects of PRS-irradiation for 9L gliosarcoma:
characterization of interphase cell death. Minim Invasive Neurosurg, 2000.
43(4): p. 197-200.
240
219. Baatout, S., et al., Increased radiation sensitivity of an eosinophilic cell line
following treatment with epigallocatechin-gallate, resveratrol and curcuma.
Int J Mol Med, 2005. 15(2): p. 337-52.
220. Quto b, S.S. and C.E. Ng, Comparison of apoptotic, necrotic and clonogenic
cell death and inhibition of cell growth following camptothecin and X-
radiation treatment in a human melanoma and a human fibroblast cell line.
Cancer Chemother Pharmacol, 2002. 49(2): p. 167-75.
221. Lefranc, F., J. Brotchi, and R. Kiss, Possible future issues in the treatment of
glioblastomas: special emphasis on cell migration and the resistance of
migrating glioblastoma cells to apoptosis. J Clin Oncol, 2005. 23(10): p. 2411-
22.
222. Lefranc, F. and R. Kiss, The sodium pump alpha1 subunit as a potential target
to combat apoptosis-resistant glioblastomas. Neoplasia, 2008. 10(3): p. 198-
206.
223. Ditsworth, D., W.X. Zong, and C.B. Thompson, Activation of poly(ADP)-
ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator
HMGB1 from the nucleus. J Biol Chem, 2007. 282(24): p. 17845-54.
224. Badie, B., et al., Dexamethasone-induced abolition of the inflammatory
response in an experimental glioma model: a flow cytometry study. J
Neurosurg, 2000. 93(4): p. 634-9.
241
225. Wolff, J.E., J. Denecke, and H. Jurgens, Dexamethasone induces partial
resistance to cisplatinum in C6 glioma cells. Anticancer Res, 1996. 16(2): p.
805-9.
226. Wolff, J.E. and H. Jurgens, Dexamethasone induced partial resistance to
methotrexate in C6-glioma cells. Anticancer Res, 1994. 14(4A): p. 1585-8.
227. Das, A., et al., Dexamethasone protected human glioblastoma U87MG cells
from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and
preventing proteolytic activities. Mol Cancer, 2004. 3(1): p. 36.
228. Satoh, M.S. and T. Lindahl, Role of poly(ADP-ribose) formation in DNA
repair. Nature, 1992. 356(6367): p. 356-8.
229. Berger, N.A., et al., Poly(ADP-ribose) polymerase mediates the suicide
response to massive DNA damage: studies in normal and DNA-repair
defective cells. Princess Takamatsu Symp, 1983. 13: p. 219-26.
230. Ha, H.C. and S.H. Snyder, Poly(ADP-ribose) polymerase is a mediator of
necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A, 1999. 96(24):
p. 13978-82.
231. Huang, Q., et al., A novel function of poly(ADP-ribose) polymerase-1 in
modulation of autophagy and necrosis under oxidative stress. Cell Death
Differ, 2008.
242
232. Kim, K.W., et al., Autophagy for cancer therapy through inhibition of pro-
apoptotic proteins and mammalian target of rapamycin signaling. J Biol
Chem, 2006. 281(48): p. 36883-90.
233. Chow, H.H., et al., Phase I pharmacokinetic study of tea polyphenols following
single-dose administration of epigallocatechin gallate and polyphenon E.
Cancer Epidemiol Biomarkers Prev, 2001. 10(1): p. 53-8.
234. Baatout, S., et al., Study of the combined effect of X-irradiation and
epigallocatechin-gallate (a tea component) on the growth inhibition and
induction of apoptosis in human cancer cell lines. Oncol Rep, 2004. 12(1): p.
159-67.
235. Ahmad, N., P. Cheng, and H. Mukhtar, Cell cycle dysregulation by green tea
polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun, 2000.
275(2): p. 328-34.
236. Fassina, G., et al., Mechanisms of inhibition of tumor angiogenesis and
vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res, 2004.
10(14): p. 4865-73.
237. Ahn, H.Y., Y. Xu, and S.T. Davidge, Epigallocatechin-3-O-gallate inhibits
TNFalpha-induced monocyte chemotactic protein-1 production from vascular
endothelial cells. Life Sci, 2008. 82(17-18): p. 964-8.
243
238. Kim, S.H., et al., Epigallocatechin-3-gallate protects toluene diisocyanate-
induced airway inflammation in a murine model of asthma. FEBS Lett, 2006.
580(7): p. 1883-90.
239. Kawai, K., et al., Epigallocatechin gallate attenuates adhesion and migration
of CD8+ T cells by binding to CD11b. J Allergy Clin Immunol, 2004. 113(6):
p. 1211-7.
240. Surh, Y.J., et al., Molecular mechanisms underlying chemopreventive activities
of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS
through suppression of NF-kappa B activation. Mutat Res, 2001. 480-481: p.
243-68.
241. Chen, C., et al., Activation of antioxidant-response element (ARE), mitogen-
activated protein kinases (MAPKs) and caspases by major green tea
polyphenol components during cell survival and death. Arch Pharm Res, 2000.
23(6): p. 605-12.
242. Tian, B., et al., Chemiluminescence analysis of the prooxidant and antioxidant
effects of epigallocatechin-3-gallate. Asia Pac J Clin Nutr, 2007. 16 Suppl 1:
p. 153-7.
243. Berno, V., et al., The 67 kDa laminin receptor increases tumor aggressiveness
by remodeling laminin-1. Endocr Relat Cancer, 2005. 12(2): p. 393-406.
244
244. Umeda, D., H. Tachibana, and K. Yamada, Epigallocatechin-3-O-gallate
disrupts stress fibers and the contractile ring by reducing myosin regulatory
light chain phosphorylation mediated through the target molecule 67 kDa
laminin receptor. Biochem Biophys Res Commun, 2005. 333(2): p. 628-35.
245. Lin, L.C., et al., Pharmacokinetics of (-)-epigallocatechin-3-gallate in
conscious and freely moving rats and its brain regional distribution. J Agric
Food Chem, 2007. 55(4): p. 1517-24.
246. Wang, J.S., et al., Validation of green tea polyphenol biomarkers in a phase II
human intervention trial. Food Chem Toxicol, 2008. 46(1): p. 232-40.
247. Béliveau, R., Gingras, Denis, ed. Les aliments contre le cancer. 2005, Edition
du Trécarré: Montréal. pp.213.

